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Abstract 
The viral hepatitis is one of the five most important infectious diseases worldwide and is caused by the 
hepatitis B virus (HBV). The development of a chronic HBV infection raises the risk to generate liver 
fibrosis, cirrhosis, and hepatocellular carcinoma. Two different therapy-concepts to treat a chronic 
HBV infection are used: the treatment with IFN-α and the therapy with nucleos(t)ide analogs. Due to 
the high variability of the HBV genome and the missing proofreading function of the viral polymerase, 
several drug-resistant mutants arise during the long term treatment with nucleos(t)ide analogs in 
chronically infected patients. Because of the strong overlapping open reading structure of the HBV 
genome, mutations in the viral polymerase also affect the genes of the other viral proteins especially 
the gene for the HBV surface proteins. 
In the present work, a series of HBV surface protein variants were generated that can arise during the 
treatment with nucleos(t)ide analogs, bearing a stop mutation in the internal loop of the small hepatitis 
B surface antigen (SHBs) (sW172*, L176*, W182*, sW199*, W196*, L216*). These HBV variants 
show a strongly reduced secretion of HBV virions. The stop mutations in the SHBs of HBV probably 
lead to the loss of the internal loop between transmembrane domain III and IV resulting in a truncated 
SHBs variant. Surprisingly, a stop mutation at position 172 in the SHBs did not fully inhibit the 
secretion of HBV particles.  
Mutations in the HBV surface proteins can also have strong consequences for the satellite virus of 
HBV: the hepatitis delta virus (HDV). This virus is dependent on the surface proteins of its helper 
virus HBV for virion assembly, secretion, and infectivity. The antiviral treatment with nucleos(t)ide 
analogs may have consequences for the clinical prognosis and treatment of a patient chronically 
infected with HBV as well as for HBV/HDV co-infected patients. For analyzing the implications of 
HBV surface protein mutations on the viral life cycle of HDV in the future, an in vitro transfection 
system to generate recombinant HDV pseudo-particles in the hepatoma cell line Huh7 was established. 
With the help of these recombinant HDV-like particles, an infection system on primary hepatocytes, 
derived from the asian treeshrew Tupaia belangeri was then established. In this context, a full 
genomic HDV RNA standard was generated in vitro to be able to quantify the newly synthesized HDV 
RNA absolutely. The production of HDV pseudo-particles in Huh7 cells could show that the SHBs is 
crucial for the viral assembly and secretion, whereas the large hepatitis B virus surface antigen (LHBs) 
is required for a successful infection of primary Tupaia hepatocytes. Using these methods, HDV 
pseudo-particles were generated, covered with HBV surface protein variants possessing characteristic 
mutations in the SHBs (sW172*, sW172L, sW196*, sW196S, sW196L) that can arise during antiviral 
therapy. The present study could show that a stop mutation at position 172 and 196 as well as an 
amino acid change from tryptophan to serine or leucine at position 196 in the SHBs blocks the viral 
assembly and secretion of HDV pseudo-particles.  
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Zusammenfassung  
Die virale Hepatitis ist eine der fünf wichtigsten Infektionskrankheiten weltweit und wird verursacht durch 
das Hepatitis B Virus. Die Entwicklung einer chronischen HBV Infektion erhöht das Risiko, Leberfibrose,  
-zirrhose oder ein hepatozelluläres Karzinom zu bilden. Zwei unterschiedliche Therapiekonzepte werden 
verwendet, um eine chronische HBV Infektion zu therapieren: die Behandlung mit IFN-α und die Therapie 
mit Nucleos(t)id Analoga. Auf Grund der hohen Variabilität des HBV Genoms und der fehlenden 
Korrekturlesefunktion der viralen Polymerase, entstehen während der antiviralen Langzeittherapie mit 
Nukleos(t)id Analoga von chronisch HBV-infizierten Patienten verschiedene Medikamenten-resistente 
Mutanten. Durch die stark überlappende Struktur der offenen Leserahmen des HBV Genoms, 
beeinträchtigen Mutationen in der viralen Polymerase auch die Gene der anderen viralen Proteine, vor 
allem das Gen, welches für die HBV Oberflächenproteine kodiert. 
In dieser Arbeit wurden eine Reihe von HBV Oberflächenproteinvarianten generiert, die charakteristisch 
während einer antiviralen Behandlung mit Nukleos(t)id Analoga auftreten können, welche eine 
Stoppmutation in der internen Schleife des kleinen Hepatitis B Virus Oberflächenproteins (SHBs) 
(sW172*, L176*, W182*, sW199*, W196*, L216*) besitzen. Diese HBV Varianten weisen eine stark 
reduzierte Sekretion von HBV Virionen auf. Die Stoppmutationen im SHBs von HBV führen vermutlich zu 
einem Verlust der internen Schleife zwischen der Transmembrandomäne III und IV, was in einer 
trunkierten SHBs Variante resultiert. Überraschenderweise führt eine Stoppmutation an der Position 172 im 
SHBs nicht zur vollständigen Inhibition der Sekretion von HBV Partikeln. 
Mutationen in den HBV Oberflächenproteinen können auch Konsequenzen für das Satellitenvirus von 
HBV haben: das Hepatitis Delta Virus (HDV). Dieses Virus ist abhängig von den Oberflächenproteinen 
seines Helfervirus HBV für dessen Zusammenbau, Sekretion und dessen Infektiosität. Die antivirale 
Therapie mit Nucleos(t)id Analoga kann Auswirkungen auf die klinische Prognose und die Behandlung 
von chronisch HBV-infizierten ebenso wie für HBV/HDV-koinfizierte Patienten haben. Um zukünftig die 
Auswirkungen von Mutationen in den HBV Oberflächenproteinen auf den viralen Lebenszyklus von HDV 
untersuchen zu können, wurde ein in vitro Transfektionssystem etabliert, um rekombinante HDV pseudo-
Partikel in der Hepatomzelllinie Huh7 zu generieren. Mit der Hilfe dieser rekombinanten HDV ähnlichen-
Partikel wurde dann ein Infektionssystem in primären Hepatozyten des asiatischen Spitzhörnchens Tupaia 
belangeri etabliert. In diesem Zusammenhang wurde ein voll-genomischer HDV-Standard in vitro 
generiert, um neu synthetisierte RNA absolut quantifizieren zu können. Die Generierung von HDV Pseudo-
Partikeln in Huh7 Zellen hat gezeigt, dass das SHBs wichtig für das virale Assembly und die Sekretion ist, 
während das große Hepatitis B Virus Oberflächenantigen (LHBs) nötig ist, um primäre Tupaia 
Hepatozyten erfolgreich infizieren zu können. Mit Hilfe dieser Methoden wurden HDV Pseudo-Partikel 
generiert, die mit HBV Oberflächenproteinvarianten umhüllt wurden, welche charakteristische Mutationen 
im SHBs (sW172*, sW172L, sW196*, sW196S, sW196L) aufwiesen, die während einer antiviralen 
Therapie auftreten können. Die Untersuchungen haben gezeigt, dass eine Stoppmutation an der Position 
172 und 196, ebenso wie ein Aminosäureaustausch von Tryptophan zu Serin oder Leucin an der Stelle 196 
im SHBs das virale Assembly und die Sekretion von HDV Pseudo-Partikeln inhibiert. 
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1. Introduction 
1.1. Viral Hepatitis  
1.1.1. Infection with the Hepatitis B Virus (HBV) 
Viral hepatitis is an inflammation of the liver and often caused by the infection with the hepatitis B 
virus (HBV). The course of infection is variable and depends on the dose of infection, the fitness of 
the virus, as well as the immune status, the gender, and age of the infected individual. Three stages of 
an HBV infection are known: acute, chronic and fulminant hepatitis B. Normally, if adults with a 
competent immune system are infected with a low dose, in 95 % of all cases, this leads to the 
elimination of the virus by the immune system and results in immunity. After inoculation of an 
immune competent individual with a high dose of HBV, this can result in an acute hepatitis B, which 
is characterized by flu-like symptoms, tiredness, abdominal pain, and jaundice (visible as yellowing of 
the eyes). Normally, the acute hepatitis heals after several weeks and patients recover and develop 
immunity. However, a severe course of the infection is the fulminant hepatitis which occurs in < 1 % 
of the infections. If untreated, fulminant hepatitis leads to death within a few days due to fatal liver 
failure. The establishment of a chronic infection with hepatitis B depends on the age of the infected 
person and is a major problem in high endemic regions. Newborns are often infected during childbirth, 
if the chronically HBV-infected mother harbours high titers of HBV. In 90 % of these cases, the 
infection results in chronic hepatitis B (Ganem and Prince 2004) leading to a higher risk to develop 
liver fibrosis and cirrhosis within 10-20 years. If untreated, this chronic viral infection may lead to the 
development of hepatocellular carcinoma (Beasley et al. 1981) that can result in death.  
 
1.1.2. HBV/HDV Co- and Super-Infection 
Hepatitis B virus surface proteins are essential for the assembly and release of HDV virions, therefore 
an HDV infection is always associated with an HBV infection (Chang et al. 1991; Jenna and Sureau 
1998, 1999; Komla-Soukha and Sureau 2006). The course of the HDV infection also depends on the 
genotype, also called ″clade″, of the infecting virus. HDV clade-1 is the most common genotype 
worldwide and is associated with a wide spectrum of severe hepatitis (Niro et al. 1997). Clades 2 and 4 
are known to induce milder forms of hepatitis (Wu 2006; Su et al. 2006), whereas for example HDV 
clade 3 is strongly associated with severe and fulminant hepatitis (Casey et al. 1993; Manock et al. 
2000; Gomes-Gouvêa et al. 2009). Two infection patterns occur for HBV and HDV infection: the 
HBV/HDV co-infection and HBV/HDV super-infection.  
A simultaneous infection of a healthy individual with HBV and HDV is called a ″co-infection″ 
resulting in an acute hepatitis B and hepatitis D (reviewed in Farci 2003). The acute co-infection 
cannot be distinguished clinically from an ordinary acute hepatitis B, although it can lead to a stronger 
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form of acute hepatitis B mono-infection. In more than 90 % of these cases the acute HBV/HDV co-
infection leads to subsequent clearance and immunity of HDV, as already described for HBV 
(reviewed in Pascarella and Negro 2011).  
The HBV/HDV super-infection describes the additional HDV infection of a patient already 
chronically infected with HBV. In contrast to the co-infection, this way of infection induces a stronger 
form of acute hepatitis. In up to 80 % of all cases, this infection pattern leads to the HDV-chronicity 
(Smedile et al. 1981, 1982). Once a chronic HDV infection is established, it can be observed that HDV 
suppresses HBV replication to low levels in vivo (Sagnelli et al. 2000; Heidrich et al. 2009). To do so, 
the hepatitis Delta antigens (HDAg) S-HDAg and L-HDAg (s = small and l = large isoform) interact 
with the interferon-inducible MxA-protein leading to a repression of the HBV enhancer activity. Thus 
the nuclear export of viral mRNA is prevented (Gordien et al. 2001, Williams et al. 2009). Liver 
diseases like liver cirrhosis (Rizzetto et al. 1983) and fibrosis (Fattovich et al. 1987) progress much 
faster in patients who are chronically infected with HDV than in patients who are infected with HBV, 
only (Fattovich et al. 2000, Taylor 2006). The prevalence to develop hepatocellular carcinoma in 
HBV/HDV super-infected patients remains a subject of controversial debates (Cross et al. 2008; 
Romeo et al. 2009). 
 
1.1.3. Seroepidemiology and Transmission of the Hepatitis B and D Virus 
Viral hepatitis is still a global health problem, although there is a safe and effective vaccine available 
since 1982 (Lavanchy 2004, 2005). According to the World Health Organization (WHO) two billion 
people show signs of past or present HBV infection (anti-HBc) including more than 240 million 
people as chronic carriers. Every year an estimated number of 600.000 people die because of the 
sequelae of an acute or chronic hepatitis B infection. This is why hepatitis B is one of the five most 
important infectious diseases worldwide (WHO 2013). Approximately 5 % of the global HBV-carriers 
are co-infected with HDV, leading to a total of 12 million HDV-carriers worldwide (Farci 2003a). The 
occurrence of HBV and HDV infection vary greatly throughout the world. High endemic regions for 
chronic HBV infections are, in particular, Third World regions such as parts of Africa and Asia, 
whereas Europe and North America have a low prevalence (reviewed in Lavanchy 2005). Similar to 
HBV, the different HDV-clades are distributed all over the world and are highly endemic to several 
African countries (Sub-Saharan region), the Amazonian region (Amazon basin), and in the Middle 
East. In industrialized countries, HDV was found preferentially in the Mediterranean region, for 
example Turkey and Italy (reviewed in Pascarella and Negro 2011). In high endemic areas with the 
risk of repeated exposure, multiple infections with several HDV-clades can occur (Wu et al. 1999). 
Since HDV particles are enveloped by the viral surface proteins of HBV, the transmission of HDV is 
related to that of HBV. In Europe and North America, HBV is transmitted via sexual contact, blood, or 
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blood products (parental). The most prominent infection pathway in Asia is from mother to child 
during childbirth (perinatal) (reviewed in Lavanchy 2005).  
 
1.1.4. Prevention of an HBV and HDV Infection 
The hepatitis B vaccination is an effective means against HBV infection. Due to the close link 
between HBV and HDV, HBV vaccination also prevents an HDV infection. The only components of 
the recombinant HBV vaccine are subviral particles, composed of the small hepatitis B surface 
proteins (SHBs) (genotype A) derived from recombinant yeast (Peterson et al. 1984; Szmuness et al. 
1980). A proper immune response after successful vaccination results in neutralization of HBV in vivo 
and in vitro and protects against infection, but fails to protect against naturally occurring vaccine 
induced-escape mutants (Carman et al. 1990), and against mutants that can arise during antiviral 
therapy (Kamili et al. 2009). To avoid this problem, the preS1-domain of HBV should be additionally 
included.  
 
1.1.5. Therapy of Chronic HBV and HDV Infection 
In spite of the fact that there is a vaccine available, more than 240 million people are chronically 
infected with HBV (WHO 2013). They bear a high risk to develop liver cirrhosis and hepatocellular 
carcinoma (HCC) (Ganem and Prince 2004, Dienstag 2008). The antiviral treatment using interferon 
or nucleos(t)ide analogs is used to prevent these long-term effects and to bring the viral replication 
efficiently to the lowest level. One possibility for the treatment of HBV or HDV infection is the 
application of interferon-α (IFN-α). It stimulates the immune system and modulates the immune 
response against HBV and HDV (reviewed in Lavanchy 2004). Depending on the HBV genotype, 
40 % of IFN-α treated hepatitis B patients can seroconvert to HBeAg negativity and in a limited 
number of cases, the treatment leads to a successful clearance of HBsAg (Korenman et al. 1991). 
However, the therapy with IFN-α implies a series of side effects (Perrillo et al. 1990; Pardo et al. 
1995) but until today, it is the only antiviral therapy against chronic HDV infection available that 
promises healing. 
The second treatment option is focused on the viral transcriptase. To this end nucleos(t)ide analogs are 
used to control the chronic HBV infection. The four common antiviral drugs, divided into nucleoside 
analogs (lamivudine and entecavir) and nucleotide analogs (tenofovir and adefovir), are derivatives of 
nucleotide triphosphates. They inhibit the HBV reverse transcriptase and therefore prevent viral 
replication and virion formation. The given nucleoside and nucleotide analogs are inactive precursors. 
They are taken orally. Within hepatocytes, they are converted into their activated forms by cellular 
kinases. Together with the naturally occurring nucleotide triphosphates, the active forms of the 
Introduction 
4 
nucleos(t)ide analogs are incorporated into the viral DNA during the reverse transcription process, 
leading to its premature termination. The treatment with nucleos(t)ide analogs has less side effects 
than the treatment with IFN-α, but during the antiviral therapy HBV resistance mutants often occur, 
leading to an antiviral breakthrough that represents a problem in antiviral treatment (Gish 2009, 
Dienstag 2009).  
The hepatitis B virus is genetically relatively stable, but may develop at some gene regions high 
variability depending on the selective pressures, similar to HIV or several RNA viruses. The high 
adaptability results from several different factors. One of them is the error-prone activity of the viral 
polymerase that results in a high nucleotide-substitution rate during replication. Promoted by the fact 
that HBsAg-positive carriers exhibit high virus titers, various genetically different but closely related 
virus variants can occur in one patient. This mixture of different virus variants is named ″quasi-
species″ and can additionally persist in the form of a mini-chromosome (this is the covalently closed 
circular (ccc)DNA form of the HBV genome) in infected liver cells. Due to the fact that this cccDNA 
within liver cells exhibits a long half-life period, several quasi-species can exist as ″virological 
memory″ in infected hepatocytes (Seeger and Mason 2000). If one of these variants has an essential 
mutation in one of the catalytic subdomains of the viral polymerase that is resistant against a used 
nucleos(t)ide analog, this mutation increases the selective advantage of this HBV variant and can 
promote the development of a full resistance to these antiviral inhibitors. Normally, the therapy with 
nucleos(t)ide analogs has proven to decrease the viral load of chronically infected HBV patients. But 
the treatment can exert a selective pressure and drug-resistant HBV mutants frequently arise during 
antiviral therapy leading to an antiviral breakthrough and resulting in treatment failure.  
An additional promising antiviral approach could be the amino-terminal myristoylated peptide 
containing amino acid 2-48 of the preS1-domain of HBV (Glebe et al. 2005). It could be shown that 
this peptide is able to block the HBV-infection as well as HDV infection in vitro, effectively (Glebe et 
al. 2005, Gripon et al. 2005, Yan et al. 2012). At present, this inhibitor is being tested in clinical 
studies. 
 
1.2. Hepatitis B Virus (HBV) 
1.2.1. Classification 
The hepatitis B virus, which belongs to the family of Hepadnaviridae, induces chronic and/or acute 
hepatitis (Feitelson et al 1986) and is characterized by a strong liver tropism and high host specificity. 
Hepadnaviridae replicate in differentiated liver cells only and show no cytopathogenicity (Chisari and 
Ferrari 1995). If they have entered their host cells, all Hepadnaviridae replicate via a reverse 
transcriptase and a pregenomic RNA (Summers and Mason 1982). A typical feature of the cells 
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infected with Hepadnaviridae is the synthesis and secretion of virions and a huge amount of subviral 
particles (Ganem 1991).  
The mammalian hepatitis B virus is the prototype of the family of Hepadnaviridae (from hepa: liver; 
DNA: type of the genome) and belongs to the genus Orthohepadnaviridae (Robinson et al. 1984, King 
et al. 2012). Orthohepadnaviridae were discovered in humans (Dane et al. 1970) as well as in Old 
World primates, in New World primate as well as several rodents of the Sciuridae (squirrels) and in 
bats (Drexler et al. 2013). In addition to the Orthohepadnaviridae, some bird species serve as hosts, 
too. The avian viruses differ in their structure and because of that, they were separated into the genus 
of Avihepadnaviridae.  
At present, nine mayor genotypes (A to I) were divided for human HBV, based on > 8 % nucleotide 
variation over the entire genome (Norder et al. 2004). Genotypes can be further distinguished in 
several subgenotypes (> 4 % nucleotide variation). The distribution of HBV genotypes over the world 
reflects the prevalent ethnical distribution (Bartholomeusz and Schaefer 2004) and the HBV genotype 
D is the most common genotype over the world.  
 
1.2.2. Viral Properties 
1.2.2.1. Morphology and Structure 
HBV is an enveloped virus with a diameter of about 45 nm (Dane et al. 1970). In the negative contrast 
electron microscope, the virions appear as characteristic double-shelled particles (Figure 1). HBV is a 
DNA-virus with a partially double-stranded genome. The viral polymerase binds to the viral DNA as 
well as a protein kinase derived from the host cell. This complex is surrounded by the nucleocapsid 
(core protein, HBc) (32 nm-34 nm in diameter) (Almeida et al. 1971). The HBV core consists of 180 
or 240 core protein subunits (HBc), which form dimers, which then again form an icosahedron with a 
T3 (180 subunits) or a T4 (240 subunits) symmetry (Crowther et al. 1994; Kenney et al. 1995). The 
core-capsid is enveloped by a lipid membrane, where three main types of surface proteins are 
embedded; the L(arge) (39 kDa, 42 kDa), the M(iddle) (31 kDa), and the S(mall) (24 kDa) HBV 
surface proteins. These three proteins form the hepatitis B virus surface antigen (HBsAg). 
Compared to the amount of capsids, HBsAg is over-expressed (Ganem 1991; Gerlich et al. 2007) 
leading to the assembly of filamentous structures (variable length) and spheres (20 nm in diameter) 
which contain no viral DNA and therefore are not infectious. In serum of HBV infected patients, the 
subviral particles can be found in up to 1000-fold excess (Ganem 1991; Gerlich et al. 2007).  
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Figure 1: Structure of HBV and subviral particles. A) Negative contrasted electron microscopical picture of virions (left), 
filaments (middle), and spheres (right). B) Schematic model of virions and subviral particles. Virions (left) and subviral 
particles (middle and right) are covered with HBsAg consisting of s-domain (red), preS2-domain (orange) and preS1-domain 
(rose). Virions additionally include the viral core capsid (HBc, black) and viral polymerase (red and blue lines) linked to the 
reverse transcription (RT, dark green) and primer domain (pr, bright green). Modified after Gerlich 2013.  
 
1.2.2.2. Genomic Structure and Organization 
HBV is known to be one of smallest mammalian DNA -viruses. Despite the fact that the HBV DNA is 
small in genome-size, it is highly complex (Figure 2). The viral genome consists of a circular, partially 
double-stranded (ds) DNA exhibiting a plus and a negative strand. The longer, complete strand with 
negative polarity has a defined 5` and 3`end with a length of 3182-3248 nucleotides (nt), depending on 
the genotype (Summers et al. 1975). The ends of the negative strand are not closed and exhibit an 
overlength of 8-10 nt (terminal redundancy) to which the primer domain of the viral polymerase is 
covalently bound (Gerlich and Robinson 1980; Bartenschlager and Schaller 1988). The viral DNA has 
a small area with triplex formation in the region where the terminal redundancy of the minus strand is 
spanned by the plus strand (Will et al. 1987). The circular structure of the DNA is caused by base 
pairing between both strands. The complementary plus strand does not encode for viral proteins and is 
therefore not transcribed. The incomplete plus strand owns a defined 5`end and a variable 3`end 
(1100-2600 nt total length), depending on how far the viral polymerase can synthesize the plus strand 
before the virus is secreted (Hruska et al. 1977; Landers et al. 1977). Another characteristic of the viral 
genome are two direct repeats (DR1 and DR2) (Dejean et al. 1984) which have an important function 
during viral replication (Siddiqui et al. 1979; Will et al. 1987).  
The negative strand encodes for four conserved, partially overlapping open reading frames (ORFs) 
(Schlicht and Schaller 1989) that differ in length (Tiollais et al. 1985) and encode for all viral proteins. 
Expression of mRNA encoding viral proteins is done by the alternative use of different start codons. 
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The ORFs encode for 1) HBV core protein (HBc) and its ″soluble form″ (HBe), 2) the viral 
polymerase including priming and spacer domain, reverse transcriptase- and RNase H-domain (80 % 
of the genome length), 3) the surface proteins (HBsAg) and the X-protein.  
The expression of the ORFs is regulated by four promoters (core, preS1, peS2/2, X) and two 
enhancers, the glucocorticoid-responsive element (GRE) increasing transcription and a negative 
regulating element (NRE) that lowers the transcription from precore/core-promotor selectively (Tang 
et al. 2001). Liver- and differentiation-dependent factors bind to the enhancer, leading to a hepatocyte 
specific transcription and replication (reviewed in Glebe 2006). The termination of the transcription is 
accomplished by a polyadenylation signal, thus, every mRNA shares a common 3`end (Ganem and 
Varmus 1987). Additional regulatory elements at the messenger RNA (mRNA)-level are known, the 
posttranscriptional regulation element (PRE) that suppresses the splicing of transcribed viral RNAs 
and enables the transport of unspliced mRNAs into the cytoplasm (Huang and Liang 1993), or the 
encapsidation signal ε at the 5`end of the pregenomic RNA (Junker-Niepmann et al. 1990). In 
combination with the viral polymerase, the ε-signal is necessary for encapsidation of the virus (Hirsch 
et al. 1990, Bartenschlager and Schaller 1992)  
 
Figure 2: Genome structure of HBV. Multi-colored arrows at the outside present the four ORFs with their encoding 
proteins: the core-ORF (black), the S-ORF (color change from yellow to red) including the preS1-domain (yellow), the 
preS2-domain (orange), and the s-domain (red). Finally, the viral polymerase is depicted in green including the terminal 
protein (bright green), the spacer domain (deep dark green), the reverse transcriptase (dark green), and the RNase H-domain 
(bright green). Black lines show the diverse transcribed mRNAs for the viral proteins with their polyA-tail and the ε-signal 
sequence. mRNAs are described from inside out: X-protein, MHBs and SHBs, LHBs, pregenomic (pg) RNA, and HBeAg. 
The two cycles in the middle represent the cccDNA strands with negative (blue) and positive (red) polarity including their 
respective promoters (bright blue) and enhancers (apricot). E: enhancer, GRE: glucocorticoid-response-element, ε: epsilon, 
encapsidation signal (modified after Glebe and Bremer 2013). 
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1.2.2.3. Viral Surface Proteins 
Three different viral surface proteins are embedded into the lipid membrane that surrounds hepatitis B 
virions and subviral particles (Almeida et al. 1971). They all are encoded by a unique ORF, the S-
ORF. Because of the use of variable initiation codons, the proteins share the same C-terminus (same 
stop codon) but have different N-termini (Heermann et al. 1984). Two different mRNAs are 
transcribed for translating HBsAg; the LHBs encoding mRNA of 2.4 kilo bases (kb) and the mRNA of 
2.1 kb encoding for MHBs and SHBs (Kaneko and Miller 1988). Thus, the HBV surface proteins 
differ in their N-termini sequence and also in their glycosylation status (Schmitt et al. 1999). The N-
glycosylation starts co-translationally within the ER (Gavilanes et al. 1982) whereas O-glycosylation 
takes place post-translationally in the Golgi apparatus during secretion (Patzer et al. 1986, Huovila et 
al. 1992). 
The Small Hepatitis B Virus Surface Antigen (SHBs) 
The smallest HBV surface protein is the SHBs, consisting of the s-domain, only. Its sequence is found 
in MHBs and LHBs, too. The SHBs is the major component of virions and subviral particles with 
essential functions during morphogenesis, virion assembly, and secretion (Bruss et al. 1994). The s-
domain exhibits at least two, probably four hydrophobic transmembrane spanning helices (Berting et 
al. 2000). This conformation leads to the formation of an internal loop (aa 28-79) and an external loop 
(aa 99-161) (Figure 3). A short linear sequence of the internal loop is involved in virion assembly and 
mediates the binding to matured nucleocapsids (Bruss 1997). The external loop carries the important 
HBsAg-determinants and is also known as antigenic loop (a-determinant) (Figure 3). At asparagine 
(Asn)-146, the antigenic loop carries an N-glycosylation site (Peterson 1981). The s-domain contains 
14 cysteins, at least eight within the external antigenic loop are supposed to cross-link the envelope 
protein with each other. This is believed to stabilize the SHBs within the viral envelope and forms its 
tertiary structure (Mangold and Streeck 1993; Mangold et al. 1995). The antigenic loop bears 
important epitopes (Norder et al. 2004) essential for neutralizing antibodies, for example derived from 
the immune reaction towards the HBV vaccine (Peterson et al. 1984; Emini et al. 1986;). Interestingly, 
mutations into the SHBs, occurring during antiviral therapy of HBV, can lead to escape variants 
(Cooreman et al. 2001; Locarnini 2005). 
The Middle Hepatitis B Virus Surface Antigen (MHBs) 
The MHBs consists of the s-domain (226 amino acids (aa)) and a 55 aa long N-terminal addition that 
is called the preS2-domain. During synthesis, the preS2-domain is translocated into the ER-lumen and 
is N-glycosylated at asparagine (Asn)-4 (Stibbe and Gerlich 1982) and further (within the Golgi-
apparatus) O-glycosylated at threonine (Thr)-37 in all genotypes, besides genotype A (Schmitt et al. 
1999). In contrast to LHBs and SHBs, MHBs apparently is not necessary either for virion assembly or 
infectivity for HBV (Bruss and Ganem 1991, Le Seyec et al. 1998) as well as HDV (Sureau et al. 
Introduction 
9 
1994). Its function for the replication cycle of HBV still remains unclear, although it is highly 
conserved within all Orthohepadnaviridae (Heermann et al. 1984). When MHBs is expressed, a 
proper N-glycosylation site at Asn-4 is necessary for the virion secretion (Block et al. 1994; Sheu and 
Lo 1994; Lu et al. 1995). 
The Large Hepatitis B Virus Surface Antigen (LHBs)  
The largest HBV surface protein (LHBs) is formed by the s-domain, the preS2-domain, and the preS1-
domain which contains 108, 118, or 119 aa (depending on the genotype). LHBs is an ingredient of the 
spheres and a major and important component of the virions. The LHBs exists in two topologies, 
either internally located into the lumen of the virion (Figure 3 B, left site), or externally located and 
exposed on the viral surface (Figure 3 B, right site) (Bruss et al. 1994; Lambert and Prange 2003). 
Both isoforms adopt essential functions in viral assembly of HBV and infectivity of HBV and HDV. 
The preS1-conformation exposed on the viral surface is essential for preS1-mediated binding to 
human hepatocytes via its potential receptor (NTCP) and therefore mediates viral entry and 
subsequent infection (Yan et al. 2012). In combination with the internal loop of SHBs (aa 28-79), the 
internal preS1-located conformation is essential for the binding of the viral envelope with the matured 
core-capsid containing the viral genome (Bruss 1997). About 50 % of the LHBs were reported to 
change its conformational state from internal to external isoforms (Bruss et al. 1994; Ostapchuk et al. 
1994; Prange and Streeck 1995). How the LHBs passes the ER-membrane is still unclear. The LHBs 
contains an acylation site at glycine 2 with myristic acid at the N-terminus (Persing et al. 1987). This 
myristoylation might mediate, together with the preS1-domain, the specific attachment of HBV to 
hepatocytes.  
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Figure 3: Hypothetical membrane topologies of HBsAg. A) MHBs (left) and SHBs (right) with their four transmembrane 
spanning domains (red) signed with Roman numerals. SHBs contains the antigenic loop (between transmembrane domain II 
and IV) including eight conserved cysteins linked via disulfide bridges (yellow dots connected to each other). B) Model of 
the LHBs topology. LHBs is depicted as its internally located isoform (i-preS, left) and its externally located isoform (e-preS, 
right). At the internally located isoform, the antigenic loop is exposed at the external side and is a binding site for neutralizing 
antibodies (lilac dotted line). At the externally located isoform, the preS1-domain is presenting its receptor-binding site (red 
dotted line). Yellow, blue, and lilac arrows and rings tagging the glycosylation site are highlighted with pink arrows. Blue 
background marks the external side of the virus as well as the ER-lumen. Rose marks the internal side of the virus or the 
cytosol of the cell (modified after Glebe and Bremer 2013).  
 
1.2.3. Viral Life Cycle and Replication 
After infection, HBV circulates within the blood stream and has to pass through small pores of the 
liver endothelium to reach the space of Dissé. There, initial low-affinity binding of HBV to 
hepatocytes is mediated by heparan-sulfate proteoglycans (HSPGs) (Schulze et al. 2007; Leistner et al. 
2008, Sureau and Salisse 2013). Successful binding of HBV to the high-affinity receptor is necessary 
for the following uptake into its host cell. For a long time, the high-affinity receptor was unknown. In 
November 2012, a Chinese scientist group around Wenhui Li reported that the sodium taurocholate 
cotransporting polypeptide (NTCP) is a functional receptor for HBV and HDV (Yan et al. 2012). 
Binding of HBV to the NTCP is mediated by the preS1 region of the LHBs. Two sites of the preS1-
domain (aa 9-18 (essential) and aa 29-48 (accessory)) and N-terminal myristic acid are believed to 
contribute to the binding event (Neurath et al. 1986a; Le Seyec et al. 1998; Glebe et al. 2005; Engelke 
et al. 2006; Leistner et al. 2008). Another binding region within the s-domain is probably also needed 
for virion uptake and fusion (Glebe et al. 2005; Jaoudé and Sureau 2005). After binding, HBV is taken 
up into an unknown compartment, by a still unknown endocytotic mechanism, where fusion of the 
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viral and cellular membranes might occur. The viral capsid is unpacked and actively transported to the 
nuclear pore complex (NPC) along microtubules because of the nuclear localization sequence (NLS) 
of the HBV core protein (Rabe et al. 2006). At the nuclear pore complex (NPC), the nucleocapsid 
binds via the α/β-importin mediated pathway to the nuclear basket and is transported into the 
karyoplasm (Kann et al. 1999; Rabe et al. 2003). Inside the karyoplasm, the relaxed circular (rc) DNA 
is completed to the plasmid-like covalently closed circular DNA (cccDNA) by a cellular DNA-
polymerase (Köck and Schlicht 1993). Then cccDNA is associated with histones and exists as mini-
chromosome besides the cellular DNA (Bock et al. 1994; Newbold et al. 1995). The formation of the 
cccDNA is the first marker of an effective infection. In contrast to retroviruses, HBV DNA does not 
require integration into the host genome to complete a replicative cycle. In contrast, a random 
integration of (sub)-genomic DNA fragments can occur leading to a dead end of the HBV viral 
replication. After formation of the cccDNA, the transcription of the minus strand takes place. Several 
sets of mRNAs (pregenomic (pg) RNAs and subgenomic RNAs) are transcribed (Rall et al. 1983) 
induced by the cellular polymerase II which starts upstream of the DR1. The skipping of the 
transcriptional stop-signals leads to the transcription of the pg-mRNA that exhibits an over-length of 
3.5 kb. After export out of the nucleus, pg-mRNA is translated into the viral polymerase (pol) and the 
HBV core protein (HBcAg) and serves as template for reverse transcription. After forming a complex 
with cellular chaperons (heat-shock protein (hsp) 90 and hsp 23) (Hu and Seeger 1996, Hu et al. 
1997), viral polymerase binds to the ε-signal at the 5`-end of the pg-mRNA (Junker-Niepmann et al. 
1990; Bartenschlager and Schaller 1992). When a sufficient amount of viral core proteins is 
synthesized, the assembly of core-capsids happens spontaneously (Seifer et al. 1993). Then, core 
proteins encapsidate the pg-mRNA-polymerase-chaperon-complex into immature particles in the 
cytosol of the cell (Bartenschlager and Schaller 1992; Hu and Seeger 1996). Within the immature 
core-particles, the encapsidated pg-mRNA serves as template for the reverse transcription via the 
reverse transcriptase domain of the viral polymerase (Summers and Mason 1982). The following plus-
strand synthesis is mediated by the DNA-dependent-DNA-polymerase activity of the viral polymerase 
and also takes place within the nucleocapsid (Lien et al. 1986; Seeger and Maragos 1989). Now, 
mature core-particles can re-migrate into the nucleus for a refill/accumulation of the intra-nuclear 
cccDNA pool (Tuttleman et al. 1986; Summers et al. 1990) or can interact with HBsAg-containing 
membranes at the ER (Miller et al. 1984; Gerelsaikhan et al. 1996), for envelopment. The other viral 
mRNAs are also exported in the cytoplasm and transcribed into HBsAg (2.4 kb and 2.1 kb) and the X-
protein (0.9 kb) (Kaneko and Miller 1988). Enveloped virions bud and get secreted via multivesicular 
bodies (MVB) (Lambert et al. 2007). In contrast to that, the formation of subviral particles can occur 
autonomously at the ER. They are released via the common secretory pathway through ER and Golgi 
(Gavilanes et al. 1982; Patzer et al. 1986; Huovila et al. 1992).  
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Figure 4: Schematic overview of viral life cycle. (1) Attachment and up-take via its high affinity receptor NTCP, (2) release 
of the viral DNA into the karyoplasms, (3) formation of cccDNA, (4) complex-formation with cellular histones, (5) 
transcription of pgRNA and mRNAs for LHBS and MHDs/SHBs, (6) transport of mRNAs into the cytoplasm, (7,8) 
formation and secretion of subviral particles via ER and Golgi, (9) translation of pgRNA into core-proteins and polymerase, 
(10) virion assembly, (11) genome maturation, (12) retransport of matured core-capsid to the nucleus, (13,14) envelopment 
and secretion of virions via MVB (modfied after Glebe and Bremer 2013). 
 
1.3. Hepatitis Delta Virus (HDV) 
1.3.1. Classification 
The hepatitis Delta virus was discovered by M. Rizzetto in 1977 while studying liver biopsies of 
patients chronically infected with HBV (Rizzetto et al. 1977). At the beginning it was regarded as a 
new antigen of HBV called Delta-antigen. Later it turned out to be a new virus with a single-stranded 
(ss) RNA genome. It belongs to the Genus Deltavirius, with HDV as its sole member (van 
Regenmortel et al. 2000). Recent studies have shown a high genetic diversity of HDV RNA over the 
world. Until now, eight mayor genotypes are described, classified as ″clades″. They are labeled as 
HDV-1 to HDV-8 (Le Gal et al. 2006). These clades show a high heterogeneity because of the missing 
proofreading function of the RNA polymerase (Imazeki et al. 1990; Fu and Taylor 1993) inducing a 
high mutation rate of the viral RNA. In a chronically infected patient, non-coding regions of the viral 
genome mutate up to 3x10-2 – 3x10-3 base substitutions per year (Lee et al. 1992). Due to this fact, the 
genetic variability differs up to 16 % within the same clade indicating that in one infected individual 
many quasispecies can be found. The genetic variability between genotypes varies between 20 %-
40 % (Dény 2006; Le Gal et al. 2006).  
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1.3.2. Morphology and Genomic Structure 
The virion of HDV is a spherical particle of about 36-45 nm (Figure 5 A). HDV contains a single-
stranded circular RNA of approximately 1.7 kb. Because of the high GC content of the nucleotide 
sequence, the viral RNA can fold itself using 74 % intra-molecular base-pairing that results in an 
unbranched rod-like structure (Wang et al. 1986, Kuo et al. 1989, Branch et al. 1989). Viral replication 
occurs via the transcription of multimeric genomic and antigenomic intermediates (Figure 5 B) (Chen 
et al. 1986, Kuo et al. 1988). The viral RNA encodes for a single structural protein; the hepatitis Delta 
antigen (HDAg). This protein exists in a short isoform (small HDAg, S-HDAg, 24 kDa) and in a long 
isoform (long HDAg, L-HDAg, 27 kDa) (Weiner et al. 1988). L-HDAg is 19 amino acids longer than 
the S-HDAg and is produced by a RNA editing mechanism which changes the stop codon of the S-
HDAg into a tryptophan (Taylor 1992, Zheng et al. 1992, Casey and Gerin 1995). The cellular enzyme 
double-stranded RNA specific adenosine deaminase acting on RNA-1 (ADAR-1), is responsible for 
this mechanism (Casey and Gerin 1995; Polson et al. 1996; Wong and Lazinski 2002). Both HDAg 
proteins enable distinct functions in the viral life cycle. While the S-HDAg is essential for viral 
replication (Kuo et al. 1989) and secretion (Wang et al. 1991), the L-HDAg is required for packaging 
(Chang et al. 1991; Ryu et al. 1992) and for direct binding with the HBV surface proteins (Chang et al. 
1991; Lee et al. 1995). It has another relevant function in the repression of viral replication (Chao et 
al. 1990). The viral replication is also balanced by the various posttranslational states of modifications 
of the S-HDAg, for example methylation (Arg-13) (Li et al. 2004), acetylation (Lys-72) (Mu et al. 
2004), phosphorylation (Ser-177) (Mu et al. 2001), and sumoylation (Tseng et al. 2010). The 
prenylation at Cys-211 of L-HDAg is crucial for viral encapsidation (Glenn et al. 1992).  
About 200 HDAg are used to encapsidate the viral RNA into a ribonucleoprotein (RNP) (Wang et al. 
1986; Gudima et al. 2002). The RNP is then enveloped with a lipid membrane coated with the surface 
proteins of HBV (Sureau 2006) explaining why HBV co- or super-infection is always required for a 
productive HDV infection cycle.  
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Figure 5: A) Schematic model of HDV covered with HBsAg (dark green, red, and yellow). B) Structure of RNA genome 
(upper part), S-HDAg and L-HDAg (middle part), and antigenomic RNA (lower part). Arrows mark the ribozyme cleavage 
site between nt 688/689 (genomic RNA) and nt 903/904 (antigenomic RNA). Circle presents the nucleotide change from 
adenine to guanine leading to the change of the stop codon (UAG) to the amino acid tryptophan (UGG). Kindly provided and 
modified after Doerr and Gerlich 2008. 
 
1.3.3. Viral Life Cycle 
Attachment and Entry 
As mentioned earlier, HDV requires the surface proteins from its helper virus HBV for attachment and 
subsequent entry into susceptible hepatocytes. It has been well established, that two sequences in the 
preS1-domain of the LHBs and the N-terminal myristoylation are needed for specific binding to its 
high affinity receptor for both viruses, HBV (Neurath et al. 1986a; Leistner et al. 2008) and HDV 
(Sureau et al. 1993, Sureau et al. 2003, Abou-Jaoudé et al. 2007) . Therefore it is not surprising, that 
the first contact between virus and hepatocytes is mediated by binding at HSPGs as further described 
for HBV (Lamas Longarela et al. 2013). HDV also uses the sodium taurocholate cotransporting 
polypeptide (NTCP) as a receptor for the infection of hepatocytes, similar to HBV (Yan et al. 2012). 
Nevertheless, many questions remain unclear: Which endocytotic pathway for internalization is used 
by the viruses? Do HBV and HDV use different post-entry steps? Are there any other receptors 
involved in the uptake-mechanism?  
After successful up-take into hepatocytes, the HDV-RNP is unpacked and transported to the nucleus 
where viral replication takes place. This process is presumably mediated by a NLS (located at aa 35-
88 from the N-terminus) of the HDAg (Xia et al. 1992; Chang et al. 1991; Tavanez et al. 2002).  
Replication Cycle  
In the nucleus, the initiation of replication is realized via a so called “double-rolling cycle” mechanism 
(Figure 6) similar to that already proposed for plant viroids and small satellite RNAs (Wang et al. 
1986; Chen et al. 1986, Branch et al. 1989). During replication, three major species of RNA occur, the 
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genomic RNA (negative polarity), the antigenomic RNA (positive polarity), and mRNA (0.8 Kb) 
encoding for HDV-proteins. Genomic RNA serves as template for the transcription of mRNA, only 
and therefore as matrix for viral proteins.  
Due to the fact that HDV does not possess its own RNA polymerase and both HDAg hold a direct 
RNA-binding domain (Wang et al. 1994), it is well established that the cellular DNA-dependent RNA 
polymerase II (pol II) is directly involved in the transcription of viral RNA (Kuo et al. 1989, 
Filipovska and Konarska 2000, Greco-Stewart et al. 2007) without formation of DNA-intermediates 
(Fu and Taylor 1993). Some other studies postulate the involvement of RNA pol I and III in viral 
replication machinery, too (reviewed in Greco-Stewart et al. 2009). With the help of additional 
transcription factors, the polymerase II and HDAg form a nuclear replication complex to initiate 
replication of mRNA and genomic-RNA. At first, a multimeric antigenomic intermediate is generated 
(Chen et al. 1986; Macnaughton et al. 2002), harboring an intrinsic endo- and exonuclease activity of 
about 85 nt that enclosed the ribozyme restriction site (nt 688 and nt 689). After generating an 
autocatalytic ribozyme pseudo-knot at the restriction site, the multimeric antigenome is cleaved into 
linear monomers (Kuo et al. 1988; Wu et al. 1998, Branch et al. 1989, Lazinski and Taylor 1994). The 
monomeric strands then are ligated to form circular antigenomic molecules which then become the 
templates for the production of more genomic RNAs by another round of the rolling cycle mechanism 
(Taylor 1992, Lazinski and Taylor 1994). The involvement of host RNA ligase remains unclear. 
Newly transcribed and translated S-HDAg is involved in the rolling-cycle mechanism again.  
Assembly and Secretion 
As long as no L-HDAg is synthesized, replication occurs as described above. Later, during the viral 
replication cycle, the production of S-HDAg switches to the synthesis of L-HDAg, performed by an 
RNA editing mechanism (Casey and Gerin 1995; Polson et al. 1996; Wong and Lazinski 2002). The 
L-HDAg serves as dominant negative inhibitor for viral replication (Chao et al. 1990) and together 
with S-HDAg, interacts with the genomic RNA to assemble the HDV RNP complex. For covering the 
RNP complex with the HBV surface proteins, it must travel to the cytoplasm. The L-HDAg harbors a 
nuclear export signal (NES) at its C-terminus (Lee et al. 2001) and after binding with the protein NESI 
(nuclear export signal L-HDAg interacting protein), the HDV RNP complex is transported to the 
cytoplasm (Wang et al. 2005). For the binding of the HDV RNP complex, the L-HDAg exhibits a 
CXXX motive at its C-terminus that undergoes prenylation (Glenn et al. 1992). In the presence of 
HBV co-infection, this posttranslational modification anchors the viral RNP in the ER, where it can 
assemble with the HBV surface proteins. For this purpose, the C-terminus of L-HDAg interacts with 
the tryptophan-rich motif at the C-terminus of SHBs (Wang et al. 1991; Komla-Soukha and Sureau 
2006) creating new infectious virions that trigger secretion of enveloped HDV particles. 
In contrast to HBV, assembly and secretion of HDV require SHBs, only (Bruss and Ganem 1991; 
Wang et al. 1991; Komla-Soukha and Sureau 2006), but for the infection of new hepatocytes, the 
LHBs of HBV is required for HDV, additionally (Sureau et al. 1993).  
Figure 6: Replication cycle of HDV
of S-HDAg-mRNA ((A)n mRNA) and 
autocatalytic cleavage of the genomic RNA into monomeric strands, 
transcription of the antigenomic RNA with multimeric antigenomic strand, 
religation and new replication cycle.
 
1.4. Model Systems for HBV and HDV
Several animal models and cell culture
secretion of HBV and HDV. They have
For studying viral replication and secretion, 
well established in vitro, but they 
transfected with HBV or HDV cDNA 
Apart from them, another human hepatoma cell line
HDV but has to be treated with 
weeks (Gripon et al. 2002). In contrast to HBV, many different cell types c
cDNA because the replication of
transcription factors. In addition, co
reproduction of the complete replication cycle including virion formation and secretion 
(Chang et al. 1991; Sureau et al. 1992
Because HBV shows a narrow host range and infects only humans and 
chimpanzees (Barker et al. 1973)
difficult. Due to the strong host specificity of HBV and HDV,
and rats, are unsuitable because they 
 
 after the rolling cycle mechanism. (1) transcription of genome (G), 
(3) multimeric genomic strand, (4) formation of ribozyme pseudo
(6) religation of the strand to antigenomic RNA, 
(8) cleavage into monomeric genomic strand
 Modified and kindly provided after Lai 1995, Doerr and Gerlich 2008
 
 systems are used for analyzing replication, infection
 several advantages and disadvantages. 
human hepatoma cell lines like Huh7 or HepG2
are not susceptible for HBV or HDV and therefore have to be 
(Neurath et al. 1986b; De Falco et al. 2001; Rabe et al. 2006)
 (HepaRG) is partly susceptible for
dimethyl sulfoxide (DMSO) and polyethylene glycol (PEG) for several 
an be transfected with HDV 
 the HDV genome occurs independently from 
-transfection of HDV- and HBV-encoding plasmids
). 
higher 
, the use of suitable animal models to study the infectivity of HBV
 classical laboratory animals
cannot be infected with HBV and HDV.  
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In the past, chimpanzees were used for infection and replication assays of HBV and HDV (Rizzetto et 
al. 1980a) but these in vivo experiments were stopped when a debate started regarding ethic and 
economic reasons. Studies of non-human HBV were done for example with duck hepatitis B virus 
(DHBV) in ducks and woodchuck hepatitis B virus (WHV) in woodchucks, though infection and 
replication systems are not completely comparable to that in humans. To name one example only, 
DHBV differs in its structure (loss of the MHBs) compared to the human HBV. Due to the fact that 
Eastern woodchucks can be infected with WHV, they are still used as infection models for 
pathogenesis and antiviral therapy to develop new immunization strategies of a chronic HBV-infection 
(reviewed in Menne and Cote 2007).  
A successful infection with human HBV is not only depending on the species but also on the 
differentiation status of the hepatocytes.  
In some studies, primary human hepatocytes (PHH) were used because they can be infected with HBV 
and HDV, although handling them is more difficult than immortalized cell lines (Gripon et al. 1988) 
and the availability is limited. Another mayor problem of PHH are the ethical concerns regarding their 
origins and their heterogeneity in quality after isolation (reviewed in Glebe and Urban 2007). Freshly 
isolated primary hepatocytes from the Southeast Asian treeshrew Tupaia belangeri are susceptible for 
human HBV and HDV (Li et al. 1995) and can be infected in vitro (Yan et al. 1996) as well as in vivo 
(Su 1987, Walter et al. 1996). They are closely related to primates (Schmitz et al. 2000) and can be 
infected with Woolley monkey hepatitis B virus (WMHBV), too (Köck et al. 2001).  
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1.5. Aim of the Work 
To date, the chronic HBV infection is treated with either IFN-α or nucleos(t)ide analogs. But during 
this antiviral therapy, HBV resistance mutants often occur, leading to an antiviral breakthrough. Due 
to the strong overlapping open reading structure of the HBV genome, mutations in the viral 
polymerase also affect the genes of the other viral proteins especially the gene for the HBV surface 
proteins. Mutations in these proteins could lead to an altered virion secretion and infectivity. In the 
past, an in vitro phenotypic resistance assay was established at the Institute of Medical Virology at the 
University of Gießen (AG Dr. Glebe) in collaboration with the Institute of Virology at the University 
of Munich (AG Prof. Protzer). In the first part of the present work,  
a) the phenotypic characterization of patient isolates from chronically infected HBV-patients 
should be continued, focusing patient isolates that possess characteristic HBV surface protein 
variants.  
b) Furthermore, the consequences of selected mutations in the SHBs on HBV assembly, the 
expression of viral surface proteins, and virion secretion should be further analyzed.  
 
The second part of this work deals with the satellite virus of HBV: the hepatitis D virus. For assembly 
and virion secretion, HDV uses the surface proteins of its helper virus HBV. Due to this fact, 
mutations in the HBV surface proteins that arise during antiviral therapy do not only affect the viral 
life cycle of HBV, but also have strong consequences for the assembly and secretion of HDV. 
Therefore,  
c) an in vitro transfection system in Huh7 cells should be established generating recombinant 
HDV pseudo-particles covered with HBV surface protein variants. 
d) In this context, a full length genomic HDV RNA standard should be generated in vitro for 
absolute quantification of HDV RNA. 
e) Using the recombinant HDV variants, an infection system for HDV on PTHs should be 
established. 
To ensure a better comparability with naturally occurring infections,  
f) plasma, derived from a chronically infected patient with HBV and HDV, should be purified 
and further analyzed for the infectivity of HDV on PTHs. 
Using the these methods and collected data,  
g) the influence of typically occurring HBV surface protein mutations arising during antiviral 
therapy on virion formation and secretion of HDV should be investigated. 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Antibiotics 
name stock solution used concentration CaNo company 
caspofungine acetate 50 mg/ml 1:10.000 SRP05500c Sequoia 
ampicillin 50 mg/ml 1:500 KO291 Roth 
penicilline/streptomycine 100 x 1:100 P11010 PAA 
 
2.1.2. Antibodies and Nuclear Staining 
2.1.2.1. Primary Antibodies 
 
specificity 
 
name 
 
epitope 
used 
concentration 
source/  
company 
ELISA IF 
anti-SHBs IgG 1) 
(1 mg/ml) 
C20/02 S-domain, AS 120-160 in 
a-determinant, conformational 
 
1:1000 
 
1:200 
Prof Gerlich, 
Gießen 
anti-SHBs IgG 1) 
 
 
(1 mg/ml) 
HB1 S-domain,  
binding-motif: CRTCTT/CKTCTT 
conformational independent 
 
1:1000 
 
 
Aurelia Zvibliene, 
Institute of 
Biochtechnology, 
Vilnius, Lithuania 
anti-MHBs IgG 1) 
(1 mg/ml) 
Q19/10 preS2-domain, N-glycosylation, 
conformational independent  
 
1:500 
 
1:100 
Prof Gerlich, 
Gießen 
anti-LHBs IgG 1) 
 
(1 mg/ml) 
MA18/7 preS1-domain, AS 20-23,  
binding-motif: LDPAF 
conformational independent  
 
1:1000 
 
1:200 
Prof Gerlich, 
Gießen 
anti-HBc AK 2) 
(10 mg/ml) 
 HBcAg 1:500 1:200 DAKO 
(CaNo. B0586) 
Anti-HBc AK 2) 
(concentration unknown) 
Gö-
Schaf 
HBcAg  
1:20.000 
 Prof Gerlich, 
Gießen 
anti-HBs biotin conjugate 
Enzygnost® 
HBsAg 6.0 
  
HBsAg 
 
1:40 
 
 
Dade Behring 
(CaNo QPW11) 
1)
 monoclonal; 2) polyclonal  
 
2.1.2.2. Secondary Antibodies 
 
name 
 
concentration 
used  
concentration 
 
company 
Alexa-Fluor 549 F(ab`)2 fragment of goat anti-
mouse IgG 
2 mg/ml 1:200 Invitrogen (CaNo. A-11020) 
Alexa-Fluor 549 F(ab`)2 fragment of goat anti-
rabbit IgG 
2 mg/ml 1:200 Invitrogen (CaNo. A-11072) 
Streptavidin-POD 1 mg/ml 1:500 Dianova (CaNo.: 016-030-084) 
donkey-anti-sheep-POD  1:500 Dianova (CaNo. 713-035-147) 
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2.1.2.3. Nuclear Staining 
name  used concentration company 
DAPI  
(4`,6-diamidino-2-phenylindol-dihydrochlorid) 
detached in dH2O 
[1mg/ml] 
 
1:400 
 
Roth (CaNo. 6335.1) 
 
2.1.3. Peptide 
For inhibition of HBV or HDV infection the following peptide was used:  
myr HBV preS1-peptide 2-48 
It is a synthetic peptide that comprises the aa 2-48 and the myristoylation site of the preS1 region of the 
hepatitis B virus (genotype D). The peptide was purchased from GenScript.  
 
2.1.4. Antivirals 
name stock concentration company 
adefovir 2 mM Sigma-Aldrich (CaNo.: SML0240) 
entecavir 1 mM Sequoia (CaNo.: SRP010887e) 
lamivudine 10 mM Sequoia (CaNo.: SRP01125l)  
tenofovir 2 mM Sequoia (CaNo.: SRP01194t) 
 
2.1.5. Buffer, Media, and Solutions 
2.1.5.1. Buffers 
name components amount/concentration company 
ELISA coating buffer (NaPP) 
 
pH 7.4 
NaCl 
Na2HPO4 x H2O 
KH2PO4 
83 mM 
8.6 mM 
2.2 mM 
 
HBSS (without MgCl2 and CaCl2)  (+/- 5 mM EGTA)  Invitrogen 
PBS (10x) 
 
 
pH 7.4 
NaCl, pH 7.4 
KCl 
Na2HPO4 x 2 H2O 
KH2PO4  
137 mM 
3.4 mM 
10 Mm 
1.8 mM 
 
PBS++ CaCl2 
MgCl2 
MgSO4  
PBS 1x  
0.9 mM 
0.52 mM 
0.16 mM 
detached in 400 ml 
 
TNE 
pH 7.4 
NaCl 
EDTA 
Tris-HCl 
140 mM 
1 mM 
20 mM 
 
TFB1 (Transforming Buffer 1) 
 
 
 
pH 5.8 with acetic acid 
MES (pH 6,2)  
RbCl  
CaCl2 x 2 H2O  
MnCl2 x 4 H2O  
H2O 
10 mM  
100 mM 
10 mM 
50 mM 
ad to 500 ml 
 
TFB2 (Transforming Buffer 2) 
 
 
 
pH 6.5 with potassium hydroxide 
MOPS  
RbCl  
CaCl2 x 2 H2O  
Glycerol 
H2O 
10 mM 
10 mM 
75 mM 
15 % (v/v) 
ad to 100 ml  
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1 M MES 
 
pH 6.2 with 5 M KOH 
MES 
H2O 
H2O  
19.52 g 
solve in 80 ml 
ad to 100 ml 
 
MOPS (10x)  
 
pH 7.0 with NaOH 
MOPS 
EDTA 
NaOAc 
41.9g 
10 mM 
50 mM 
 
10x MOPS gel running buffer  MOPS (pH 7.0) 
Sodium acetate 
EDTA 
0.4 M 
0.1 M 
10 mM 
 
SEAP-buffer Diethanolamin (100 %)  
MgCl2 (1 M stock solution) 
L-Homoarginine  
dH2O 
10.51 g 
50 µl 
0.089g 
ad to 50 ml 
 
 
 
Roth  
3 M sodium acetate 
pH 5.2 
Sodium acetate  
dH2O 
40.8 g 
ad to 100 ml 
 
6x loading dye Glycerine 
Bromphenol blue 
add TAE 
60 ml 
0.1 g 
100 ml 
 
RNA loading buffer  
(for formaldehyde gels) 
10x MOPS 
Formamide (deionized) 
Formaldehyde 37 % 
H2O 
50 µl 
250 µl 
89 µl 
111 µl 
 
 
Roth 
Trypsin/PBS (1:5) PBS 1x 
Trypsin/EDTA (5x) 
500 ml 
100 ml 
 
PAA 
TAE (50x) 
 
pH 8 with glacial acetic acid 
Tris 
glacial acetic acid 
EDTA (0.5 M) 
242 g 
57.1 ml 
100 ml 
 
 
2.1.5.2. Media 
name components amount/concentration company 
DMEM with phenolred   Invitrogen 
DMEM without phenolred    Invitrogen 
HGM (Hepatocytes Growth 
Medium) 
(according to Block et al. 
1996, modified) 
DMEM without phenolred 
ITS Mix 
BSA 
Glutamax I (5 M) 
Dexamethasone (1:10.000) 
Gentamycine (50 mg/ml) 
1 L 
10 ml 
2 g 
10 ml 
100 µl 
2 ml 
Invitrogen 
Invitrogen 
Roth 
Invitrogen 
Invitrogen 
Invitrogen 
LB-medium BactoTM-Trypton 
BactoTM-yeast extract  
NaCl 
H2O 
10 g 
5 g 
10 g 
1 l 
Becton Dickinson  
 
Becton Dickinson  
 
Incubation medium 
(immunostaining) 
DMEM without phenolred 
BSA 
 
1% 
 
Sigma-Aldrich 
Cell culture medium 2 % 
(transfection) 
DMEM without phenolred 
FCS 
Pyruvat 
Penicillin/Streptomycin 
500 ml 
10 ml 
5 ml 
5 ml 
Invitrogen 
PAA 
Cell culture medium 5 % DMEM 
FCS 
Penicillin/Streptomycin 
500 ml 
25 ml 
5 ml 
Invitrogen 
PAA 
Cell culture medium 10 % DMEM 
FCS 
Penicillin/Streptomycin 
500 ml 
50 ml 
5 ml 
Invitrogen 
PAA 
Freezing medium DMEM  
FCS 
DMSO 
6 ml 
2 ml 
2 ml 
Invitrogen 
PAA  
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2.1.5.3. Solutions 
name components amount/concentration company 
0.5 M H2SO4    
collagenase solution Collagenase Type IV 
DMEM without phenolred 
250 mg 
100 ml 
 
Invitrogen 
matrigel  1:20 Becton Dickinson 
substrate for ELISA OPD-tablets 
Perhydrol (30) 
H2O 
4 
5 µl 
12 ml 
 
Merck 
substrate for SEAP-assay pNitrophenolphosphate 
H2O 
0.6 mg 
5 ml 
Sigma-Aldrich 
embedding medium for IF Mowiol 4-88 
H2O 
Glycerine (87 %) 
Tris/Cl, pH 8.5; 0 
DABCO 
2.4 g 
6 ml 
6 g 
12 ml 
100 ml 
Sigma-Aldrich  
 
Merck 
 
Sigma 
paraform aldehyde, PFA  
(3 %) 
 
 
PFA 
3M KOH 
PBS (10x) 
H2O 
6 g 
200 µl 
20 ml 
180 ml 
Merck 
O-Phtalaldehyde dH2O 
H2SO4 (conc) 
O-Phtalaldehyde 
Brij 35 (10 %) 
add dH2O 
400 ml 
37 ml 
100 mg 
1.5 ml 
500 ml 
 
 
Sigma 
Pierce 
NED-reagent Boric acid 
H2O 
H2SO4 conc. 
NED 
Brij-30 (10 %) 
Ad H2O 
2.5 g 
300 ml 
111 ml 
300 mg 
1.5 ml 
500 ml 
Sigma-Aldrich 
 
 
Sigma-Aldrich 
Pierce 
PBS/Triton X-100 0.2% PBS (1x) 
Triton-X-100 
500 ml 
1 ml 
 
Sigma 
RNA blue marker Bromphenol blue (1 %) 
EDTA (250 mM) 
Glycerine (80 %) 
375 µ 
25 µl 
625 µ 
 
OPD-ELISA substrate OPD-tablets 
H2O 
Hydrogen peroxide 
4 tablets 
12 ml 
5 µl 
DAKO (CaNo S2045) 
1 % Casein-Block solution   Thermo Scientific  
(CaNo 37528)  
 
2.1.6. Commercial Kits, Enzymes, and Competent Bacteria 
name CaNo. company 
Nucleo Spin RNA II 740955 Machery-Nagel 
High Pure Viral Nucleic Acid Kit 11858874001 Roche 
Sample Preparation System DNA 06K12-24 Abbott 
FuGene HD Transfection Reagent Kit  #04709691001 Roche 
Plasmid Plus Midi Kit 12943 Qiagen 
QIAquick PCR Purification Kit 28104 Qiagen 
FuGene HD Transfection Reagent E2311/2 Promega 
Verso 1-Step QRT-PCR Kit + ROX vial AB-4100c Thermo Fisher Scientific 
ABsolute Blue QPCR SYBR Green Mix + ROX vial AB-4166b Thermo Fisher Scientific 
ABsolute QPCR SYBR Green Capillary Mix AB-1285b Thermo Fisher Scientific 
Absolute QPCR Capilliary Mix AB-1283b Thermo Fisher Scientific 
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Phusion® High-Fidelity DNA Polymerase F530s Thermo Fisher Scientific 
Competent bacteria Stellar, In-Fusion HD Cloning System 639643 Clontech  
dNTPs mix (10 mM) R0192 Thermo Fisher Scientific 
DNase I, RNase free (1 U/µL) EN0521 Thermo Fisher Scientific 
RNase A, DNase and protease free EN0531 Thermo Fisher Scientific 
Shrimp Alkaline Phosphatase  EF0511 Thermo Fisher Scientific 
T7 High Yield RNA Synthesis Kit #E2040S NEB Biolabs 
DpnI #ER1705 Thermo Fisher Scientific 
wst-1, cell proliferation reagent 11644807001 Roche 
TMB Xtra Ready-to-use-substrate 4800L Biocompare 
Proteinase K, recombinant, PCR grade 3L78-60 Abbott 
 
2.1.7. Cell Lines 
 AML12 
The AML12 is a murine hepatoma cell line, that was derived from livers of transgenetic mice, 
overexpressing the transforming growth factor α. These cells show typical hepatocyte features, 
high expression of mRNA for serum and gap junction proteins for example (Wu et al. 1994). 
 
 Huh7 
The Huh7 cell line is a human well differentiated hepatoma cell line derived from a hepatocellular 
carcinoma of a 57-year old Japanese man (Nakabayashi et al. 1982). 
 
Huh7 Munich 
The cell line Huh7 Munich is a progeny of the Huh7 cell line. These cells should have no 
functional reimport of matured core-capsids into the nucleus (personal communication of Prof. 
Dr. U. Protzer, Institute for Virology, Munich). 
HepG2 
The HepG2 cell line is an immortal human hepatoma cell line derived from a hepatoma biopsy of 
a 15-year old American man. This cell line synthesizes several liver specific human plasma 
proteins and contains no HBV-DNA (Aden et al. 1979).  
 
Primary Tupaia Hepatocytes (PTHs) 
For infection assays freshly isolated primary hepatocytes from the East-Asian tree shrew Tupaia 
belangeri were used. As well as primary human hepatocytes (PHHs), PTHs belong to the kind of 
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cells which can be infected with the human Hepatitis B virus (Glebe et al. 2003; Köck et al. 
2001). The animals are from the animal breed located formerly at the Institute of Anatomy and 
Cell Biology, now the animals are hosted at the central animal facility (″zentrales Tierlabor″) at 
the Justus-Liebig-University in Gießen (JLU-No. 410-M, projectID: 767).  
 
2.1.8. Viruses Derived from Serum/Plasma of Chronically Infected Individuals 
ID1) fraction GE/ml used GE 
ID 309 pool 4 4x1011 1x108 
ID 395 4 2.4x109 1x106 
ID 423 7 8.65x109 1x107 
1)
 internal identification number the Institute of Medical Virology, JLU Gießen 
 
2.1.9. Plasmids 
2.1.9.1. Standard Plasmids 
name template source/company 
pSEAP2-control pSEAP2-control Clontech (CaNo. 631717) (Berger et al. 1988) 
pCH9-3091 
(wild type, wt) 
pBR322 derivate with 1.1 HBV 
overlength genome, genotype D, 
serotype ayw1 
(GenBankID DQ464168.1) 
kindly provided by Prof. Dr. U. Protzer  
pSVLD3 3x HDV genome kindly provided by Karin Schultheiß (Institute for 
Medical Virology, Gießen) (Kuo et al. 1989) 
 
2.1.9.2. HBV-Expression Plasmids for HBV Phenotypic Assay 
name source 
pCH9-3091-pol_RK 172-2  
kindly provided by 
Dr. Maria Neumann-
Fraune from 
Uniklinikum Köln 
pCH9-3091-pol_RK 172-4 
pCH9-3091-pol_KW 11a-1 
pCH9-3091-pol_KW 6a-6 
pCH9-3091-pol_KW 8-6 
pCH9-3091-pol_KW 14-8 
pCH9-3091-pol_KW 13a-2 
pCH9-3091-pol_KW 4a-7 
 
For phenotypic characterization of isolates from chronically infected HBV-patients in HBV resistance 
assay, HBV expression plasmids from different patient isolates were generated. On that score, the HBV 
polymerase-ORF of isolates from chronically infected HBV-patients was inserted in the HBV wild type 
plasmid pCH9-3091. 
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2.1.9.3. Plasmids for Analyzing HBV Variants Harbouring Stopmutants within the S-ORF 
 
mutation source 
name of the plasmid used name in the 
dissertation 
rt-domain s-domain 
pCH9-3091-preS1M1T M1T silent mutation M1T 
 
 
 
 
kindly provided 
by Dr. Maria 
Neumann-Fraune 
from Uniklinikum 
Köln 
pCH9-3091-sW172* 172*1) A181T W172* 
pCH9-3091-sW172L 172L A181V W172L 
pCH9-3091-sW176* 176* T184M W176* 
pCH9-3091-sW182* 182* V191I W182* 
pCH9-3091-sW196* 196* M204I W196* 
pCH9-3091-sW196S 196S M204I W196S 
pCH9-3091-sW196L 196L M204I W196L 
pCH9-3091-sW199* 199* V207I W199* 
pCH9-3091-sW216TAA 216TAA V224 W216* (nt-mutation:TAA) 
pCH9-3091-sW216TGA 216TGA V224 W216* (nt-mutation:TGA) 
1)
 * stop mutation  
 
2.1.9.4. Plasmids Encoding HBV Surface Proteins for Generating Recombinant HDV in 
Cell Culture 
plasmid name name in dissertation source 
pCH9-delCMV-nurLHBs_sM125R_sT125I LMS  
kindly provided by 
Julia Heger, see 
masterthesis Heger 
2012  
pCH9-delCMV-nurLHBs-mM1T_sM125R_sT125I LXS 
pCH9-delCMV-nurLHBs-mM1T_sM1T_sM125R_sT125I LXX 
pCH9-delCMV-nurLHBs_lM1T_sM1T_sM125R_sT125I XMX 
pCH9-delCMV-nurLHBs_lM1T_mM1T_sM125R_sT125I XXS 
pCH9-delCMV-nurLHBS_lM1T_mM1T_sM1T_sm125R_sT125I XXX 
 
The initiation codons (M) of the three surface proteins (l, large; m, middle; s, small) are mutated. The 
mutations in the subgenomic L-ORF constructs have no influence on the secretion of subviral particles 
(Heger 2012). All plasmid constructs imply the binding sequence for the HB1-antibody (binding-motif: 
CRTCTT/CKTCT). The wild type plasmid was marked with the letters LMS implying that all surface 
proteins are intact. The corresponding mutation was highlighted with X. 
 
2.1.10. PCR, Primer, Probes, and Mastermixes 
2.1.10.1. Primer and TaqMan Probes for Quantitative Polymerase Chain Reaction 
(qPCR) 
Primer and probes for qPCR were purchased from Eurofins MWG, metabion, and biomers.net. 
X-PCR  
Primer 
X2 sense 
X2 antisense 
 
TaqMan probe 
HBV-TaqMan 
 
 
5`- gacgtcctttgty1)tacgtcccgtc 
5`- tgcagagttgaagcgaagtgcaca 
 
 
5`- FAM 2)-ctccccgtctgtgccttctcatctgccg-TAMRA 3) 
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HOPE-PCR  
Primer 
HOPE-sense 
HOPE-antisense 
 
 
5`-actaggaggctgtaggcata 
5`-agactctaaggcttcccg 
HDV-PCR  
Primer 
HDV2-sense 
HDV2-antisense 
 
TaqMan probe 
HDV-TaqMan 
 
 
5`-tccagaggaccccttca 
5`-ccgggataagcctcact 
 
 
5`- FAM 1)-agaccgaagcgaggaggaaagca-TAMRA 2) 
1) y: C/T; 2) FAM: 6-Carboxy-Fluorescein; 3) TAMRA: Tetramethylrhodamin 
 
2.1.10.2. Primer for Generating an HDV-RNA Standard 
HDV amplification 
plasmid  pSVLD3 
primer 
HDV3-sense 
HDV3-antisense 
 
5`- ggtgcaaatcaaagaactgc 
5`- aggaattctcggaaagaagg 
generation of HDV RNA 
standard in vitro  
primer 
HDV T7-sense 
HDV T7-antisense 
 
5`- gtacgtcgactaatacgactcactatagggagagaattcctttgatgttccccag 
5`- gtacgctagcgaattctcggaaagaaggataagg 
 
2.1.10.3. Sequencing Primer for HDV-RNA-Standard 
Primer for sequencing HDV template primer 
HDV Sequenzierung3 
HDV Sequenzierung2 
 
5`- acccccttcgaaagtgac 
5`-gaattcctttgatgttccccag 
 
2.1.10.4. Mastermixes for Hot Start and Gradient PCR 
Amplification of HDV genome out of 
pSVLD3 plasmid 
33 µl 
10 µl 
1 µl 
3 µl (10 pmol/µl) 
3 µl (10 pmol/µl) 
+ 5 µl 
H2O 
5x High Fidelity Buffer  
dNTPs 
HDV3-sense 
HDV3-antisense 
pSVLD3 plasmid 
Polymerase mix 0.5 µl 
4 µl 
0.5 µl 
H2O 
5x High Fidelity Buffer 
Phusion High Fidelity DNA polymerase 
 
2.1.10.5. qPCR Mastermixes 
HOPE-qPCR 8 µl 
1 µl (10 pmol/µl) 
1 µl (10 pmol/µl) 
+ 10 µl 
ABsolute Blue QPCR SYBR Green Mix 
HOPE sense 
HOPE antisense 
purified DNA 
X-qPCR 7 µl 
1 µl (10 pmol/µl) 
1 µl (10 pmol/µl) 
1 µl (5 pmol/µl) 
+ 10 µl 
QPCR Capillary Mix 
X2 sense 
X2 antisense 
HBV-TaqMan probe 
purified DNA 
HDV-RT-qPCR 0.25 µl  
12.5 µl 
1.25 µl 
1 µl (10 pmol/µl) 
1 µl (10 pmol/µl) 
1 µl (5 pmol/µl) 
3 µl 
+ 5 µl 
Enzyme Mix 
QPCR Mix 
RT Enhancer 
HDV2 sense 
HDV2 antisense 
HDV TaqMan probe 
H2O 
purified RNA 
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All quantitative polymerase chain reactions (qPCR) and reverse transcription qPCRs were performed in a 
96- well Light Cycler 480 II (Roche). Before running the PCR, mastermixes and purified RNA or DNA 
were pipetted into a 96-well microtiter plate and centrifuged at 700 g for 2 minutes to spin down included 
mastermixes and purified RNA or DNA. 
 
2.1.11. Equipment, Consumable Supplies, and Software 
Centrifuges and rotors 
Rotina 420R        Hettich 
Centrifuge 5810R        Eppendorf 
Tablecentrifuge 5417R       Eppendorf 
Tablecentrifuge 5417       Eppendorf 
Tablecentrifuge 5430       Eppendorf 
Beckmann LE 80, water cooled      Beckmann 
SW28.38 rotor        Beckmann 
SW60 TiD rotor        Beckmann 
 
Tubes and plates 
CryoTubes        Nunc/Thermo Scientific 
reaction tube (0.5 ml, 1.5 ml, 2 ml)      Eppendorf 
reaction tube low bind (0.5 ml, 1 ml)      Eppendorf 
reaction tube (1.5 ml)       Sarstedt 
Maxisorp 96-wellplate       Nunc, Thermo Scientific 
Polysorp, 96-wellplate       Nunc, Thermo Scientific 
96-well PCR plate        KISKER, Biotec 
96-deepwell plate        Thermo Fisher Sientific 
96 well cell cultre plate       Becton Dickinson 
96 well microtiter plate       Thermo Fisher Sientific 
Cellstar Tissue Culture dishes 145x20 mm     Greiner Bio-one GmbH 
Cellstar Tissue Culture dishes 100x20 mm     Greiner Bio-one GmbH 
Multiwell 24 well Becton Dickinson  
Multiwell 6-well Becton Dickinson 
Falcon 15 ml 17x120 ml Becton Dickinson  
Falcon 50 ml 30x115 ml Becton Dickinson  
Reaction tube 12 ml       Greiner Bio-one GmbH 
Reaction tube 8 ml        Sarsted 
Open top Polyclear centrifuge tubes (26428)     Seton Sientific 
Open top Polyclear centrifuge tubes (25116)     Seton Sientific 
 
Pipettings 
pipette tip plugged (10 µl, 200 µl 1000µl)     Axym 
pipette tip unplugged (10 µl, 200 µl 1000µl)     Sarsted 
low-bind pipette tip (10 µl, 200 µl, 1000µl)     Sorenson 
Single-serving pipette (1 ml, 5 ml, 10 ml, 25 ml, 50 ml)    BD Bioscience 
 
Incubator 
Incubator (213)        Thermo Fisher Scientific 
Stericult 200 incubator        Forma Scientific 
HERATherm        Thermo Fisher Scientific 
Innova 44 Incubator Shaker Series      New Bruswick Scientific  
 
Immunofluorescence 
Microscope cover glasses 12 mm Ø      MAGV, Germany 
Microscope slide 76x26 mm       Menzel-Gläser 
 
Other equipment 
Picodrop Microliter UV/Vis spectrophotometer      Biozym 
Refractometer        Carl Zeiss 
Flexible-tube pump masterflex easyload model 7521-35 COLE-Parmer instrument CO 
Flexible-tube pump masterflex 45 easy load II, model 77201-60 COLE-Parmer instrument CO 
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Freedom Evo 100/4D       Tecan 
LightCycler 480 II        Roche 
Mastercycler gradient       Eppendorf 
ELISA-washer Hydroflex       Tecan 
ELISA-shaker ZLI 164       Amersham Bioscience 
EL808 microplate reader       BioTec 
TCS SP5 confocal microscope      Leica 
 
Software 
LAS AF         Leica 
Microsoft Office 2010 Excel       Microsoft 
Microsoft Office 2010 Word       Microsoft 
Microsoft Office 2010 PowerPoint      Microsoft 
SigmaPlot 8.0        Systat Software GmbH 
SPSS         IBM 
Picodrop software        Biozym 
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2.2. Methods 
2.2.1. Preparation of an RNA-Standard in vitro for HDV qPCR 
2.2.1.1. Amplification of one HDV Genome out of the Plasmid pSVLD3  
To absolutely quantify the viral RNA of HDV in a specific reverse transcription quantitative polymerase 
chain reaction (RT-qPCR) an RNA-standard had to be synthesized. Due to the fact that the HDV-genome 
was present three times in the plasmid pSVLD3, specific primers were synthesized (see 2.1.10.2) in order 
to amplify only one of the trimers of the plasmid. Therefore, a manual hot start PCR was performed in 
combination with a gradient PCR (58 °C–70 °C). Because of the fact that this DNA is then used in the T7 
High Yield RNA Synthesis Kit (NEB) to generate in vitro RNA for the HDV RT-qPCR, specific primers 
were used attaching the T7-promotor at the amplified HDV DNA.  
The plasmid pSVLD3 (560 ng/µl) was diluted 1:100 and 1:1000. 5 µl of each dilution were mixed with 
40 µl PCR mastermix (see 2.1.10.4). Twelve different gradient steps of both dilutions were used. The 
samples were incubated in the gradient cycler at 98 °C for 1 minute and then cooled down to 80 °C. Now 
5 µl of the polymerase mix were added (see 2.1.10.4) and PCR was continued with following steps: 
temperature time cycles 
98 °C 1 min 1 
98 °C 10 sec 35 
62 °C 30 sec 
72 °C 36 sec 
72 °C 10 min 1 
4 °C ∞ 1 
Thereafter a 0.9 % ethidium bromide (EtBr) gel was performed to examine if there were additional bands 
beneath the specific bands. Three fractions without additional bands of each dilution were pooled and 
DpnI digested. Therefore, 50 µl of the pooled PCR template were incubated with 1 µl DpnI and 10 µl 
Tango-Buffer at 37 °C for 1 h. Inactivation of the enzyme was done at 80 °C for 20 minutes. To isolate 
the PCR template, a methylene blue gel was done.  
 
2.2.1.2. Isolation and Purification of the PCR Templates 
To isolate and purify the PCR template, a methylene blue gel was performed. For this purpose, PCR 
templates were mixed with 6x loading dye, pipetted on a 0.9 % agarose gel without EtBr and unpicked at 
75 V. After running of the gel, it was stained with 0.02 % methylene blue solution (in H2O) for 
15 minutes under constant shaking. Following, the gel was washed with H2O under constant shaking until 
the gel was discoloured. Then, bands were cut out, transferred into two reaction tubes including 450 µl 
QG buffer and dissolved at 50 °C for 10 minutes under constant shaking.  
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DNA was purified out of the gel with the PCR purification Kit (Qiagen), eluted in 30 µl elution buffer 
and measured with the picodrop microlitre UV/V spectrophotometer (Biozym). 
 
2.2.1.3. Synthesis of RNA in vitro and Phenol/Chloroform Extraction 
The synthesis of RNA in vitro was done with the T7 High Yield RNA Synthesis Kit (NEB) as described 
in the manufacturer’s instructions. This kit was designed for in vitro transcription of RNA using the T7 
RNA polymerase. This polymerase is derived from the phage T7 and is extremely promoter-specific. The 
linearized and amplified DNA encoding the HDV genome and containing the T7 specific promotor was 
used as a template for in vitro transcription. Therefore, the T7 DNA-dependent RNA polymerase binds to 
its specific promotor and catalyzes the synthesis of RNA in 5`-3`direction. Then, the newly synthesized 
RNA can be purified and used as a standard for RT-qPCR.  
After linearization and amplification of HDV DNA encoding for the HDV genome containing the T7-
promotor 1 µg and 2 µg of purified PCR product was used to synthesize HDV-RNA. 
Amplified DNA was mixed as followed 
1µg or 2µg PCR product 
2 µl 10x Reaction Buffer 
2 µl ATP 
2 µl GTP 
2 µl UTP 
2 µl CTP 
2 µl T7 RNA Polymerase Mix 
add to 20 µl H2O 
RNA-synthesis mixture was incubated for 2 h at 37 °C.  
Subsequently a phenol/chloroform extraction was performed to purify the newly synthesized RNA. 20 µl 
reaction volume were filled up with 160 µl RNase free water to an end volume of 180 µl. Then 20 µl of 
3 M sodium acetate (pH 5.2) and 20 µl 5 M ammonium acetate were added and gently mixed by pipetting 
up and down. The following reaction steps were done under an extractor hood. After mixing, 200 µl 
phenol/chloroform (1:1) were added and mixed by gently pipetting up and down. After that, the reaction 
mixture was centrifuged at 14000 rpm for 5 minutes. The aqueous phase was taken off and transferred 
into a new reaction tube. 200 µl chloroform were added and mixed by gently pipetting up and down. Then 
the reaction mixture was centrifuged at 14000 rpm for 15 minutes. Aqueous phase was taken off again 
and transferred into a new reaction tube. This step was repeated once again. Afterwards 1000 µl 100 % 
Ethanol (EtOH) were added and the approach was incubated for 30 minutes at -20 °C. After another 
centrifugation step (14000 rpm, 15 minutes, 4 °C) the supernatant was gently removed and abolished. The 
pellet was eluted in 30 µl RNase and DNase free water. The RNA concentration was measured with the 
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picodrop microliter UV/Vis spectrophotometer (Biozym) and quality was checked with a formaldehyde 
gel.  
 
2.2.1.4. Formaldehyde Gel 
5 µl RNA probe were mixed with 5 µl RNA loading dye and loaded onto a 1 % formaldehyde gel. To 
produce a denaturating formaldehyde gel (endvolume 100 ml) 1 g agarose powder was added to 72 ml 
nuclease-free water and melted. Then 10 ml 10x MOPS buffer were added. Following steps were 
performed under an extractor hood. 18 ml formaldehyde (37 %) solution were added and mixed well. 
RNA was separated for 6 h at 30 V under an extraction hood. Finally, the formaldehyde gel was stained 
with EtBr and bands were visualized with UV-light. 
 
2.2.1.5 Calculation of Genome Equivalent 
Two different amounts (1 µg and 2 µg) of HDV-plasmid DNA were used to generate an RNA-standard 
for quantitative HDV PCR. After RNA synthesis the concentration of total RNA was measured. The 
RNA-concentration of both approaches was above 2 µg/µl. For further calculation of genome equivalents 
in the quantitative PCR, the amount of each single nucleotide in the HDV-RNA sequence was determined 
and the exact weight of the ss HDV-RNA was calculated. The total amount of RNA was then determined 
for each approach. Therafter, the calculated amount was multiplied with the Avogadro constant and the 
amount of substance was calculated to the total amount of genome equivalent per microliter (GE/µl). 
 
2.2.2. Preparation of Competent Bacteria for Transformation (″chemical method″) 
For the transformation of plasmid-DNA into the E.coli strain Stellar (component of the In-Fusion HD 
Cloning System, Clontech), competent bacteria were prepared. Therefore 4 ml LB-medium were 
inoculated with 20 µl of an existing bacteria suspension and incubated for 12-16 h at 37 °C. Then 2 ml of 
the overnight bacteria culture were transferred into 40 ml of fresh LB-medium and incubated at 37 °C 
until an optical density (OD) 550 of 0.45 was measured. After that, bacteria suspension was aliquoted into 
50 ml flasks and incubated on ice for 15 min. The following steps were performed on ice at 4 °C. The 
bacteria suspension was centrifuged at 2500 revolutions per minute (rpm) for 15 minutes at 4 °C. The 
pellets were gently resuspended in 2 ml ice cold TBF1. 14 ml of ice cold TBF1 were added and bacteria 
were incubated on ice for 15 minutes again. The centrifugation (2500 rpm, 15 minutes, 4 °C) was 
repeated, pellets were gently taken up in 1.6 ml precooled TBF2 and incubated on ice for another 
15 minutes. The bacteria suspension was aliquoted and stored at -70 °C. To test the competence of the 
bacteria, a control transformation with a control plasmid was performed.  
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2.2.3. Transformation 
2.2.3.1. Transformation of Plasmid-DNA into E.coli 
The transformation of plasmid-DNA into E.coli was performed on ice. Competent bacteria were 
incubated for 5 minutes in a precooled reaction tube, then 50 µl bacteria were added to 2 µl (approx. 
20 ng) plasmid-DNA and incubated for 20 minutes. Afterwards, the bacteria were exposed to a heat-
shock (42 °C) for 45-50 sec and subsequently incubated on ice for 2 minutes. Then 950 µl of LB-medium 
were added to each tube. Bacteria were transferred to an Erlenmeyer flask and incubated at 37 °C on a 
shaker for 1 hour. 20 µl of each transformation culture were exposed on LB-agar-plates containing an 
adequate amount of antibiotics and incubated over night at 37 °C. A single colony was picked with a 
sterile pipette tip and cultivated over night at 37 °C in an Erlenmeyer flask with 40 ml LB-medium and 
ampicillin (final concentration: 50 µg/ml) on a shaker at 180-200 rpm. 
 
2.2.3.2. Plasmid-Preparation with the Plasmid-Plus-Midi-Kit (Qiagen) 
The plasmid preparation was performed with the Plasmid-Plus-Midi-Kit (Qiagen) according to the 
manufacturer`s recommendations.  
The isolated plasmid DNA was eluted from the column using DNase and Rnase free H2O. To define the 
plasmid-DNA concentration, the Picodrop Microliter spectrophotometer was used. The results were 
converted into µg/µl according to a standard DNA-curve. 
 
2.2.4. Cultivation of Immortalized Cell Lines 
2.2.4.1. Freezing and Thawing of Eukaryotic Cell Lines 
For freezing, cells were trypsinized from 10 cm cell culture plates, resuspended in DMEM 5 % FCS, and 
then centrifuged by 1500 rpm for 10 minutes in a cooled table top centrifuge. After centrifugation, the cell 
pellet was carefully resuspended in 1.5 ml freezing medium. The cells were incubated on ice for 
10 minutes. Afterwards, another 1.5 ml freezing medium were added. Then the cell-suspension was 
aliquoted in 1 ml freezing tubes, frozen at -70 °C overnight and stored in the gas phase (-178 °C) of a 
liquid nitrogen tank the other day.  
To thaw immortal cell lines, the freezing tubes were warmed in a water bath at 37 °C. Then, the cell-
suspension was mixed with 10 ml DMEM 10 % FCS and then carefully transferred to a 15 ml falcon 
tube. The cell-suspension was centrifuged at 200 g for 3 minutes. Then the cell pellet was resuspended 
with 10 ml DMEM 10 % FCS. The cells were sown on 10 cm cell-culture plates and incubated at 37 °C, 
5 % CO2. 
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2.2.4.2. Passaging of Immortalized Cell Lines 
Huh7, AML12 and HepG2 cells were cultivated in 5 % FCS/DMEM and regularly splitted before 
reaching a confluent stage. Cells were incubated into an incubator at 37 °C, 96 % humidity, 7 % CO2. 
Before passaging HepG2 cells, cell culture plates were coated with collagen type I. For this purpose 5 ml 
of a collagen Type I solution (0.2 mg/ml) were layered on the cell culture plate. Collagen solution was 
distributed by gently swinging and then removed from the plate. 
 
2.2.5. Phenotypic Resistance Assay for Characterization of Patient Isolates 
The phenotypic resistance assay was established in the working group of D. Glebe at the Institute of 
Medical Virology by A. Geipel (2011), and further modified by H. Niekamp (2013) and performed in this 
thesis after following protocols. 
 
2.2.5.1. Transfection 
Huh7 Munich cells were sown in a ratio 1:3 on 10 cm cell culture dishes in DMEM 5 % FCS. After 
reaching a confluency of 80 %, cells were transfected with plasmid-DNA using the transfection reagent 
FuGene HD (Promega) in a ratio of 4:1 (FuGene (µl):plasmid-DNA (µg)). A total amount of 8 µg 
plasmid-DNA (7 µg plasmid-DNA, 1 µg pSEAP2control-plasmid) and 32 µl FuGene HD transfection 
reagent were transfected. The transfection mixture was pipetted in DMEM without FCS, vortexed well 
and incubated at RT for 15 minutes. In the meantime, the medium was removed and the cells were 
washed 1x with 5 ml PBS++. 10 ml of fresh and preheated DMEM 2 % FCS were added to the cells. 
After the incubation time, the transfection mixture was added and cells were incubated over night at 
37 °C. The replication efficiency of the transfected HBV in the presence of nucleos(t)ide analogs was 
tested by a phenotypic assay (see 2.2.5.2). 
For transfection of HBV variants with stop mutations in the S-ORF, cells were sown 1:2 on 10 cm plates 
and transfection was performed as described before. Then, the supernatant was analyzed for secreted 
HBV virions and subviral particles by an ELISA (enzyme linked immunosorbent assay), qPCR or 
caesium chloride (CsCl)-gradient. 
For transfection of HDV-genome in combination with differently mutated surface proteins of HBV, 3 µg 
pSVLD3, 4 µg plasmids encoding LHBs-expressing HBV-constructs, and 1 µg pSEAP2control were 
incubated on Huh7 cells over night. After washing as described in 2.2.5, cells were cultivated on 24 cm 
cell culture dishes for the following 12 days with DMEM without FCS. The supernatant of day 2, 4, 6, 9 
and 12 after transfection were analyzed for HDV-genomes. A SEAP-assay was performed at day 3 after 
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transfection to calculate the transfection efficiency (see 2.2.5.3). Cell viability was tested by WST-1 test 
(see 2.2.6).  
 
2.2.5.2. Phenotypic Assay 
Four nucleos(t)ide analogs were diluted in 2 % FCS/DMEM without phenolred. 100 µl of each dilution 
were provided on a 96 cell cell culture plate depicted in Table 1. Each nucleos(t)ide analog was prepared 
with six different dilutions and six not inhibited wells (without any nucleos(t)ide analogs). These samples 
were prepared three times (Table 1). For every analyzed plasmid, 96 data points could be produced. The 
HBV wild type plasmid pCH9-3091 was additionally transfected and served as control for the replication 
capacity of the tested patient isolates.  
Table 1 Schematic overview of pipetted nucleos(t)ide analogs with different concentrations.  
 Adefovir Entecavir Lamivudine Tenofovir 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 200 µM 2000 nM 200 µM 200 µM 
B 40 µM 400 nM 40 µM 40 µM 
C 8 µM 80 nM 8 µM 8 µM 
D 1.6 µM 16 nM 1.6 µM 1.6 µM 
E 0.32 µM 3.2 nM 0.32 µM 0.32 µM 
F 0.064 µM 0.64 nM 0.064 µM 0.064 µM 
G  
no inhibitor 
 
no inhibitor  
 
no inhibitor  
 
no inhibitor  H 
 
 
Therefore, transfected cells were washed 1x with 10 ml PBS and 5 ml of trypsin/PBS (1:5) were added 
and trypsinized at 37 °C. The cells were gently resuspended and carefully transferred into 50 ml falcon 
tubes including 20 ml preheated DMEM 2 % FCS. The cells were centrifuged at 60 g for 6 minutes (first 
washing step). Afterwards the supernatant was decanted and resuspension and centrifugation steps were 
repeated two more times. After the second washing step the resuspended cells were transferred into a new 
50 ml falcon tube. Finally, the cell pellet was gently resuspended in 20 ml preheated 2 % FCS/DMEM 
(without phenolred). 100 µl of each transfection sample were added to a single well of a 96-well cell 
culture plate prepared with six different dilutions of four nucleos(t)ide analogs. Cell culture plates were 
incubated for three days at 37 °C. Then, the supernatant was removed and transferred into a new 96-well 
plate to isolate the viral DNA using the automated pipette robot Freedom Evo (Tecan) (see 2.2.8).  
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2.2.5.3. Calculation of Transfection-Efficiency by Secreted Alkaline Phosphatase- (SEAP-) 
Detection Assay 
Detection of secreted alkaline phosphatase assay was used to calculate the transfection efficiency. 
Therefore, 50 µl supernatant (eight-fold samples) of cells that were not inhibited with any nucleos(t)ide 
analog were transferred to a 96-well plate and the endogenous phosphatase was inactivated at 65 °C for 
30 minutes. Due to the fact that the secreted alkaline phosphatase is heat-resistant, this enzyme is not 
inactivated during this inactivation-process. Afterwards, 100 µl 2x SEAP-buffer and 50 µl SEAP-
substrate were added to each well. The optical density (OD) was measured at a wavelength of 450 nm in 
an ELISA-reader when the first standard reached an OD of 1.0. To calculate the transfection efficiency in 
%, an internal SEAP-standard was used. For this purpose, the supernatant of pSEAP2-control transfected 
cells served as a positive control and was diluted in a 1:2 dilution series. The supernatant of untransfected 
cells served as a negative control. The mean value of eight-fold samples was calculated and compared to 
the signal of the internal SEAP-standard. The values that were obtained were calculated to the 
transfection efficiency in %. 
 
2.2.5.4. Statistical Analysis of the Data from Phenotypic Resistance Assay in vitro 
Newly synthesized viral genome equivalents, measured in the supernatant of Huh7 cells transiently 
transfected with HBV-expressing plasmids, were converted to relative numbers. Therefore, the mean 
value of all non-inhibited numbers was calculated and determined as 100 %. The data were analyzed 
using a non-linear regression model with three parameters to calculate the IC50 and IC90 values and based 
on that, the resistance factors 50 (RF50) and RF90 were calculated (Figure 7 A). The IC50 indicates the half 
of maximum of viral replication at a given concentration of the inhibitor. The IC90 indicates the inhibition 
by 90 % of a tested inhibitor on viral replication. The resistance factors indicate the differences of the IC 
from wild type to the tested mutant (Figure 7 B). For calculation of resistance factor, consensus curves of 
the tested wild types were generated and used. 
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Figure 7: A) Regression model for calculation of IC50 and IC90. Figure shows replication (%, Y-axis) depending on used 
concentration of inhibitor (logarithmic scaling, X-axis). Inhibition curves are indicated with sigmoid functions in the upper right 
area. The amplitude is presented as a and indicates the difference between no and maximum inhibition. The parameter b defines 
the gradient of the curve (difference of the X-axis between the x-values with corresponding y-values of 1/6 a and 5/6 a). The 
parameter x0 defines the inflection point (y=1/2). B) Calculation of IC50 and IC90 as well as resistance factor 50 and 90 (RF50, 
RF90). Figure shows replication (%, Y-axis) depending on used concentration of inhibitor (logarithmic scaling, X-axis). The IC50 
indicates the inhibition by half of a particular substance on the viral replication. The IC90 indicates the inhibition by 90 % of a 
tested inhibitor on viral replication. The RF50 and RF90 indicate the differences of the IC from wild type to the tested mutant. 
Figures were kindly provided and modified by H. Niekamp (Niekamp 2013 in press) and Dr. A. Geipel (poster presented at 
International Meeting on Molecular Biology of Hepatitis B Virus, Oxford, UK, 2012).  
The significance of the IC differences of the tested mutants compared to the wild type was statistically 
analyzed with an univariate ANOVA (analysis of variants). For ANOVA, concentrations of tested 
inhibitors with no inhibitory effects on the wild type were not considered. If many data records were 
compared to the consensus wild type curves, the α-niveau after Bonferroni (Köhler et al. 2007) was 
adjusted. The resistance limits were indicated in the results.  
2.2.6. Cell Viability Test with WST-1 (Roche) 
The viability test was done after manufactur`s recommendations. 5 ml of a 1:50 dilution of WST-1 
reagent (water soluble tetrazolium salt) diluted in 2 % FCS/DMEM without phenolred was pipetted onto 
the cells and incubated for 30 minutes at 37 °C. 100 µl of each supernatant were transferred into a 96 well 
microtiter plate. Extinction of the colored substrate was measured by a photometer at a wave length of 
450 nm (reference wavelength: 620 nm).  
The WST-1 reagent is a colorimetric assay that allows the measurement of the relative amount of cell 
proliferation in cell culture. It includes soluble tetrazolium salt which is cleaved into formazan by cellular 
enzymes. For a long time, the reduction of the tetrazolium salt into formazan was attributed to the 
mitochondrial succinate-dehydrogenase and was therefore an indicator of an active cell redox activity. 
Recent studies show that this reduction process is largely more dependent on other enzymes in different 
cellular compartments, for example in the cytoplasm and in the regions of plasma membranes (Bernas 
and Dobrucki 2002). Nevertheless, the amount of reduced tetrazolium salt correlates to the number of 
metabolically active cells and is manifested in a color change from light red into yellow. 
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2.2.7. Isolation of Viral Genomes from Supernatant, Plasma, or Cell Lysates 
For quantification of viral nucleic acid by qRT-PCR the viral RNA or DNA has to be purified from serum 
or out of infected cells. Therefore different commercial kits were used.  
 
2.2.7.1. Isolation of Intracellular Viral RNA and DNA 
12 to 15 days after infection of PTHs with HBV or HDV, the intracellular RNA was purified with the 
Nucleo Spin RNAII Kit (Macherey-Nagel) after manufactor`s instructions. Isolated RNA was dissolved 
in 60 µl elution buffer and frozen at -70 °C.  
 
2.2.7.2. Manual Isolation of Viral RNA and DNA in the Supernatant or in Serum 
Viral RNA or DNA from serum, plasma or supernatant was purified by using the High Pure Viral Nucleic 
Acid Kit (Roche). Purification procedure was performed after manufactor`s recommendations with 
following modifications: the lysis was stopped by adding 100 µl of isopropanol after incubation at 72 °C 
for 10 minutes. Purified DNA or RNA was eluted in 50 µl elution buffer. 
 
2.2.7.3. Automated Isolation of viral DNA in the Supernatant with Freedom EVO  
To isolate the viral DNA from the supernatant of transiently transfected cells for the phenotypic 
characterization, the automatic pipette robot Freedom EVO 100/4D (Tecan) was used in combination 
with the Sample Preparation System DNA Kit (Abbott). Used buffers were adjusted to the volume of the 
probe and a pipetting protocol was established for the automatic pipette robot.  
Lysing the supernatant was done by mixing 100 µl supernatant from transiently transfected cells with 
120 µl lysis buffer (70 µl H2O, 40 µl lysis buffer, 10 µl external proteinase K (Abbott)). After incubation 
(58 °C, 15 minutes), additional 300 µl lysis buffer and 20 µl magnetic beads were added and incubated 
once again. Purified DNA binds to the magnetic beads. By the use of a magnet, the beads were pulled to 
the wall of the reaction tube and the supernatant could be removed. 300 µl of washing buffer (Wash1) 
were added and the DNA was incubated at 58 °C for 2 minutes. Supernatant was removed and the beads 
with bound DNA were washed twice with washing buffer (300 µl, Wash2). To eliminate remaining 
ethanol, magnetic beads were incubated at 80 °C for 15 minutes. Separation and elution of the DNA from 
magnetic beads was done by adding 100 µl H2O and incubation at 80 °C for 8 minutes. 
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2.2.8. qPCR  
2.2.8.1. SYBR-Green Based qPCR 
For the detection of HBV-DNA in the supernatant of cell culture the HOPE-PCR was performed with 
SYBR Green as the detection dye. Concerning the HOPE-project, the quantitative HOPE-PCR was 
established (Geipel 2011) that is able to discriminate between plasmid-DNA and the relaxed circular 
HBV DNA. The specific HOPE-primers are deliberately chosen to bind preferentially to regions of the 
newly synthesized viral genomes amplifying a 300 bp fragment. The binding of the specific HOPE-
primers on the plasmid-DNA would lead to the amplification of a longer PCR fragment. Due to the fact 
that the elongation time is optimized for the shorter fragments (300 bp), the amplification of the plasmid-
DNA is about 1000-fold less efficient than the amplification of the newly synthesized, relaxed circular 
HBV DNA (Geipel 2011). Purified HBV DNA from Huh7 cells transiently transfected with the HBV wt 
plasmid served as a standard for absolute quantification. Therefore, Huh7 cells were transfected with the 
HBV wt plasmid pCH9-3091 (see 2.2.5.1) and incubated for three days without any inhibitor. Then, the 
supernatant was purified (see 2.2.7.2) and HBV genome equivalents were calculated with the help of the 
WHO-standard. 
Before running the PCR, 10 µl of the mastermix were pipetted into the well of a 96-well plate. 10 µl 
template DNA were also added and the HOPE-PCR was performed (Table 2) in a 96- well LightCycler 
480 II (Roche). 
Table 2: Light Cycler program for HOPE-PCR 
 activation amplification melting curve cooling 
cycles 1 40 1 1 
target 
temperature (°C) 
95 95 60 72 95 60 95 40 
measurement    single   continuously  
time 15 min 15 sec 10 sec 20 sec 10 sec 15 sec  30 sec 
step size 
(°C/min) 
      6  
acquisition mode  quantification     
 
2.2.8.2. TaqMan Probe Based qPCRs 
For X-PCR and HDV-PCR, specific TaqMan-probes were used as the detection dye (Heid et al. 1996).  
2.2.8.2.1. X-PCR  
The detection of HDV DNA using the X-PCR was performed after Jursch et al. (2002). This PCR is very 
sensitive and highly specific because the used primers and probes recognize a highly conserved region in 
the X-ORF of the viral genome.  
To perform the X-PCR, 10 µl of mastermix (see 2.1.10.5) were mixed with 10 µl purified DNA. PCR was 
performed as described in Table 3 in a 96- well Light Cycler 480 II (Roche). For absolute quantification, 
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HBV DNA, purified from human serum of a chronically infected HBV patient with a certain 
concentration of HBV DNA, was used. 
Table 3: Light Cycler Program for X-PCR 
 
2.2.8.2.2. HDV RT-qPCR  
For the detection of HDV RNA, primers were used that recognize highly conserved regions at the C-
terminus of the small hepatitis delta antigen. For HDV RT-qPCR 5 µl purified RNA in solution were 
pipetted into each well of a 96-well PCR plate. The probes were incubated for 1 minute at 95 °C in the 
Light Cycler to denature secondary structures of the RNA. Afterwards, 20 µl of mastermix (see 2.1.10.5) 
were added and the PCR was performed as described in Table 4. Plasmid contaminations were removed 
by DNase-digestion before HDV RT-qPCR. Therefore 1 µl DNase I (RNase free, protease free), 0.2 µl 
H2O and 0.8 µl 10x Reaction Buffer with MgCl2 were mixed. 2 µl of the DNase mastermix were mixed 
with 5 µl purified RNA and incubated for 1 h at 37 °C. To inactivate the DNase I the probes were 
incubated for 5 minutes at 95 °C. After cooling down, the RT-qPCR mastermix was added. For absolute 
quantification, an in vitro generated full length genomic HDV RNA standard was used (see 2.2.1). 
Table 4: Light Cycler Program for HDV-PCR 
 reverse transcription activation amplification cooling 
cycles 1 1 40 1 
target temperature [°C] 50 95 95 60 72 40 
measurement none none none none single none 
time 15 min 15 min 15 sec 30 sec 15 sec 30 sec 
ramp rate (°C/s) 4.4 4.4 4.4 2.2 4.4 4.4 
temperature  
(-1°C per cycle) 
   50   
step size (°C/min)    1   
step delay (cycles)    1   
acquisition mode   quantification  
 
2.2.9. Preparation of a Sucrose Gradient for Isolation and Purification of HBV 
and HDV 
The isolation and purification of HBV and HDV from serum or plasma of chronically infected patients 
was done with a continuous sucrose gradient as described previously (Glebe et al. 2003, Glebe and 
Gerlich 2004). Plasma or serum of chronically infected patients was centrifuged at 3000 rpm for 15 min 
to purify the plasma or serum from larger aggregated particles. 30 ml of the purified plasma or serum 
were layered on a sucrose cushion consisting of 6 ml 15 % sucrose/TNE (w/w) and 2 ml of 10 % 
 activation amplification cooling 
cycles 1 45 1 
target temperature (°C) 95 95 62 72 40 
measurement none none single none none 
time 15 min 10 sec 15sec 13 sec 30 sec 
temperature (-1°C per cycle)   50 sec   
step size (°C/min)   1   
acquisition mode  quantification  
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sucrose/TNE (w/w) and centrifuged at 25.000 rpm, 16 hours at 10 °C in a SW28.38 rotor in the LE 80 
ultracentrifuge (Beckmann, water cooled). After centrifugation the supernatant was decanted and the 
pellet, containing virus and subviral particles was dissolved in 1 ml cold TNE and layered on a 
discontinuous sucrose density gradient (3 ml 60 %, 4 ml 45 %, 4 ml 35 %, 5 ml 25 %, 5 ml 15 % sucrose 
dissolved in TNE (w/w)). The sucrose gradient was centrifuged at 25.000 rpm, 15 hours at 10 °C and then 
fractionated from the bottom to the top. Protein concentration was measured with the picodrop microlitre 
spectrophotometer (Biozym) and density was measured via refractrometry. 20 µl of each fraction were 
purified for the qPCR. HBV DNA was detected with the HBV X-PCR and HDV RNA was detected with 
the HDV RT-qPCR. The concentration of virions was calculated as genome equivalent per ml (GE/ml).  
 
2.2.10. Preparation of a Linear Caesium-Chloride (CsCl)-Gradient 
To analyze viral particles, a linear caesium chloride (CsCl)-gradient was performed (Gerlich et al. 2010; 
Bremer et al. 2009b). In a total volume of 1 ml, plasma or cell culture supernatant was treated with or 
without Nonident P-40 (NP40) (1 % final concentration (f.c.)) and TCEP (50 mM f.c.) for 1 h at room 
temperature. In the meantime 1.7 ml of 24 % CsCl (density: 1.21 g/ml) and 1.42 ml of a 42 % CsCl 
(density: 1.45 g/ml) dissolved in TNE (w/w) were mixed using a gradient-mixer to make a linear gradient. 
After the incubation, the treated or untreated samples were gently layered on the CsCl-gradient and 
centrifuged at 37.000 rpm, 18 hours at 10 °C a SW60 TiD rotor in the LE 80 ultracentrifuge (Beckmann, 
water-cooled). Afterwards the gradient was fractionated from the bottom to the top in 300 µl aliquots with 
a peristaltic pump. In each fraction the density of CsCl was measured by refractometry. For the detection 
of viral DNA or RNA, 200 µl of each fraction were purified with the High Pure Viral Nucleic Acid Kit 
(Roche) (see 2.2.7.2). Then a qPCR for HBV or a RT-qPCR for HDV was performed.  
 
2.2.11. Isolation and Cultivation of Primary Tupaia Hepatocytes (PTHs) 
Primary hepatocytes from the Asian tree shrew Tupaia belangeri were freshly isolated and cultivated to 
perform infection assays with HBV and HDV purified from serum, plasma or cell culture supernatant. 
The isolation was carried out according to a modified two-step-collagenase method first described by 
Seglen et al, (1976). After isolation, cells were cultivated in modified hepatocytes growth medium as 
described by Glebe et al (2003).  
In brief, the liver of a 2-4 year old tupaia was prepared and perfused via the portal vein with first 5 mM 
EGTA/HBSS (20 minutes) following 5 mM EGTA free HBSS (10 minutes). After that, the liver was 
incubated in a recirculation system with preheated (37 °C) sterile filtrated collagenase solution 
(20 minutes) until the liver capsules became porous. After washing and pelleting the cells (3 times, 4 °C, 
40x g, 6 minutes), they were gently resuspended in 40 ml ice-cold hepatocytes growth medium including 
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10 % FCS and collagen-coated 24-well cell culture plate with or without cover slips. After an incubation 
time of 4 h (37 °C, 5 % CO2), plating medium was removed and switched to FCS free HGM (500 µl).  
 
2.2.12. Infection of PTHs with HBV and HDV  
If not described differently, three days after isolation, PTHs were infected with purified HBV or HDV. 
Virus fractions were thawed and kept on ice. For infection, PTHs were washed once with 500 µl 
preheated hepatocytes growth medium containing caspofungine (5 µg/µl f.c.). Hepatocyte growth 
medium for infection contains a final concentration of 5 µg/µl caspofungine, 4 % PEG 8000, and 1x108 
GE (0.2 µl) purified HBV or 1x107 GE (0.6 µl) purified HDV. To inhibit the infection with HBV or 
HDV, cells were preincubated with myr preS1 peptide (1 µM f.c.) for 30 minutes. PTHs were infected 
with a total volume of 300 µl infection medium for 16 h at 37 °C. Then, the inoculum was removed and 
cells were washed two times with 500 µl preheated hepatocytes growth medium/caspofungine. Cells were 
incubated and cultivated with 500 µl fresh hepatocytes growth medium/caspofungine for the following 12 
(for HDV) to 15 (for HBV) days. Supernatants of day 4, 7, 11, and 15 of HBV infected cells were 
analyzed by ELISA. HDV infected cells were lysed on day 12 after infection with Nucleo Spin RNAII 
Kit from Macherey-Nagel (see 2.2.7.1). 
 
2.2.13. ELISA against Secreted HBV Surface Proteins 
Secreted subviral particles and uncoated capsids were detected with a sandwich-ELISA against the LHBs 
(1 µg/ml MA18/7), MHBs (2 µg/ml Q19/10), and SHBs (1 µg/ml C20/02), or HBc (20 µg/ml DAKO, 
1:20.000 Gö-Schaf). A 96-well microtiter plate was coated with 100 µl of the respective capture 
antibodies listed above and diluted in coating buffer for 24 h at 4 °C. For washing of the microtiter plates, 
an automated ELISA-washer (TECAN) was used. The washing program included four washing steps (2 x 
0.1 % Tween20/PBS and 2 x PBS, 300 µl per well). Afterwards, the wells were blocked with 200 µl of 
10 % FCS/TNE for 2 h at room temperature. After washing, 100 µl of cell culture supernatant or 
supernatant from infected PTHs were incubated over night at 4 °C. For quantification, an HBsAg-
standard (ID1) was used; diluted 1:2 in 1 % Casein/PBS (10-0.3 ng/ml HBsAg). On the next day the 
washing steps were repeated and 100 µl of the detection antibody (anti-HBs biotin conjugate Enzygnost 
HBsAg 6.0, 1:40 diluted in 0.1 % Casein/PBS) were incubated on a shaker for 1 h at room temperature. 
After washing, streptavidin-POD (diluted 1:500 in 0.1 % Casein/PBS) was added and incubated on a 
shaker for another 30 minutes. Wells were incubated on a shaker with 100 µl of OPD-ELISA-substrate 
(for MA18/7-, C20/02- and core-ELISA) or TMB Xtra Ready-to-use-substrate (for Q19/10-ELISA) in the 
dark for 5-15 minutes. The reaction was stopped with 50 µl 0.5 M sulphuric acid. If the OPD-ELISA-
substrate was used, extinction of the colored substrate was measured photometrically at 492 nm 
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(reference-wavelength: 620 nm). If the TMB Xtra Ready-to-use-substrate was used, extinction of the 
colored substrate was measured photometrically at a wave length of 450 nm. 
 
2.2.14. UREA-Assay 
Urea production and secretion of primary hepatocytes can be used to determine their cell viability. 
Therefore 100 µl of the supernatant of infected PTHs were pipetted into a 96 microtiter plate. 75 µl o-
phtalaldehyde and 75 µl napthylethylendiamine-reagent were added. After an incubation of 5-15 minutes 
in the dark at room temperature, reaction was measured photometrically at 492 nm (reference-
wavelength: 620 nm). To calculate the secreted amount of urea, an urea-standard was pipetted (25 mM–
0.3 mM urea, 1:2 diluted). The measured amount of secreted urea was allocated with the detected amount 
of HBsAg or HDV-RNA.  
 
2.2.15. Staining for Immunofluorescence 
After fixation, cells on cover slips were permeabilized with 0.2 % TritonX 100/PBS at RT for 30 minutes. 
Afterwards, the cover slips were washed with PBS and blocked with 10 % FCS/DMEM without 
phenolred for 30 minutes. The cells were incubated with a monoclonal primary antibody against the HBV 
surface antigens (5 µg/ml C20/02, 5 µg/ml MA18/7, 10 µg/ml Q19/10) and the HBV capsid (50 µg/ml 
anti HBc, DAKO) for 1.5 hour at 37 °C. After incubation, the cover slips were washed five times with 1x 
PBS and stained with a secondary antibody either anti-mouse-Alexa-594 (10 µg/ml) or anti-rabbit-Alexa-
488 (10 µg/ml) respectively, at 37 °C for 30 minutes. Then the washing steps were repeated and finally 
nuclei were stained with DAPI (2.5 µg/ml) at RT for 10 minutes. Afterwards, the cover slips were washed 
again and embedded on microscope slides using moviol.  
All samples were analyzed with the TCS SP5 confocal microscope (Leica). 
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3. Results 
3.1. Phenotypic Characterization of Isolates from Chronically Infected HBV-
Patients  
The long-term treatment of chronically HBV-infected patients with nucleoside- and nucleotide analogs 
often leads to the selection of resistance mutants in the gene of the viral polymerase (Zoulim and 
Locarnini 2009). For phenotypic characterization of isolates from chronically infected HBV-patients, an 
in vitro phenotypic resistance assay was established at the Institute of Medical Virology at the University 
of Gießen (AG Glebe) in collaboration with the Institute of Virology at the University of Munich (AG 
Protzer), to test the sensitivity of resistance mutations against the four commonly used nucleoside and 
nucleotide analogs in clinical practice (Geipel 2011). To continue this work, phenotypic characterization 
of five patient isolates from chronically infected HBV-patients possessing characteristic HBV surface 
protein variants was done. The results are shown in Table 5. The corresponding resistance profiles can be 
found in the appendix, Figure 31-35. 
Table 5: Results of the phenotypic resistance test of five patient isolates against four clinical used nucleos(t)ide analogs 
adefovir (ADV), tenofovir (TDV), entecavir (ETV) and lamivudine (LMV). Five isolates from chronically infected HBV-
patients were analyzed with the phenotypic resistance assay to characterize their resistance profiles against four clinically used 
nucleos(t)ide analogs. Relevant mutations for resistance are indicated within the rt-domain. Mutations in the rt-domain and the s-
domain of the viral polymerase as well as genotype (gt) of each isolate are noted. No resistance is marked in green, intermediate 
resistance is marked in orange and full resistance is marked in red. The viral fitness describes the replication capacity of the 
patient isolate and was calculated relative to the replication capacity to the wild type and is presented in %. The resistance factors 
RF50 and RF90, the correlation of tested mutant to wild type (R2), as well as the significance (sign) are indicated. The α-niveau 
was adjusted after Bonferroni (Köhler et al. 2007) with following limits of significance: non-significant (ns) ≙ p > 0.01, 
significant (*) ≙ p < 0.01 
isolate mutation gt  ADV TDV ETV LMV viral 
fitness [%] rt-domain s-domain  
wt     
D 
RF50 1 1 1 1 100 
RF90 1 1 1 1 
sign --- ---- ---- ---- 
R2 0.97 0.99 0.99 0.99 
KW 6a-6 V191I W182*  
D 
RF50 --- 1.3 10.3 1.3 247 
RF90 --- 0.9 10.3 0.9 
sign * * * ns 
R2 0.99 0.89 0.95 0.96 
KW 11a-1 L164M 
I266R 
S143L, 
L175S, 
L216* 
 
D 
RF50 --- 1.1 7.2 652.5 25 
 RF90 0.3 1.2 24.4 134.8 
sign * ns * * 
R2 0.86 0.99 0.89 0.35 
KW 14-8 M204I 
 
W196S  
A 
RF50 1.0 2.1 134.9 >1000 37 
 RF90 0.7 2 >1000 >1000 
sign Ns * * * 
R2 0.98 0.91 0.87 0.03 
RK-172-2 L180M 
M204V 
I195M 
L209V 
 
A 
RF50 2.0 2.3 52.09 >1000 19 
RF90 1.9 2.5 660.53 >1000 
sign * * * * 
R2 0.99 0.99 0.91 0.75 
RK 172-4 A181T 
M204V 
W172*  
A 
RF50 2.0 3.1 2.7 653 2 
RF90 1.54 7.3 12.5 >1000 
sign * * * * 
R2 0.99 0.97 0.99 0.94 
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In the phenotypic resistance assay, an intermediate resistance to the drug ETV could be detected for this 
isolate (Table 5, KW 6a-6, appendix Figure 31). Due to the strong overlap of the open reading frame of 
the relaxed circular HBV genome, mutations in the ORF of the viral polymerase directly affect the ORF 
of the viral surface proteins (Figure 8 A, page 45). Patient isolate KW 6a-6 showed the mutation rtV191I, 
which leads to a stop mutation at position 182 in the SHBs (sW182*). 
The stop mutation at position 216 in the SHBs (sL216*) was observed in patient isolate KW 11a-1. 
Phenotypic analysis of this clone showed a resistance to LMV and a weak resistance to ETV, a resistance 
to ADV or TDV could not be detected (Table 5, KW 11a-1, appendix Figure 32).  
A long-term treatment with the nucleoside analogue LMV is known to induce the primary mutation 
rtM204I, as shown in the patient isolate KW 14-8. The mutation rtM204I leads to the amino acid change 
from tryptophan to serine in the SHBs (sW196S) (Figure 8 B). The isolate KW 14-8 demonstrated a 
strong resistance to LMV and ETV. It also showed a weak resistance to TDV. A resistance to ADV was 
not observed (Table 5, KW 14-8, appendix Figure 33).  
The isolate RK 172-2 had the mutations L180M and M204V in the rt-domain, which also leads to the 
changes I195M and L209V in the viral S-ORF. The consequences of these mutations for the SHBs are 
unknown. A strong resistance to LMV and ETV could be observed in the phenotypic assay. These 
mutation patterns also showed a weak resistance to TDV and ADV (Table 5, RK 172-2, appendix Figure 
34).  
The amino acid change from alanine (A) to threonine (T) or valine (V) at position 181 of the rt-domain 
induces a stop mutation at position 172 of the SHBs (Figure 8 A, page 45). Sequence analysis of the 
isolate RK 172-4 showed the mutation rtV181T with the additional mutation rtM204V. The data from 
phenotypic resistance assay demonstrated a strong resistance to LMV but only an intermediate resistance 
to ADV. Surprisingly, a weak resistance to ETV and TDV could also be observed (Table 5, RK 172-4, 
appendix Figure 35).  
 
The phenotypic characterization of five tested isolates, derived from chronically infected HBV patients, 
showed typical resistance patterns for all four common nucleos(t)ide analogs. In most of the cases, the 
viral fitness of the tested patient isolates was strongly decreased compared to the viral fitness of the 
wildtype.  
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3.2. Characterization of Known HBsAg-Mutations During Antiviral Therapy of 
Chronic Hepatitis B 
During long-term antiviral therapy with nucleos(t)ide analogs, mutations in the catalytic subdomain of the 
viral polymerase arise. Due to the strong overlapping open reading structure of the HBV genome, 
mutations in this domain lead to mutations in the internal loop in the SHBs between transmembrane II 
and IV (Zoulim and Locarnini 2009) (Figure 8). Some mutations in the viral surface proteins are known 
to induce altered infectivity or virion secretion (Warner and Locarnini 2008). In this work, the 
consequences of mutations in the viral surface proteins especially in the SHBs on the viral life cycle 
should be analyzed in more detail, because it is known from the literature that the SHBs is crucial for 
viral assembly and secretion (Bruss 1997). 
 
3.2.1. Secretion of Enveloped Virions and Subviral Particles 
To analyze if mutations in the internal loop of the SHBs influence the secretion of virions and subviral 
particles, single mutations (stop mutations or amino acid changes, see Figure 8) were inserted into the 
HBV full genome wild type plasmid pCH9-3091 via site directed mutagenesis by Dr. Maria Neumann-
Fraune (Uniklinikum Köln), and kindly provided by her for this thesis. With the help of these plasmids, 
these HBV surface portein mutants should be analzyed in terms of their ability to secrete virions and 
subviral particles. To do so, Huh7 cells were transiently transfected with HBV expression plasmids 
encoding HBV full genomes with mutations in the SHBs depicted in Figure 8.  
  
Figure 8: Overview of the generated HBV surface protein variants. Generated HBV surface protein variants in the HBV S-
ORF with the corresponding mutations in the P-ORF and nucleic acid changes in the viral DNA. Nucleotide changes were 
introduced via site-directed mutagenesis. Viral DNA is depicted as a black dotted line. Nucleotide changes in the viral DNA are 
highlighted in light-blue. Typical amino acid changes that resulted from the nucleotide change in the P-ORF (green bar) and 
stop mutations and/or amino acid changes in the S-ORF (red bar) are highlighted in dark-blue. A) Generated nucleotide changes 
in the viral DNA causing stop mutations in the S-ORF at position W172, L176, W182*, W196*, W199, and L216. B) Generated 
nucleotide changes in the viral DNA causing amino acid changes in the S-ORF at position W172 and W196.  
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Figure 9: Detected genome equivalents in the supernatant of Huh7 cells transiently transfected with HBV expression 
plasmids encoding stop mutants within their S-ORF. Newly secreted viral particles were detected with qPCR in the 
supernatant of cells transiently transfected with stop mutants three days after transfection. Figure presents data of one approach 
(duplicates). The results are representative data of three independent experiments.  
 
Three days after transfection, viral DNA could be detected in the supernatant of all stop mutants (Figure 
9). The secretion of viral DNA was decreased by a factor of 5 to 10 in supernatant of mutants with a stop 
mutation at position 172 or 176 of the SHBs (Figure 9). Mutations at other positions of the SHBs had no 
influence on the secretion of viral DNA (Figure 9). 
According to the literature, some mutations, for example the 172* mutation in the HBV surface protein, 
are believed to be defective in secretion of subviral particles and virions (Warner and Locarnini 2008). 
The analysis of viral DNA in the supernatant of transiently transfected cells cannot distinguish between 
viral DNA encapsidated in virions or uncoated core-particles. Therefore, the secretion of HBsAg was 
screened by a sandwich-ELISA against LHBs, MHBs, and SHBs.  
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Figure 10: Results of the ELISA against all three HBV surface proteins and HBV core. Supernatant of Huh7 cells 
transiently transfected with HBV surface protein variants was tested for newly secreted HBsAg and HBV core-particles, three 
days after transfection. A) Results of the ELISA against LHBs using MA18/7. B) Results of the ELISA against MHBs using 
Q19/10. C) Results of the ELISA against SHBs using C20/02. D) Results of the ELISA against HBV core, using a polyclonal 
antibody against the core antigen derived from rabbit (DAKO). Cut-off for each ELISA is presented with red dotted line. 
 
In the supernatant of Huh7 cells transfected with the HBV wt, all three HBV surface proteins could be 
detected (Figure 10 A, LHBs-ELISA, B MHBs-ELISA, C SHBs-ELISA). When initiation codon of LHBs 
was mutated (mutant M1T), only SHBs and MHBs but no LHBs could be found (Figure 10, M1T B and 
D). In most of the tested HBV variants with mutations in the S-ORF, a stop mutation in the SHBs 
prevented secretion of HBsAg (Figure 10, A, B, C, all mutants including a stop mutation) with the 
exception of the mutant 172* and 176*. A stop mutation at position 176 in the SHBs leads to the 
secretion of 30 % LHBs (Figure 10 A). 20 % of SHBs secretion compared to the wt could be observed for 
mutant 172* (Figure 10 C). An amino acid change from tryptophan to serine or leucine did not affect the 
secretion of HBsAg (Figure 10, A, B, C, 172L, 196S, 196L). MHBs-secretion was reduced after amino 
acid changes at position 172 and 196 (Figure 10 B).  
During the synthesis of HBV in cell culture, a considerable amount of uncoated capsids is secreted 
(Nassal 1992; Bremer et al. 2009a; Bardens et al. 2011). Therefore, a sandwich-ELISA against HBV core 
was used to detect HBcAg in the supernatant of transfected cells. Uncoated capsids could be detected for 
all tested mutants and wild type HBV. Stop mutations or amino acid changes at positions 172, 196 as well 
as at position 216 in the SHBs seemed to increase the secretion of uncoated core-capsids (Figure 10 D). 
Results 
48 
To show that the effects found in ELISA and qPCR were not cell type- or species-specific, stop mutants 
were also transiently transfected in two other hepatoma cell lines; the murine AML12 and the human 
HepG2 cell lines. Analysis of the supernatant for newly synthesized and secreted virions and subviral 
particles showed the same results as already described for Huh7 transfected cells (see appendix Figure 36, 
Figure 37).  
The present data show, that a stop mutation at the position 182, 196, 199, and 216 blocks the secretion of 
HBsAg. A stop mutation at position 172 results in the decreased secretion of SHBs, whereas secreted 
LHBs is detectable if a stop mutation at position 176 in the SHBs takes place. An amino acid change at 
position 172 and 196 in the SHBs rescued the secretion of HBsAg. 
 
3.2.2. Immunohistochemical Analysis of HBV Surface Protein Variants 
To analyze the synthesis of HBsAg of HBV variants in cell culture, immunohistochemical staining for 
selected mutants was performed.  
After immunohistochemical staining against LHBs, MHBs, and SHBs, newly synthesized HBV surface 
proteins could be detected in Huh7 cells transfected with the HBV wild type plasmid (Figure 11, left 
section, red panel). These Huh7 cells also expressed the HBV core antigen (Figure 11, left section, green 
panel). MHBs and SHBs could be observed in cells transfected with the HBV plasmid encoding for a 
LHBs deficient mutant, with the preS1-start codon (methionine, M) of LHBs mutated into a codon for 
threonine (T) (M1T) (Figure 11, M1T, right section, red panel). No LHBs could be visualized after 
immunohistochemical staining (Figure 11, M1T, right section, red panel LHBs). For both, wt and M1T 
mutant, most of the transfected cells express HBV core simultaneously with HBV surface proteins 
(Figure 11, white arrow). 
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Figure 11: Immunohistochemical analysis of HBV proteins of wt or M1T transfected Huh7 cells. Three days after transient 
transfection, cells were stained for HBsAg (red, Alexa-594) and HBV core (green, Alexa-488). Newly synthesized HBsAg was 
detected using monoclonal antibodies against LHBs (MA18/7), MHBs (Q19/10), and SHBs (C20/02). As a marker for newly 
synthesized hepatitis B virions, core capsids were stained with a polyclonal antibody (DAKO). Nuclei were stained with DAPI 
(blue). White arrows mark cells expressing only HBV core. Yellow arrows mark cells that are shown in more detail in the lowest 
panel with a cut view through z-stack-images of single cells. Scale bars: 50 µm.  
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Figure 12: Immunohistochemical analysis of HBV proteins of HBV-variants with mutations at position 172 of the SHBs. 
Huh7 cells were transfected with plasmids encoding either a stop mutation at position 172 (172*) or an amino acid change from 
tryptophan to leucine (172L) in the SHBs. Newly synthesized HBsAg was detected using monoclonal antibodies against LHBs 
(MA18/7), MHBs (Q19/10), and SHBs (C20/02) (red panel, Alexa-594). As a marker for newly synthesized hepatitis B virions, 
capsids were stained with a polyclonal antibody (DAKO) (green panel, Alexa-488). Nuclear staining was performed with DAPI 
(blue). White arrows mark cells expressing only HBV core. Yellow arrows label cells that are shown in more detail in the lowest 
panel with a cut view through z-stack- images of single cells. Scale bars: 50 µm.  
 
In case of a stop-mutation or an amino acid change at position 172 in the SHBs, expression of all HBV 
surface proteins can still be detected (Figure 12, red panel). As seen in wt or M1T transfected cells, some 
cells show expression of HBV core antigen, only (Figure 12, green panel, white arrows). 
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Figure 13: Immunohistochemical analysis of HBV proteins of HBV-variants with mutations at position 196 of the SHBs. 
Huh7 cells were transfected with plasmids encoding for amino acid changes in SHBs at position 196 (196S or 196L). Newly 
synthesized HBsAg was detected using monoclonal antibodies against LHBs (MA18/7), MHBs (Q19/10), and SHBs (C20/02) 
(red panel, Alexa-594). As a marker for newly synthesized hepatitis B virions, capsids were stained with a polyclonal antibody 
(DAKO) (green panel, Alexa-488). Nuclear staining was performed with DAPI (blue). White arrows mark cells expressing only 
HBV core. Yellow arrows label cells that are shown in more detail in the lowest panel with a cut view through z-stack- images of 
single cells. Scale bars: 50 µm.  
 
Expression of HBV surface proteins still could be visualized even though mutants had an altered amino 
acid sequence from tryptophan (W) to serine (S) (W196S) or leucine (L) (W196L) at position 196 (Figure 
13, red panel, yellow arrow). But if there is a mutation to a stop-codon at position W196 (196*) instead of 
a tryptophan, expression of HBsAg could not be detected by IF (compare Figure 14, 196* left section, red 
panel with Figure 13 and Figure 14, right section, red panel, yellow arrow). Synthesis of HBV core 
antigen could also be observed in transfected Huh7 cells with plasmids encoding for mutants at position 
196 in the SHBs (Figure 13 and Figure 14, with white arrow). 
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Figure 14: Immunohistochemical analysis of HBV proteins of HBV-variants with mutations at position 196 in the SHBs. 
Huh7 cells were transfected with plasmids encoding for either a stop mutation at position 196 (196*) or an amino acid change 
from tryptophan to serine (196S) of the SHBs. Newly synthesized HBsAg was detected using monoclonal antibodies against 
LHBs (MA18/7), MHBs (Q19/10), and SHBs (C20/02) (red panel, Alexa-594). As a marker for newly synthesized hepatitis B 
virions, capsids were stained with a polyclonal antibody (DAKO) (green panel, Alexa-488). Nuclear staining was performed 
with DAPI (blue). White arrows mark cells expressing only HBV core. Yellow arrows show cells co-expressing HBsAg and 
HBV core. These cells are shown in more detail with a cut view through z-stack-images of single cells. Scale bars: 50 µm.  
 
Untransfected cells stained with monoclonal antibodies against HBsAg as well as wt transfected cells 
stained with the secondary antibodies only, showed no positive fluorescence signal (see appendix Figure 
38).  
Cells transfected with surface protein mutants do not differ in their morphology from the HBV wild type. 
All surface proteins could be detected in Huh7 cells transfected with the wt plasmid or plasmids encoding 
for HBV with amino acid changes in the SHBs (172L, 196S, 196L). The amino acid change from 
methionine to threonine at position 1 of the LHBs, resulting in a stop mutation of the HBs start codon, 
leads to inhibited synthesis and thus not to a secretion of LHBs in subviral particles. Instead, synthesis of 
MHBs and SHBs and secretion of subviral particles was not influenced when LHBs was mutated. A stop 
mutation at position 172 in the SHBs did not change the expression of SHBs. In contrast, a stop mutation 
at position 196 in the SHBs led to the loss of HBsAg expression. The results are summarized in Table 6, 
page 77. 
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3.2.3. Comparison of Sedimentation Behavior for Purified HBV with Cell Culture 
Derived HBV in the CsCl-Gradient 
To distinguish between the secretion of enveloped virions and uncoated core capsids and to verify which 
effect stop mutations have on the packaging of virions, a caesium chloride-gradient was performed.  
Normally, virions peak at 1.24–1.25 g/ml CsCl after centrifugation, whereas naked core-particles have 
their maximum at a CsCl-density of 1.30 to 1.36 g/ml (Sureau et al. 1986). Supernatant of stop mutants or 
purified HBV from human serum were treated with detergent (NP40) and reducing agent (TCEP) to 
remove the coat of the virions. Then uncoated cores and enveloped virions were separated by CsCl- 
gradient.  
 
Figure 15: CsCl-gradient of serum derived HBV compared to cell culture derived HBV. To distinguish between enveloped 
virions and uncoated core-capsids, supernatant of HBV wt transfected cells or HBV purified from human serum was treated with 
detergent (NP40) and reducing agent (TCEP) (1 h, RT). For serum derived HBV and cell culture derived HBV 1x106 GE/ml 
were used. Afterwards, samples were layered on a linear CsCl-gradient and centrifuged. Gradient was fractionated from the 
bottom to the top, purified and analyzed with qPCR for viral DNA. A) CsCl-gradient of purified HBV derived from serum of a 
chronically infected patient. B) CsCl-gradient of cell culture derived HBV (wt). Red line exhibits genome equivalents of 
untreated virus-sample. Black line shows genome equivalents after treatment with detergent and reducing agent. Green lines 
indicate the density of CsCl. Red bars indicate the fractions where enveloped virions are expected. Black bars indicate the 
fractions where uncoated capsids are expected. Representative data of three independent experiments are depicted.  
 
Detected density of CsCl decreased from lower to higher fractions (Figure 15, green lines). Without 
NP40/TCEP-treatment, a peak of viral DNA could be observed at a density of 1.26 g/ml CsCl (fraction 6, 
see also appendix Table 7) using purified HBV from human serum (Figure 15 A, red line). This peak is in 
consistence with the density where enveloped HBV virions normally peak (Sureau et al. 1986) (Figure 15, 
red virion). After treatment with detergent (NP40) and reducing agent (TCEP) the peak of viral DNA 
shifted to higher densities of CsCl (1.36 g/ml, fraction 4) (Figure 15 A, black line and appendix Table 7), 
corresponding to uncoated capsids (Sureau et al. 1986) (Figure 15, black capsid). The cell culture derived 
HBV behaved the same in the CsCl-gradient. Without treatment, enveloped virions could be detected at a 
density of 1.26 g/ml CsCl (fraction 7) (Figure 15 B, red line, and appendix Table 7), too. A second peak 
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of viral DNA was observed (fraction 4) (Figure 15 B, red line) in the same densities (1.4 g/ml) and 
fractions (fractions 3-4) as uncoated core-capsids (Figure 15 B, black line and appendix Table 7). A 
second characteristic peak of viral DNA accumulating in low densities in the last fractions can be 
measured in all treated CsCl-gradients (Figure 15 A and B, black lines and appendix Table 7 and 
following Figures 17, 18, 19, 37, 38).  
HBV purified from human serum and cell culture derived HBV behaved similarly in CsCl-gradient and 
on that score they are comparable with each other.  
 
3.2.4. Analysis of a LHBs Deficient HBV Mutant Using the CsCl-Gradient 
An HBV variant with a mutated start codon (M1T) was designed to analyze virus secretion without LHBs 
(Figure 16 A). The amino acid change from methionine (M) to threonine (T) at position 1 in the LHBs 
leads to the skipping of the LHBs start codon, resulting in the inhibition of LHBs secretion. The 
supernatant from cells transiently transfected with the HBV mutant M1T was either untreated or reduced 
with NP40 and TCEP, ultracentrifuged in the CsCl gradient, and examined.  
 
Figure 16: CsCl-gradient of mutant with amino acid change in the start codon of LHBs. Supernatant of transiently 
transfected cells with HBV surface protein variant M1T was treated with NP40 and TCEP (1h, RT), layered on a linear CsCl-
gradient and ultracentrifuged. 1x106 GE/ml were used. The gradient was fractionated from the bottom to the top, purified, and 
analyzed for viral DNA with qRT-PCR. A) Schematic presentation of the mutation M1T in the LHBs start codon, inhibiting 
LHBs production. B) CsCl-gradient of mutant M1T. Red bars indicate the fractions where enveloped virions are expected. 
Black bars indicate the fractions where uncoated capsids are expected. Representative data of three independent experiments are 
depicted. 
After centrifugation, the CsCl-gradient shows that a peak of viral DNA could be detected in lower 
fractions (fractions 3-5) with higher densities of cesium chloride (1.37 g/ml–1.29 g/ml) independent of 
the treatment (Figure 16, red and black line and appendix Table 8). The peak of viral DNA presumably 
corresponds to uncoated core capsids. A second characteristic increase of viral DNA was also detected in 
the last fractions after treatment with NP40 and TCEP (Figure 16 B, black line and appendix Table 8). 
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This CsCl-gradient shows that the loss of the initiation codon of LHBs does not only lead to an inhibited 
secretion of subviral particles, but also to a complete block of the secretion of enveloped virions.  
 
3.2.5. Analysis of HBV Variants with Mutations at Position 172 into the SHBs 
Using the CsCl-Gradient 
During antiviral therapy with adefovir, the mutation V181T in the rt-domain of the viral polymerase 
occurred, leading to the S-ORF mutation at position sW172 to sW172* or sW172L. A stop mutation at 
this position results in a truncated SHBs variant missing the C-terminus (Figure 17 A). This truncated 
SHBs variant loses the transmembrane domain III and IV and the internal loop between both domains. An 
amino acid change at this position probably maintains the C-terminus of the SHBs (Figure 17 A). To 
examine the influence of these mutations on virion secretion, reduced and non-reduced supernatant of 
transfected cells was analyzed using a linear CsCl-gradient.  
 
Figure 17: CsCl-gradient of mutants with changes at position 172 of the SHBs. Supernatant of transiently transfected cells 
with HBV surface protein variant 172* or 172L was treated with NP40 and TCEP (1h, RT), layered on a linear CsCl-gradient and 
ultracentrifuged. 1x106 GE/ml for both HBV surface protein variants were used. The gradient was fractionated from the bottom 
to the top, purified, and analyzed with qPCR for viral DNA. A) Schematic depiction of localization of mutations in the SHBs at 
position 172 highlighted in red (modified after Komla-Soukha and Sureau 2006). To analyze the influence on viral assembly and 
secretion, the tryptophan at position 172 was mutated into a stop codon (172*) or an amino acid change from tryptophan to 
leucine (172L) was performed B) CsCl-gradient of mutant 172*. C) CsCl-gradient of mutant 172L. Red bars indicate the 
fractions where enveloped virions are expected. Black bars indicate the fractions where uncoated capsids are expected. 
Representative data of three independent experiments are depicted. 
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A stop mutation at position 172 or an amino acid change at the same position led to the secretion of 
enveloped virions in densities of 1.24 g/ml as well as uncoated core-capsids in densities between 
1.35 g/ml and 1.36 g/ml (Figure 17 B and C, red lines and appendix Table 9) for both mutants without 
treatment. After reducing procedure, all enveloped virions were uncoated and the viral DNA shifted to 
higher densities (1.35 g/ml-1.36 g/ml for both mutants).  
 
3.2.6. Analysis of HBV Variants with Mutations at Position 196 into the SHBs 
Using the CsCl-Gradient 
The antiviral treatment with lamivudine leads to the mutation M204I in the viral polymerase. Due to the 
overlap of the ORFs, this mutation leads also to a mutation at position 196 into the S-domain. For further 
analysis of the influence of mutations at position 196 on virion secretion, supernatant of transfected cells 
was examined in a CsCl-gradient in its reduced and non-reduced form.  
 
Figure 18: CsCl-gradient of mutants with mutations at position 196 into the SHBs. Supernatant of transiently transfected 
cells with HBV surface protein variants 196*, 196S, 196L were treated with NP40 and TCEP (1h, RT), layered on a linear CsCl-
gradient, and ultracentrifuged. 1x106 GE/ml for all three HBV surface protein variants were used. The gradient was fractionated 
from the bottom to the top, purified and analyzed with qPCR for viral DNA. A) Schematic depiction of mutations into the SHBs 
at position 196 highlighted in bright blue (modified after Komla-Soukha and Sureau 2006). To analyze the influence on viral 
assembly and secretion, the tryptophan (W) at position 196 was mutated into a stop codon (196*) or an amino acid change from 
tryptophan to leucine (196L) or serine (196S) was performed. B) CsCl-gradient of tested mutant W196*. C) CsCl-gradient of 
tested mutant 196S. D) CsCl-gradient of tested mutant 196L. Red bars indicate the fractions where enveloped virions are 
expected. Black bars indicate the fractions where uncoated capsids are expected. Representative data of three independent 
experiments are depicted. 
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CsCl-analysis of SHBs mutants 196S (Figure 18 C and appendix) and 196L (Figure 18 D and appendix 
Table 10) showed enveloped hepatitis B virions in densities of 1.25 g/ml (196S) and 1.26 g/ml (196L). 
Uncoated capsids could be detected in densities of CsCl of about 1.36 g/ml (196S) and 1.37 g/ml (196L) 
(Figure 18 C and D, red lines and appendix Table 10). The treatment with reducing agent and detergent 
lead to the uncoating of the virus and to a shift of the viral DNA to higher densities of CsCl (Figure 18 C 
and D, black lines and appendix Table 10). In contrast to the altered amino acid sequence, the stop 
mutation at position 196 results in the secretion of uncoated capsids, only, because with or without 
treatment, the sole peak of viral DNA was localized in densities of CsCl between 1.35 g/ml and 
1.37 g/ml, typical for the sedimentation density for core particles (Figure 18 B, black and red line and 
appendix Table 10). 
Stop mutations in the SHBs at positions 176, 182, 199, and 216 lead to the secretion of uncoated capsids, 
but enveloped virions are only observed in mutants possessing a stop mutation at position 176 and 216 in 
the SHBs. A stop mutation at these positions does not inhibit the packaging of virions. The HBV surface 
variants 182* and 199* only secrete uncoated core capsids. (see Figure 39 and Table 11, Figure 40 and 
Table 12). 
Table 6 (page 77) summarizes the previously gained results from the HBV surface protein variants.  
 
3.3. Establishment of a Transfection and Infection System for HDV Pseudo-
Particles 
To test the infectivity of HBV mutants, a new recombinant infection system had to be established. The 
hepatitis delta virus is a satellite virus of HBV and uses the HBV surface proteins for viral assembly, 
secretion, and infection (Bruss and Ganem 1991; Sureau et al. 1993). In this context, it is an excellent 
opportunity to analyze the ability of HBV surface protein mutants to infect PTHs. Due to the fact that 
there is no adequate RNA-standard for absolute quantification of HDV-RNA, an RNA-standard had to be 
established in vitro. Therewith, it would be possible to absolutely quantify HDV-RNA in cell culture or 
human plasma.  
 
3.3.1. Production and Establishment of an HDV RNA-standard for RT-qPCR 
HDV-plasmid DNA was used to generate a full length RNA-standard for quantitative HDV PCR. After 
the synthesis of RNA the concentration of total RNA was measured with the picodrop Microlitre UV/Vis 
spectrophotometer (Biozym) and the amount of genome equivalents per microliter was calculated. A total 
particle number of 3.31x1012 GE/µl for sample one and 2.25x1012 GE/µl for sample two was calculated. 
The purity of in vitro generated RNA-standard was analyzed performing a formaldehyde gel.  
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Figure 19: Formaldehyde gel of in vitro generated HDV RNA-standard. HDV genome was amplified out of the HDV 
encoding plasmid pSVLD3, which served as a template for the synthesis of HDV RNA. After in vitro transcription of the HDV 
RNA, a formaldehyde gel was performed to examine the purity. 5 µl of each sample (1: 1.66x1013 GE, 2: 1.13x1013 GE) were 
loaded onto the gel.  
 
As shown in Figure 19, there was a single band detected for each sample indicating that an in vitro RNA-
standard was generated by the T7 High Yield RNA Synthesis Kit (NEB) with high purity. 
Both approaches were diluted to a final concentration of 1x109 GE/µl. To test the sensitivity of the newly 
generated RNA-standard by RT-qPCR, one sample was used in a tenfold serial dilution, starting with 
2x108 GE. The original plasmid DNA (pSVLD3, EcoRI digested) served as a control and was used in the 
same concentrations. 
 
Figure 20: Titration of control plasmid (pSVLD3, EcoRI digested) and in vitro generated RNA-standard. The HDV 
encoding plasmid pSVLD3 (EcoRI digested) and the newly synthesized RNA standard were titrated from 2x108 GE to 2x101 GE 
and analyzed in the HDV RT-qPCR. Data presented the average ± SD of three independent experiments including three 
repetitions.  
 
Titration of RNA-standard and control plasmid showed a continuous decrease in RNA and plasmid 
concentration to a total concentration of 2x103 GE. From that point the qPCR gets inaccurate. In a range 
of 2x108 to 2x104 GE RNA standard was as sensitive as the control-plasmid (Figure 20).  
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Because of a high plasmid background from the transfection procedure in cell culture derived HDV 
pseudo-particles, a DNase I digestion was done before starting the RT-qPCR. To test if RNA-standard 
was influenced by the DNase digestion, a DNase I and RNase A digestion was realized (see 2.2.8.2.2) and 
plasmid-DNA was used as a control.  
To further investigate if the DNase treatment influences the amount of used RNA, freshly thawed RNA-
standard was pipetted after the DNase digestion and before the qPCR was running (Figure 21, lane 9). 
 
Figure 21: RNA-standard with and without RNase A and DNase I digestion. Data present the average ± SD from titrated 
RNA-standard (from 1x109 GE to 1x103 GE) compared to control-plasmid-DNA (pSVLD3, EcoRI digested). Experiment 
includes three repetitions. RNA-standard was titrated and treated with DNase I and/or RNase A. Lanes 1 to 7 show titrated RNA-
standard with 109 up to 103 GE. In lane 8 highest RNA-standard is shown without DNase-treatment. Lane 9 shows highest RNA-
standard freshly thawed before running the qPCR. Lane 10 shows highest RNA-standard with DNase and RNase treatment. 
Lanes 11 and 12 show DNase treated and untreated control-plasmid-DNA. 
 
The quality and amount of RNA-standard is not influenced by DNase treatment (Figure 21, compare 
lane 1-7 with lane 8). After RNase A digestion, no RNA could be observed (Figure 21, lane 10). The 
amount of DNase I treated control-plasmid was reduced (Figure 21, compare lane 11 and 12). 
Thus, it was possible to generate an RNA standard in a clearly defined manner, which was suitable as a 
standard for the absolute quantification of newly synthesized RNA of the subsequent experiments.  
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3.4. Characterization of HDV from Human Plasma 
3.4.1. Characterization of HDV Derived from Human Plasma in a Linear CsCl-
Gradient 
Human plasma of a chronically infected patient, co-infected with HBV and HDV, was analyzed with a 
linear CsCl-gradient. Therefore, 5x106 GE/ml HDV derived from this human plasma were treated with 
NP40 and TCEP, and a CsCl-gradient was performed.  
  
Figure 22: CsCl-gradient of a human plasma chronically infected with HDV and HBV. Human plasma (5x106 GE/ml HDV) 
was treated with or without NP40/TCEP (1 h, RT). Afterwards, samples were layered on a linear CsCl-gradient and centrifuged. 
Then, the gradient was fractionated from the bottom to the top, purified and analyzed for viral RNA with specific RT-qPCR. 
Green triangles show density of CsCl for each fraction. Red dots show GE of untreated human plasma. Black dots show GE of 
treated human plasma.  
 
After centrifugation, taken fractions were purified and the HDV specific RT-qPCR was performed to 
detect viral RNA. A peak of hepatitis delta RNA was observed in densities between 1.29 g/ml-1.30 g/ml 
CsCl (fractions 6 and 7) (Figure 22, red line). After treatment with detergent and reducing agent, HDV 
RNA could not be traced anymore (Figure 22, black line). HBV DNA could not be observed. 
 
3.4.2. Purification of Plasma-Derived HDV with a Continuous Sucrose Gradient 
For infection assay with PTHs, HDV, derived from human plasma, was purified with a continuous 
sucrose gradient (7.7x106 GE/ml) (see 2.2.9). After centrifugation, the fractions were photometrically and 
refractometrically determined. HDV-RNA was detected and quantified with RT-qPCR. 
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Figure 23: Sucrose gradient of a human plasma from a patient chronically infected with HDV/HBV. Human plasma from a 
chronically infected patient was purified with a continuous sucrose gradient. After ultracentrifugation, the gradient was 
fractionated from the bottom to the top. Then, the fractions were photometrically (protein concentration) and refractometrically 
(density of sucrose) determined. After purification, HDV-RNA was detected and quantified with RT-qPCR. Red line shows 
measured GE/ml in a logarithmic order. Green line shows measured density of sucrose in %. Black line shows measured protein 
concentration in mg/ml. 
 
The protein concentration increased up to 27 % sucrose (fraction 15) and demonstrated a small plateau 
between 30 – 20 % sucrose (fractions 15-20), resulting in a peak in 17 – 15 % sucrose (fraction 21 and 
22) (Figure 23, black line). The protein accumulation in these fractions was also detectable, which is 
visualized in an orange protein-cloud (also see appendix Figure 41, orange arrow). Viral RNA peaked in 
fractions with a density of 39-45 % sucrose (fractions 7 and 8) (Figure 23, red line). HBV-DNA could not 
be detected again.  
 
3.4.3. Infection of PTHs with Purified HDV Derived from Human Plasma 
To find out if purified HDV is also able to infect primary Tupaia hepatocytes, the fractions seven to nine 
of the sucrose gradient in Figure 23 were tested. To inhibit the infection with HBV or HDV, cells were 
preincubated with myr preS1 peptide. Twelve days after infection, the cells were lysed and analyzed for 
newly synthesized HDV-RNA. As a control for susceptibility of PTHs for HDV, some cells were mono-
infected with HBV and newly synthesized and secreted HBsAg was measured in a SHBs specific ELISA 
(C20/2) as a marker of infection.  
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Figure 24: Infection of PTHs with patient derived HDV purified by sucrose gradient centrifugation. Freshly isolated PTHs 
were infected with purified HBV (1x108 GE) or HDV (1x107 GE) on day three after isolation. To inhibit the HBV or HDV 
infection, cells were preincubated with myr preS1-peptide (1 µM f.c.) for 30 minutes at 37 °C. A) Infection of PTHs with 
purified HDV from fraction seven, eight, and nine with (dotted grey bars) and without (monocolored grey bars) myr preS1-
peptide inhibition. B) Control-infection with HBV with (grey bars) and without (black bars) myr preS1-peptide inhibition. Data 
present the average ± SD from three repetitions. Red line shows cut-off. d.p.i = days post infection. 
 
Successful infection with purified HDV on PTHs could be detected in all tested fractions. The HDV-
infection could be inhibited with myr preS1-peptide (Figure 24 A). Figure 24 B presents a typical 
infection curve of PTHs with purified HBV. From the seventh day after the infection, a higher amount of 
HBsAg could be measured. Detected SHBs decreased over time when the infection was inhibited with 
preS1 (Figure 24 B, grey bars), resulting in a successful inhibition of infection (Figure 24 A, black bars). 
 
3.4.4. Analysis of the Kinetic of Infectivity for HBV and HDV on PTHs 
It was reported that PTHs are susceptible for HBV on day one to day four after isolation, but infection 
was more effective on day two and three after isolation (Çağ 2004). To show if this effect is the same 
with HDV, PTHs were infected with HBV and HDV, purified from human serum or plasma, at several 
points of time after isolation. Infection was inhibited by pre-incubation of PTHs with myr pres1-peptide 
(30 minutes, 37 °C) on every infection day. The supernatant of infected cells was changed at day 1, 4, 7, 
and 12 after infection. On day 12 after infection, PTHs were lysed. The supernatant was analyzed for 
newly synthesized and secreted HBsAg as a marker for a successful HBV infection. Cell lysates were 
analyzed for newly synthesized HDV RNA as a marker for an effective HDV infection. 
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Figure 25: Kinetic of HBV and HDV susceptibility of PTHs. PTHs were infected with purified HBV (1x108 GE) or HDV 
(1x107 GE) from day two to day 12 after isolation. On each infection day, cells were pre-incubated with myr preS1-peptide 
(1 µM f.c., 30 min, 37 °C) to inhibit HBV or HDV infection. Detection of newly secreted SHBs in the supernatant was done by 
SHBs-ELISA (C20/02). Lysed cells were analyzed for newly synthesized HDV-RNA. Data from all preS1-inhibited days were 
pooled, the mean value was determined, and the percentage of infectivity compared to infection day two was calculated and 
depicted as + preS1. Infectivity of HBV and HDV was expressed as percentage of infectivity. Cut-off is marked with red dotted 
line. Duplicates for each point of time of infection were performed. (published in A. König, B. Döring, C. Mohr, J. Geyer, D. 
Glebe. ″Hepatitis B virus and bile acids compete for binding to the Na+/taurocholate cotransporting polypeptide (NTCP) to enter 
hepatocytes″. (in revision). modified). 
 
Freshly isolated primary hepatocytes from the Asian treeshrew Tupaia belangeri were susceptible for 
HBV as well as HDV two to three days after isolation (Figure 25, black and grey bars). Four days after 
isolation, susceptibility decreased to an amount of 50 % for HBV (Figure 25, black bars) and about 80 % 
for HDV (Figure 25, grey bars). After the fifth day of isolation, PTHs were no longer susceptible for 
HBV or HDV. An effective inhibition of HBV and HDV infection by incubation with myristoylated 
preS1 peptide was achieved on every infection day (Figure 25 + preS1).  
PTHs are susceptible for HBV and HDV two to four days after isolation. The infection efficiency 
decreased on day four, after isolation.  
 
3.4.5. HBV/HDV Co- and Super-Infection of PTHs 
Two types of HBV/HDV infection are known: co-infection and super-infection. Due to the fact that 
HBV/HDV co- or super-infection have not been systematically investigated in cell culture experiments in 
vitro on primary hepatocytes, the following experiments were done. To analyze HBV/HDV super-
infection, PTHs were infected with purified HDV or HBV two days after isolation, and two days later 
they were infected with the other virus. For imitation of an HBV/HDV co-infection, PTHs were infected 
with both viruses two days after isolation. As a negative control, infections were inhibited by adding an 
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HBV myr preS1-peptide at all times. After 15 days, supernatant and cell lysates were analyzed for newly 
synthesized and secreted HBV or HDV as further described.  
 
Figure 26: HBV/HDV co- and super-infection of PTHs. PTHs were infected with purified HBV (1x108 GE) and HDV 
(1x107 GE) simultaneously to imitate a HBV/HDV co-infection. To analyze HBV/HDV super-infection, PTHs were infected 
with purified HBV or HDV on day two after isolation and then infected vice versa four days after isolation. HBV and HDV 
single-infections were performed on day two and four after isolation. Inhibition of infection was performed by pre-incubation of 
PTH with myr preS1-peptide (1 µM f.c.) for 30 min. 15 days after infection, the supernatant was analyzed for newly secreted 
HBsAg. Furthermore, cells were lysed and analyzed for newly synthesized HDV RNA. HBsAg in the supernatant of infected 
cells was measured with C20/02-ELISA as a marker for newly secreted HBV and is depicted as HBsAg [ng/ml]. Cut-off of 
HBsAg is presented with blue dotted line. Newly synthesized HDV was detected with RT-qPCR and depicted as log10 GE/well. 
Cut-off of HDV RT-qPCR is presented with red dotted line. Data present the average ± SD from three repetitions. 2 d.p.i. = 2 
days post isolation, 4 d.p.i. = 4 days post isolation 
 
Infection of PTHs with HBV and HDV was possible on day two and four after isolation (Figure 26, black 
and grey bars part in the middle). Susceptibility for HBV infection decreased over time (Figure 26, single 
black bars, part in the middle) while PTH are equally susceptible for HDV on both days (Figure 26, single 
grey bars, part in the middle). The imitation of HBV/HDV super- and co-infection seemed to be possible 
in PTHs (Figure 26). HBV/HDV co-infection was as effective (Figure 26 co-infection) as super-infection 
with HBV and HDV (Figure 26, super-infection). The infection of HBV seemed to be more effective 
when PTHs were firstly infected with HDV (Figure 26, super infection right bars).  
Infection of PTHs with HBV and HDV was possible on day two and four after isolation. HBV/HDV 
super- and co-infection seemed to be possible in PTHs. 
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3.5. Characterization of Recombinant HDV Pseudo-Particles from Cell Culture 
3.5.1. Production of HDV Pseudo-Particles in Cell Culture with Different Variants 
of HBV Surface Proteins 
It is well known that the hepatitis delta virus needs the surface proteins of its helper virus HBV for 
secretion and infection (Sureau et al. 1993; Komla-Soukha and Sureau 2006). For following infection 
assays with recombinant HDV, HDV pseudo-particles with mutated HBV surface proteins were produced 
to analyze the influence of surface proteins on secretion. Co-transfected Huh7 cells were cultivated for 12 
days and supernatant was investigated for newly secreted viral RNA  
 
Figure 27: Kinetic of generated recombinant HDV pseudo-particles with several combinations of HBV surface proteins. 
After transient transfection of Huh7 cells with plasmids encoding for HDV and HBV surface proteins, supernatant was collected 
on day two, four, six, nine. and twelve after transfection and analyzed for newly secreted HDV pseudo-particles, HDV like-
particles were generated with all three surface proteins (LMS), with LHBs, and SHBs (LXS) or with only LHBs (LXX), MHBs 
(XMX), or SHBs (XXS) respectively. As a negative control HDV pseudo-particles were generated without any surface proteins 
(XXX). The X marks mutated HBsAg. Red dotted line marks the cut-off for HDV RT-qPCR. Pictured kinetic is an example for 
three independent experiments.  
 
Secreted HDV RNA was observed if Huh7 cells were co-transfected with the plasmid encoding for HDV 
in combination with HBV plasmids encoding for either all three HBV surface proteins (LMS), as well as 
the LHBs and SHBs (LXS), or the SHBs (XXS), solely (Figure 27). These data show that SHBs alone is 
sufficient for HDV-secretion. HDV pseudo-particles exclusively enveloped with LHBs or MHBs could 
not be observed (Figure 27, LXX, XMX). In addition, HDV-pseudo-particles could not be secreted if an 
HBsAg-deficient plasmid was co-transfected (Figure 27, XXX).  
The SHBs alone was sufficient for HDV-secretion. The secretion of HDV pseudo-particles could be 
observed if LHBs and SHBs or all three HBV surface proteins surrounded the HDV pseudo-particles.  
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3.5.2. Infection of PTHs with Recombinant HDV Pseudo-Particles 
Synthesized HDV pseudo-particles, derived from cell-culture, were tested in the infection assay to verify 
their ability to infect PTHs. Therefore, supernatant containing HDV pseudo-particles after transfection of 
day six to twelve was concentrated with Vivaspin20. Then, concentrates were analyzed in HDV specific 
RT-qPCR again for absolute quantification of HDV like-particles. Equal amounts of HDV RNA were 
used to infect PTHs. As a control for infection, HDV purified from human plasma, was used. To inhibit 
the HDV infection, cells were pre-incubated with myr preS1-peptide (1 µM f.c., 30 min, 37 °C). Twelve 
days after infection, cells were lysed and newly synthesized HDV-RNA was detected with specific RT-
qPCR. 
 
Figure 28: Infection of PTHs with recombinant HDV from cell culture. Infection assay was done with concentrated 
supernatant of generated HDV pseudo-particles (1x106 GE). 12 days after infection, PTHs were lysed, viral RNA was purified 
and analyzed for newly synthesized RNA by HDV specific RT-qPCR. Infection was inhibited by pre-incubation of the cells with 
myr preS1-peptide (1 µM) (30min, 37 °C) (dotted grey bars) and served as a negative control. The X marks mutated HBsAg in 
the surface proteins. As a positive control, PTHs were also infected with purified HDV (1x106 GE) derived from human plasma. 
Cut-off is shown with red dotted line. Data present the average ± SD from three repetitions. 
 
The infection was effective in PTHs if purified HDV (Figure 28, HDV) or HDV pseudo-particles 
including the LHBs (Figure 28, LMS, LXS,) were used. PTHs were not infected with HDV pseudo-
particles enveloped with SHBs, only. Supernatant from transiently transfected cells with HDV and an 
HBsAg deficient plasmid was used as a negative control. The infection of purified HDV and HDV 
pseudo-particles derived from cell culture could be inhibited by applying HBV myr preS1-peptide (Figure 
28, dotted grey bars).  
A successful HDV infection of PTHs was observed if HDV like-particles possessed the LHBs. 
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3.5.3. Neutralization of Infection of Cell Culture-Derived and Plasma-Derived 
HDV Using Monoclonal Antibodies 
Monoclonal antibodies against the HBV surface proteins were reported to inhibit HBV-infection (Sureau 
et al. 1992, Glebe et al. 2003). The following study should show, if monoclonal antibodies against the 
HBsAg can neutralize the HDV infection, too. Therefore purified and recombinant HDV possessing all 
three HBV surface proteins was preincubated with monoclonal antibodies against HBsAg before infection 
of PTHs was done. Twelve days after infection newly synthesized HDV-RNA was detected with RT-
qPCR. 
 
Figure 29: Infection of PTHs with recombinant HDV pseudo-particles and purified HDV derived from human plasma 
neutralized with mABs against HBV surface proteins. Recombinant HDV and HDV purified from human plasma were 
preincubated (1 h, 20 °C) under continously shaking with monoclonal antibodies (5 µg f.c.) against HBV surface proteins. Then, 
PTHs were infected with cell culture derived HDV pseudo-particles including all three surface proteins (LMS) and purified HDV 
derived from human plasma (1x106 GE), three days after isolation. Duplicates for each approach were performed. Data present 
infectivity in %. 
 
Recombinant HDV as well as purified HDV were neutralized with mABs against LHBs (MA18/7) and 
SHBs (C20/02, HB1) (Figure 29) and hence did not infect PTHs. The infection rate was reduced about 
40 %-50 % when HDV was neutralized by an antibody that recognizes MHBs (Q19/10) (Figure 29). 
These results indicate the significance of LHBS and SHBs for an effective infection. The MHBs seems to 
be of minor importance for viral infectivity.  
Infection of PTHs with purified HDV from human serum and recombinant HDV pseudo-particles could 
be neutralized with monoclonal antibodies against LHBs and SHBs. 
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3.6. Production of Recombinant HDV with Mutations in the HBV Surface 
Proteins 
To analyze the influence of HBV surface protein variants (with stop mutants or amino acid changes in 
their S-ORF) on HDV assembly and secretion, HDV pseudo-particles were generated including selective 
HBV stop mutations. Therefore, Huh7 cells were co-transfected with plasmids encoding for HDV and 
selected HBV surface protein variants (M1T, 172*, 172L, 196*, 196S, 196L), and cultivated over nine 
days. The supernatant was then examined for newly secreted HDV pseudo-particles using the HDV 
specific RT-qPCR.  
 
Figure 30: Kinetic of HDV-production with stop mutants. Huh7 cells were co-transfected with plasmids encoding HDV and 
selected HBV surface protein variants (M1T, 172*, 172L, 196*, 196S, 196L). As a negative control an HBsAg lacking plasmid 
was used (XXX). A plasmid encoding HBsAg from wt (wt) was used as a positive control. The supernatant was harvested on day 
two, four, six, and nine after transient transfection, purified and viral RNA was detected with HDV specific RT-qPCR. Cut-off is 
presented with red dotted line.  
 
Mutations at position W172* or W196*/S/L in the SHBs seemed to have crucial functions for virion 
assembly and secretion. The assembly and secretion of HDV pseudo-particles is inhibited when HDV is 
co-transfected with HBV stop mutants W172* and W196* as well as an HBsAg deficient plasmid (XXX) 
(Figure 30). An altered amino acid sequence at position W196 leads to decreased virion assembly and 
secretion, too (Figure 30, W196S, W196L). In contrast, HDV pseudo-particles enveloped with wild type 
HBsAg (wt), a mutant with the amino acid change from tryptophan to leucine at position 172 in the 
SHBS (172L), exhibited normal virion assembly and secretion (Figure 30). The missing LHBs had no 
effects on virion assembly and secretion (Figure 30, M1T). 
The position 172 in the SHBs and the position 196 in the internal loop of the SHBs have crucial functions 
in secretion of HDVpseudo-particles.  
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4. Discussion 
During the long-term treatment of a chronic hepatitis B infection with antiviral inhibitors, HBV resistance 
mutants often occur, leading to an antiviral breakthrough. The genome of HBV is highly compact and, 
due to this, mutations that arise in the viral polymerase, during the antiviral therapy, also affect the genes 
of the other viral proteins, especially the gene for the HBV surface proteins. These mutations do not only 
affect the secretion and infectivity of HBV, but also have strong consequences for its satellite virus: the 
hepatitis delta virus. HDV is dependent on the HBV surface proteins for assembly and virion secretion. 
Due to this, mutations in the HBV surface proteins also influence the viral life cycle of HDV.  
In the first part of this study, the phenotypic characterization of patient isolates from chronically infected 
patients should be continued, focusing patient isolates that possess characteristic HBV surface protein 
variants. Then, HBV surface protein mutants were generated, possessing single mutations in the SHBs, to 
analyze the influence of these selected single-mutations in the SHBs on the assembly and secretion of 
virions. In the second part, an in vitro transfection system in Huh7 cells should be established to generate 
recombinant HDV pseudo-particles. Using these HDV pseudo-particles, an infection system for HDV on 
PTHs should be established. To ensure a better comparability, plasma, derived from a chronically co-
infected HBV/HDV patient, was further characterized. In this context, a full length genomic HDV RNA 
standard should be generated for absolute quantification of HDV RNA. Using these methods, the 
influence of the selected HBV surface protein variants on the ability of recombinant HDV to assemble 
and secrete HDV like-particles should be investigated.  
 
4.1. Phenotypic Resistance Profile of Special Patient Isolates During Antiviral 
Therapy  
In the last years, many projects on the analysis of resistance mechanism induced by different 
nucleos(t)ide analogs and its consequences on virion formation, secretion, and viral fitness were 
performed. Therefore, a large number of in vitro assays were established to characterize resistance 
mutants. Furthermore, with the help of such resistance assays, several characteristic primary mutations 
could already be defined, that obviously are the results of the treatment with one of the four common 
nucleos(t)ide analogs; (lamivudine (LMV), entecavir (ETV), adefovir (ADV), and tenofovir (TDV)) 
(reviewed in Zoulim and Locarnini 2009, 2013). In this work, typical resistance patterns for all four 
common nucleos(t)ide analogs were also observed with the phenotypic resistance assay. 
The sequence analysis of patient isolate KW 11a-1 revealed a stop mutation at position 216 in the SHBs 
(sL216*), which is not correlated with any known resistance mutation in the rt-domain of the viral 
polymerase. Phenotypic analysis of this clone showed resistance to lamivudine (LMV) and a weak 
resistance to entecavir (ETV), only. This mutation pattern is not yet described in the literature. Therefore, 
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more tests have to be done to characterize the stop mutation at position 216 in the SHBs in more detail, 
which probably indicates a new resistance pattern for LMV and ETV.  
A long-term treatment with the nucleoside analog LMV is known to induce mutations, especially in the 
YMDD motif, the catalytic domain of the HBV polymerase (Stuyver et al. 2001) mediated primarily by 
the mutations at position V191I, M204I, or M204V in the rt-domain. These mutations were also found in 
the tested patient isolates including characteristic mutations in the SHBs. The patient isolate KW 6a-6 
exhibits the mutation pattern rtV191I sW182* (Wakil et al. 2002, Kazim et al. 2006). In contrast to what 
was published, a lamivudine resistance could not be observed, but a weak resistance to ETV was detected. 
It can be speculated that a second, compensatory mutation leads to this special phenotype. Compensatory 
mutations have known influence on the viral fitness, and can also affect the known resistance pattern.  
In the literature, the primary mutation rtM204I is often associated with the secondary mutation rtL80I/V, 
but can also occur in combination with rtL180M to a lesser extent (Warner and Locarnini 2008). In the 
case of the patient isolate KW 14-8, no typical secondary mutation was observed. The primary mutation 
rtM204I leads to the amino acid change from tryptophan (W) to serine (S) in the SHBs (sW196S). As 
expected, the patient isolate KW 14-8 demonstrated a strong resistance to LMV and ETV, and also 
showed a weak resistance to tenofovir (TDV), but a resistance to adefovir (ADV) was not observed. 
These findings are conform to the observations of other groups (reviewed in Zoulim and Locarnini 2009, 
2013). Another important primary mutation, correlated with LMV resistance, is the mutation rtM204V, 
that is often associated with the mutation rtL180M (Warner and Locarnini 2008). This mutation pattern is 
known to result in a strong LMV resistance and it was shown that patients who exhibit this mutation are 
also less responsive against EDV (Bartholomeusz and Locarnini 2006). In addition, this mutation pattern 
is described to not influence ADV or TDV (Ghany and Liang 2007). As expected, these observations are 
consistent to the tested patient isolate RK 172-2 that has the mutation pattern rtI195M rtM204V. This 
isolate shows a strong LMV resistance, but also presents a weak resistance to TDV and ADV. The 
resistance to ADV cannot be explained with the mutation pattern rt195M rtM204V of this patient isolate. 
This effect has already been described by A. Geipel and H. Niekamp (Geipel 2011; Niekamp 2013). The 
additional ADV and TDV resistance in this isolate needs to be observed and analyzed in more detail. It 
can be assumed that more unknown secondary mutations influence these two primary mutations 
significantly.  
A resistance to ADV is associated with the mutations rtA181T/V and rtN236T (Warner and Locarnini 
2008; Villet et al. 2008; Angus et al. 2003), and is also known to induce a LMV resistance (Yatsuji et al. 
2006). The mutation rtV181T induces a stop mutation in the SHBs at position 172 (Warner and Locarnini 
2008). The tested patient isolate RK 172-4 showed the mutation rtV181T with the additional mutation 
rtM204V. The results from the phenotypic resistance assay demonstrated a strong resistance to LMV, but 
only a weak resistance to ADV. Surprisingly, an intermediate resistance to EDV and tenofovir could also 
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be observed that could not be linked to a known resistance mutation. Similar to the patient isolate RK 
172-2 deeper analyses are needed, but they are beyond the scope of this thesis.  
 
4.2. Influence of Mutations within the HBV S-ORF that Arise During Antiviral 
Therapy on the Viral Life Cycle of HBV  
Many phenotypic resistance assays were established to characterize special mutations in the rt-domain 
that were selected during the treatment with the commonly used nucleos(t)ide analogs. Due to the strong 
overlapping open reading structure of the HBV genome, mutations in the rt-domain also induce mutations 
in the other viral proteins. The s-gene (surface-gene) is completely overlapped by the polymerase-ORF 
and, therefore, mutations in this region lead to amino acid changes in the s-gene, too, resulting in 
mutations in the viral envelope proteins (Figure 8, page 45). These mutations may lead to modified 
secretion, infectivity, and immunogenicity. For some of these envelope protein mutations, altered virion 
secretion (sW172* (Warner and Locarnini 2008)) or the loss of binding capacity for neutralizing 
antibodies (sG145R, vaccine escape mutant (Torresi et al. 2002a)) are already described (Billioud et al. 
2012).  
In this study, most of the tested HBV-isolates of patients treated with antiviral inhibitors showed typical 
resistance profiles, some of them resulting in characteristic surface protein mutations. To analyze them in 
more detail, autonomously replicative-competent HBV variants, possessing typically occurring envelope 
protein mutations, were generated and kindly provided by Dr. M. Neumann-Fraune (Uniklinikum Köln) 
for this work (Figure 8, page 45 and Table 6 page 77). After the transient transfection in Huh7 cells, the 
supernatant was harvested and analyzed by qPCR, ELISA, immunohistochemical staining, and CsCl-
gradients. The data are summarized in Table 6. After analyzing the supernatant of the transfected cells for 
viral DNA, it seemed to be the case that all HBV mutants secreted virions (Table 6 page 77). Cells that 
are transfected with wild type HBV replicative plasmids are known to secrete uncoated capsids in 
addition to enveloped virions in the cell culture. On that score, a sandwich-ELISA against the HBcAg 
was performed to verify if the detected DNA is derived from enveloped virions or uncoated capsids. 
Using the results of the ELISA as a basis, uncoated HBV capsids were secreted into the supernatant of 
transfected cells in addition to enveloped virions. This effect was already described in the literature 
(Nassal 1992; Sun and Nassal 2006; Bremer et al. 2009a). It is speculated by some authors that these 
capsids are secreted at the plasma membrane via an alternative mechanism requiring the adaptor protein 
ALIX (apoptosis-linked gene 2-interacting protein X) that is involved in the concentration and sorting 
process of cargo proteins of the MVB (Bardens et al. 2011). But the reasons for this phenomenon are still 
unknown. 
It is described in the literature that some HBsAg mutants show a modified replication capacity that leads 
to a reduced secretion (reviewed in Sheldon et al. 2006). These observations are conform to the findings 
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of the ELISA and the phenotypic resistance assay, because the viral fitness as well as the secretion of 
HBsAg is reduced if a stop mutation takes place in the SHBs. In this context, one exception has to be 
mentioned: the 172* mutant, because a weak signal for SHBs is observed in the ELISA (summarized in 
Table 6, page 77). It also has to be mentioned that the missing HBsAg signal in the ELISA does not 
contribute to the presumption that the stop mutants are secretion deficient. It can be supposed that amino 
acid changes in the SHBs lead to conformational changes of this protein which then can affect the 
antigenic loop. The antigenic loop bears important epitopes for the recognition of neutralizing antibodies 
(Peterson et al. 1984; Emini et al. 1986), and it is an important region for the detection of several 
antibodies of diagnostic kits. The need of the correct folding of the antigenic loop for the recognition of 
antibodies was already shown by Glebe et al (2003). A ″misfolded″ SHBs and, therefore, antigenic loop, 
induced by different stop mutations, may lead to an altered conformational structure and modified 
antigenicity that can result in a diagnostic escape. The ELISA-kit that was used is able to detect the 172* 
mutant, but nothing is known concerning the detection capacity for the other stop mutants (Avellón et al. 
2011). Due to the fact that these observations were also made in two other hepatoma cell lines (human: 
HegG2; murine: AM12) it could be shown that the results are not cell type- or species-specific. The 
suggestion of an altered conformational structure of the SHBs resulting in detection-escape of diagnostic 
kits is supported by the fact that enveloped virions are detected in the CsCl-gradient. This method takes 
advantage of the fact that molecular particles can be separated because of their different densities. The 
comparison of cell-culture derived wild type HBV to serum derived HBV illustrates that both types of 
viruses behave the same in CsCl-gradient and, therefore, the results of this study can prove if virions 
and/or uncoated capsids are secreted. The treatment of the virions with detergent and reducing agent leads 
to the removal of the viral envelop resulting in a shift of the uncoated capsids to higher densities. The fact 
that after the reducing procedure, the HBV DNA is detected in the same densities in which uncoated 
capsids are supposed to be, leads to the suggestion that the envelopes of all virions are removed. The 
results of the present work show that a stop mutation in the C-terminus of the SHBs (176*, 216*) leads to 
a reduced secretion of enveloped virions. This is true for most of the tested mutants (summarized in Table 
6 page 77). In this context, two stop mutants attract attention: the SHBs mutants 182* and 199*. For both 
mutants, no HBsAg could be detected in the HBsAg-specific ELISA but analyses of both mutants in the 
CsCl-gradient detected a very small amount of secreted HBV virions. It can be assumed that the secretion 
of these HBV surface protein variants is too low and, therefore, detection of HBsAg in the ELISA is 
located under the detection limit. During CsCl-gradient centrifugation, these secreted virions were 
concentrated in fractions where enveloped virions float and, therefore, they could be measured with the 
HBV specific qPCR. Nevertheless, the HBV surface protein mutants 176*, 182*, 199*, and 216* should 
be further analyzed with immunofluorescent staining, verifying the expression of HBV envelope proteins. 
Because of what has been found so far, the question arises, if these stop mutants secrete virions that are 
also competent to infect hepatocytes.  
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In this experimental procedure, three stop mutations are of special interest: the mutant M1T, the 172* 
mutant, and the 196 stop mutant. A stop mutation at position 172 in the SHBs can occur during long-term 
treatment with the nucleotide analog adefovir. In 2008, Warner and Locarnini postulated that this mutant 
is defective in the secretion of virions and HBsAg, leading to the retention and accumulation of virions 
within the cells (Warner and Locarnini 2008). This is contrary to the fact that the SHBs-specific ELISA 
has proven the secretion of 20 % of SHBs for the mutant 172*. Immunohistochemical staining against the 
LHBs, MHBs, and SHBs confirmed this result. All envelope proteins can be visualized in the 
immunofluorescence indicating that the surface proteins are synthesized and expressed in mutants bearing 
a stop mutation at position 172. The western-blot analysis of Warner and Locarnini (2008) also 
demonstrated that the expression of LHBs and MHBs is inhibited, although a stop mutation at position 
172 in the SHBs takes place. Specific ELISA against secreted LHBs and MHBs that were done in the 
present work confirmed these results, although both proteins were synthesized and expressed 
(immunohistochemical staining). According to these findings, it can be speculated that a stop mutation at 
position 172 does not inhibit the expression of LHBs and MHBs but blocks the secretion of both HBV 
surface proteins leading to the rebound and accumulation of virions within the cells. Proceeding from 
these data, the question arises if HBV surface protein variants, having a stop mutation at position 172 in 
the SHBs that leads to the inhibition of LHBs and MHBs secretion, but shows a reduced SHBs secretion, 
are able to infect hepatocytes? To prove its ability to infect new hepatocytes, this mutant should be tested 
in infection assays. Due to the missing LHBs on the secreted HBV surface protein variant sW172*, it can 
be assumed that an effective infection will not be possible. 
In contrast to the work of Warner and Locarnini (2008), the CsCl-gradient of the HBV variants with a 
stop mutation at position 172 in the SHBs shows that enveloped virions are secreted. Based on this 
finding, this study showed that mutants bearing a stop mutation at position 172 in the SHBs are secretion 
competent, but this competence is strongly reduced compared to the wild type. Due to this reduced 
secretion capacity, one might assume that the detection methods which were used in the mentioned paper 
(Warner and Locarnini 2008) are less sensitive than the ones used in this study and, therefore, the residual 
secretion of the HBV mutant 172* could not be detected. This detection escape could be a crucial 
problem for the HBV diagnostics, too. Warner and Locarnini (2008) could additionally show that the 
mutant 172* can have a dominant negative effect on the HBV wt. A minor sensitivity of commercial 
diagnostic kits in combination with a strongly decreased secretion capacity of mutants plus a strongly 
decreased viral load that probably is located under the detection limit of several diagnostic methods could 
mask a viral break-through during antiviral therapy and would lead to a wrong diagnosis. This diagnostic 
escape plays a crucial role for the infection and treatment of naïve patients because it could mean that also 
these infections remain undetected and antiviral therapy failed. To analyze this possible scenario, future 
studies should take a closer look at the dominant negative effect of the 172* mutant.  
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Two other interesting stop mutants attracted attention because it was shown that both mutations, the 
mutation 196* and the mutation M1T, significantly affect the virion packaging and secretion as only 
uncoated capsids were detected in the supernatant of transfected cells. For the HBV variant M1T, the 
results confirmed the expectations. The start codon of LHBs is changed, leading to the loss of its start 
signal during transcription and to no expression of the LHBs. In this experimental setting, the secretion 
deficient mutant M1T was generated as a control for the wild type virus. Due to the fact that the LHBs is 
necessary for the interaction of the viral envelope with the mature core-capsids for the secretion of mature 
HBV virions (Bruss 1997), LHBs plays an essential role for the viral life cycle.  
Surprisingly, a stop mutation at position 196 in the SHBs seemed to block the secretion of enveloped 
virions and subviral particles as well as the synthesis and expression of all three surface proteins, 
completely. The secretion of virions was rescued if a serine or leucine was present at position 196 instead 
of the amino acid tryptophan. The analyzed HBsAg mutations sW196L/S/stop are typical mutations 
associated with a resistance to LMV at position M204I/V.  
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Table 6: Summary of expressed and secreted HBV surface proteins variants, subviral particles, uncoated HBV capsids, and secreted HDV pseudo-particles enveloped with different 
HBV surface protein variants. 
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4.3. Establishment of an RNA Standard for HDV RT-qPCR 
HDV infections are diagnosed by three common procedures: 1) an ELISA to detect anti-HDV antibodies 
(anti-HDAg IgM and IgG) in human serum or plasma, 2) the radioimmunoassay, 3) the visualization by 
immunofluorescence or immunohistochemical staining in liver biopsies. The detection of HDV RNA in 
plasma or serum of infected individuals is done in each laboratory by individual in-house PCRs using 
internal laboratory standards if any is available. These PCR systems and individual standards strongly 
differ in their quality. Due to the fact that, compared to HBV, an infection with HDV is rare, neither a 
standardized detection method nor an international reference standard for quantification presently exists 
(Olivero and Smedile 2012). Some laboratories use serum of a chronically infected HDV patient for 
quantification, but the availability of this material is limited. In order to optimize this situation, a full 
length genomic HDV RNA standard (clade 1) was generated in vitro for the in-house PCR of the 
laboratory in Gießen, to be able to set up a reliable quantification of HDV RNA in cell lysates, human 
serum, plasma, or supernatant from transfected cells. It could be shown that the in vitro generated full 
length genomic HDV RNA standard can be used in a range from 2x108 GE down to 2x103 GE. RNA 
standards generated by others (Ferns et al. 2012; Scholtes et al. 2012; Katsoulidou et al. 2013) 
demonstrated an equal sensitivity for their standards and qPCR systems. But it has to be taken into 
consideration that the PCR systems strongly differ in their use of individual PCR kits, probes, primers, 
and standards (HDV plasmid-DNA, HDV purified from plasma, RNA of a short subgenomic fragment). 
These differences can affect the efficiency of the qPCR. To name some examples, short subgenomic 
fragments of HDV RNA probably possess extremely strong rod-like structures (Schaper et al. 2010) that 
complicate the effective binding of the primers, whereas the use of HDV plasmid-DNA as a standard does 
not provide any information about the efficiency of the reverse transcription step. Therefore, it still 
remains difficult to compare and interpret the efficiency of the different PCR protocols and standards of 
different research groups.  
The sequence analysis of all eight known HDV clades (after Le Gal et al. 2006) was used to analyze if the 
primers were able to detect all HDV clades. The analysis showed that the primers bind in regions at the 
C-terminus of the S-HDAg that are highly conserved (Casey et al. 1993), predicting the recognition of all 
eight HDV clades. Therefore, the in-house PCR of Gießen in combination with the in vitro generated full 
length genomic HDV RNA standard makes this system appropriate for the detection and quantification of 
HDV RNA in plasma samples, supernatant of cell culture, as well as cell lysates. However, no other 
serum samples or cloned HDV genomes of other HDV clades were available during this work. 
In future studies, the competence to detect all eight HDV clades should be tested. In addition, it would be 
desirable to generate an international reference standard as well as a uniform qPCR protocol for the 
quantitative detection of HDV RNA that can be used by different laboratories.  
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4.4. Characterization of HDV Derived from Human Plasma of a Chronically 
Infected Patient 
For characterization, HDV-positive plasma was analyzed with a linear CsCl-gradient to separate virions 
and uncoated capsids. In the present work, it could be shown that the virions floated at a density of 1.29-
1.3 g/ml CsCl. These findings are in line with the data of Roggendorf et al. and Bordier et al. 
(Roggendorf et al. 1987, Bordier et al. 2003). In contrast to these findings, Rizetto et al. and Bonino et al. 
specified the buoyant density of HDV in CsCl-gradient to 1.25 g/ml (Rizzetto et al. 1980b, Bonino et al. 
1986). The reason why HDV could be detected in different densities of CsCl is not the use of different 
HDV clades because HDV-3 (Bordier et al. 2003) and HDV-1 (Roggendorf et al. 1987) float in similar 
densities. Different origins of the HDV particles (purified virions from liver tissue of humans, 
chimpanzees, woodchucks, mice, or from plasma of chimpanzees) as a reason for differences in buoyant 
density of HDV can also be neglected because Rizetto et al. analyzed the serum of infected chimpanzees, 
and Roggendorf et al. analyzed HDV derived from liver tissue samples of an infected chimpanzee 
(Rizzetto et al. 1980b; Roggendorf et al. 1987a). Both HDV-samples float at a density of 1.25 g/ml. The 
discrepancy in the detected buoyant density of HDV in CsCl-gradient cannot be explained and, therefore, 
further investigation is needed to analyze this mismatch. Nevertheless, the findings of the present work 
confirm the results of Roggendorf et al. (1987) and Bordier et al. (2003) who showed that HDV floats at a 
density of 1.29-1.3 g/ml CsCl. 
The treatment with detergent and reducing agent lead to the complete degradation of the HDV particle. 
This means that the RNP dissociates if the integrity of the viral envelope is affected, and the viral RNA is 
not protected against RNase-based destruction, anymore. The HDV RNP does not seem to provide 
comparably efficient protection of the viral genome as the HBV capsids do. Abou-Jaoudé and Sureau 
(2007) demonstrated this effect for HDV, too.  
 
4.5. Infection of PTHs with Purified HDV 
In the past, infection assays of primary human hepatocytes (PHH), primary woodchuck hepatocytes 
(PWH), as well as primary hepatocytes from chimpanzees (PCH) were always done with HDV derived 
from cell culture or serum of HDV-infected chimpanzees treated with HDV cDNA (Sureau et al. 1991; 
Gudima et al. 2007, 2008). For the first time, it could be shown in this thesis that HDV, purified from 
chronically infected patients, can infect PTHs.  
Before performing the infection assay, the virus was purified from the plasma, as described for HBV 
(Glebe et al. 2003; Glebe and Gerlich 2004). The peak of viral RNA was observed at densities of 39-45 % 
sucrose. In contrast to the data obtained by the CsCl-gradient, results from the sucrose gradient are in line 
with the findings presented in the literature for sucrose gradients for HDV (Rizzetto et al. 1980b).  
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The plasma was derived from a patient, chronically infected with HDV and HBV, but HBV DNA was 
neither detected in the CsCl-gradient nor in the sucrose-gradient. It is known that HDV represses the 
HBV replication and secretion in chronically infected patients (Williams et al. 2009; Gordien et al. 2001). 
The concentration of HBV genomes in the fractions after centrifugation was probably under the detection 
limit of the qPCR (detection limit: 10 GE). 
A successful infection of PTHs with the purified fractions of HDV indicates that PTHs are susceptible for 
HDV. Using the established methods, these results of the present work are in line with the findings of 
other groups which also showed that PTHs can be infected with HDV in vitro and in vivo (Li et al. 1995; 
Yan et al. 1996, Yan et al. 2012). The infection with HDV can be neutralized with monoclonal antibodies 
especially against the SHBs and LHBs, and the infection can be blocked by using myr preS1-peptide. 
These findings are completely conform to the literature (Yan et al. 2012; Lütgehetmann et al. 2012, 
Lamas Longarela et al. 2013). In the present work, it was also demonstrated that PTHs are susceptible for 
HDV on day two to day four after isolation, as it is already known from HBV (Çağ 2004). Due to the fact 
that HDV is dependent on the envelope proteins of HBV for virion assembly and infectivity, the results 
support the findings that the specific receptor for HBV and HDV, the NTCP, is present on the plasma 
membrane, only a short period of time after isolation of primary hepatocytes (Liang et al. 1993).  
When comparing the infectivity of serum derived HBV to plasma derived HDV for PTHs in the present 
study, it was observed that more hepatitis B virions (calculated as genome equivalents) are needed for an 
effective infection (1x108 GE) than hepatitis D virus particles (1x106 GE) in the specific setting used here. 
A possible reason for the differences in infectivity could be the different up-take mechanism and, 
therefore, the different endocytotic pathway of HBV and HDV. It was speculated that these differences 
could probably be caused by their different proportion of HBsAg and, therefore, by their different use of 
other co-receptors (Bonino et al. 1984, 1986; Sureau et al. 1991). Bonino et al. (1986) showed that the 
surface protein composition of HDV particles is more related to that of subviral particles than to hepatitis 
B virions because the HDV envelope exhibits only 1 % or less of the LHBs (Bonino et al. 1986). 
Normally, HBV particles from genotype D exhibit approximately 16 % LHBs. Furthermore, the 
interaction of SHBs with the HDV RNP could induce conformational changes in the SHBs, which may 
expose other domains of the surface proteins on the viral envelope, leading to the binding of additional 
receptors, which then mediate other uptake mechanisms. Another possible reason for the different 
amounts of HBV and HDV required for an effective infection of PTHs might be the different quality of 
the human serum and plasma that was used. For infection with another HBV preparation a smaller 
amount of purified HBV was sufficient (1x106 GE) for a successful infection (Saniewski 2009). The 
discrepancy of the infection efficiency between these two human HBV positive sera may be explained by 
a different efficiency of the purification procedure and is also dependent on the quality of the serum itself. 
Due to their buoyant density of approx. 1.18 g/cm3 in CsCl, subviral particles, especially filaments, 
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cannot be separated completely from virions. A large number of subviral particles produced in HBV 
infected patients can interfere with the infection process and lead to a less efficient infection outcome.  
Furthermore, it could be shown that co-infection of HBV and HDV and super-infection of HBV infected 
primary hepatocytes with HDV were possible. In the past, co- and super-infection studies were first done 
with susceptible chimpanzees, which were infected with HBV and HDV to examine and compare the 
clinical manifestation of a co- or super-infection to that in humans (Purcell et al. 1987). Because of the 
ethical concerns, the limited availability, and the high costs, these experiments were stopped. Until today, 
only a few co-transfection analyses in hepatoma cell lines with replication-competent HBV and HDV 
expressing plasmids (Wu et al. 1991), and some co- and super-infection assays in humanized mice 
(Lütgehetmann et al. 2012; Giersch et al. 2014) were done to analyze the intracellular interaction of HBV 
and HDV. In fact, infection assays on primary Tupaia hepatocytes in vitro with naturally occurring HDV 
and HBV derived from infected patients, to analyze co- and super-infection were never done before. 
Although it was possible to infect PTHs with both viruses, no differences were observed between 
HBV/HDV co- or super-infections in the present study. A RT-qPCR was used for the detection of the 
HDV infection. Therefore, it is not sure if single PTHs are co-infected with both viruses simultaneously 
or if mono-infections occur as well. Mono- and co-infections can be analyzed in future projects with 
immunofluorescence. Normally, in patients who are super-infected with HBV and HDV, the infection 
course tends to result in a chronic HDV infection over months, leading to the suppression of HBV 
replication and antigen expression. This was not observed in the present study because of the limited time 
scale of the in vitro experiments. Co- as well as super-infection with HBV and HDV resulted in equal 
amounts of newly secreted HBsAg and newly transcribed HDV RNA. The reason might be that PTHs are 
susceptible for HBV and HDV only in a short time period after isolation (Yan et al. 2012). It is 
conceivable that a different in vitro infection system would be more appropriate for further co- and super-
infection studies, for example a stably transfected cell line that constitutively expresses the hepadnaviral 
high affinity receptor NTCP to study the HBV/HDV co- and super-infection in vitro. It might be that in 
such a system the co- and super-infection develops similarly to the naturally occurring infection course 
and, therefore, adequate information about the entry, the used endocytotic pathways of both viruses, and 
their interaction within the cell can be provided. Because of the lack of time, this experiment was carried 
out only once. Therefore, variances cannot be excluded and this experimental setting has to be repeated to 
verify the results presented in this work.  
 
4.6. Production and Detection of Recombinant HDV Enveloped with Different 
Combinations of HBsAg 
Virion formation, the release of mature virions, and the infectivity for HBV and HDV is often 
compromised by mutations within the viral genome that frequently arise during antiviral therapy as well 
as under the pressure of the immune-system, for example during occult hepatitis B infection. In order to 
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study the effects of the mutations in the relevant surface proteins, a transfection system was established to 
generate HDV like-particles enveloped with defined mutants of HBV surface proteins. In conformity with 
the literature, the Huh7 cell line was used to generate these HDV pseudo-particles (Sureau et al. 1991; 
Wu et al. 1991; Gudima et al. 2007). The present study shows that the transiently transfected cells secrete 
recombinant HDV after three days, indicating that the transfected cells readily synthesize the mutated 
HBV surface proteins, leading to the assembly of HDV (Gudima et al. 2007). As expected, HDV pseudo-
particles were generated and secreted when HDV was covered with all three surface proteins, the LHBs 
and the SHBs or the SHBs, only. These findings are conform to the literature and indicate that the SHBs 
alone is sufficient for HDV-secretion, too (Chang et al. 1991; Sureau et al. 1993). In previous studies 
conducted by Sureau and coworkers, it could be shown that the C-terminus of the SHBs, especially one 
amino acid in the internal loop of the SHBs, is the crucial region for the binding of HBsAg and HDV 
RNP. This interaction mediates the envelopment and secretion of mature hepatitis D virions (Jenna and 
Sureau 1999; Komla-Soukha and Sureau 2006). In contrast to HDV, the assembly and secretion of mature 
hepatitis B virions do not depend on SHBs, solely, but also on the LHBs-isoform that is exposed on the 
internal site of the viral envelope. The internal loop of the SHBs as well as a domain in the preS1/preS2 
region are necessary for the encapsidation of mature core particles of the hepatitis B virus (Bruss 1997). 
The MHBs does not seem to be necessary for virion assembly or infectivity for HBV (Bruss and Ganem 
1991; Le Seyec et al. 1998) as well as HDV (Sureau et al. 1994), and its function in the viral life cycle of 
both viruses still remains unclear. However, some studies postulate that the MHBs facilitates the secretion 
of hepatitis B virions and subviral particles (Garcia et al. 2009). Nevertheless, the present work shows 
that a transfection system to generate HDV pseudo-particles was successfully established.  
After transient transfection, the cells were cultivated up to 12 days. Because of the rapid growth of the 
cells, they had to be split within a very short period of time, which made handling difficult. Probably, 
HepG2 cells could be used, not only to avoid some difficulties in handling, but also because they are 
more related to differentiated liver cells than Huh7 cells. Another particular feature is that they can be 
arrested in their cell cycle by adding DMSO (Kost and Michalopoulos 1991) while cultivating. For 
reasons that are still unknown, this treatment slows down the cell proliferation and is known to promote 
the production of virus particles. This cell line could be an appropriate alternative to the Huh7 cells but it 
has to be mentioned that the transfection efficiency of HepG2 is lower than that of Huh7 cells 
(transfection efficiency of HepG2: 10 %; transfection efficiency Huh7: 50-75 %) (Chang et al. 1987). 
Moreover, this cell line has not yet been used to produce HDV pseudo-particles, so it still has to be tested, 
if these cells are really qualified to generate recombinant HDV.  
After transient transfection, there was a high amount of DNA-background that was caused by plasmids 
that might be bound to the plasma membrane or on the cell culture plate. Those plasmids are not taken-up 
into the cells after transfection and can be detected subsequently by qPCR. A. Geipel (2011) showed that 
the application of several washing steps and the transfer of the cells to a new cell culture plate reduced the 
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plasmid-background after transient transfection. Barrera et al. (2004) included a DNase I digestion before 
running the PCR. These improvements were also used in this work to decrease the DNA-background. 
Nevertheless, there is still plasmid-DNA detectable. Probably the plasmid background is not fully reduced 
by washing steps as shown by A. Geipel (2011). An additional explanation could be an incomplete DNase 
digestion because of the huge amount of plasmids in the supernatant. One idea would be to extend the 
time of DNase digestion or to use higher amounts of DNase, like Barrera et al. (2004) did in their work. 
They used 4 U DNase to digest the plasmid-DNA, whereas 1 U of DNase was taken in this study.  
To optimize the system, the ratio of the HDV plasmid and the plasmid encoding the HBV surface protein 
mutants could be titrated. Several distinct plasmid-concentrations were used in the literature to produce 
HDV pseudo-particles. Gudima and Taylor et al (2007), for example, use a ratio of 1:4 HDV to HBV 
envelope protein expressing plasmids. In this study a ratio of 1:1.3 was used according to the ratio taken 
by Sureau and colleagues (1:1, 1:2) (Jenna and Sureau 1999; Abou-Jaoudé et al. 2007). It has to be 
mentioned that the direct comparison of these different transfection assays is difficult because different 
transfection reagents and HBV surface protein plasmids, which are regulated by different promoters, were 
used. Taylor and colleagues, for example, used HBV surface protein expressing plasmids derived from 
genotype A under the control of an SV40 promotor known to lead to a high constitutive expression rate of 
the protein (Gudima et al. 2007). In contrast, Sureau and colleagues utilized HBV envelope encoding 
plasmids, derived from genotype D, which was under the control of the natural HBV promotor (Jenna and 
Sureau 1999). The subgenomic HBV envelope protein expressing plasmids that were used in this work 
were under the control of the natural HBV promoter, too, and, therefore, they provide a more related 
HBsAg-expression in cell culture compared to naturally occurring infections in hepatocytes. The 
improvement of the plasmid ratio between HDV and HBV could be helpful to find out the optimal ratio 
that leads to a maximized yield of HDV pseudo-particles and minimized cell stress.  
 
4.7. Infection of PTHs with Recombinant HDV in Comparison with Purified 
HDV 
Secreted HDV like-particles enveloped with all three HBV surface proteins, with the LHBs and SHBs or 
covered with only the SHBs, were tested in the infection assay to prove their ability to infect PTHs. 
Supernatant from transiently transfected cells with the HDV-plasmid and an HBsAg deficient plasmid 
was used as negative control. PTHs were also infected with HDV, purified from a chronically infected 
patient that served as positive control. This work shows that HDV pseudo-particles possessing the LHBs 
are able to infect PTHs, confirming the observations that have already been made by other groups (Sureau 
et al. 1991, 1991; Jaoudé and Sureau 2005; Abou-Jaoude and Sureau 2007). PTHs were not infected when 
they were treated with either the supernatant of cells transfected with the HDV-plasmid and an HBsAg 
lacking plasmid or HDV like-particles covered with the SHBs, only. It can be summarized that HDV like-
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particles derived from cell culture, are able to infect PTHs, demonstrating that an infection system for 
recombinant HDV pseudo-particles was successfully established. 
If the efficiency of the infection of recombinant HDV and purified wt HDV (derived from human plasma) 
is compared, it is important to highlight that the infectivity of recombinant HDV is lower than the 
infectivity of purified HDV derived from human plasma. This observation has already been made by 
Sureau and colleagues (Sureau et al. 1992). These differences in the infectivity can be explained with the 
generation procedure because it must be considered that the production of HDV pseudo-particles covered 
with different HBV surface protein variants was performed in immortalized hepatoma cell lines that do 
not necessarily have the same features like primary cells. It might be that cell culture derived HDV 
pseudo-particles are not totally similar in their surface protein composition and, therefore, the efficiency 
of infection cannot totally be compared to plasma-derived HDV. Further experiments, for example 
western blot analyses of cell culture derived HDV compared to plasma-derived virus, would give an 
indication of the amount of the HBsAg. A further explanation for the differences in the infectivity of 
HDV derived from human plasma and cell culture could be the purification procedure and the production 
process of the recombinant HDV like-particles. Because of apoptotic processes, a lot of cell debris and 
unfinished virus-like particles probably are released into the supernatant of transfected cells. This cell 
debris and unfinished virus-like particles could be concentrated, too, when HDV pseudo-particles derived 
from cell culture were enriched during the concentration procedure. These particles may reduce the 
infection efficiency by interfering and preventing the binding of the LHBs with the preS1 region of the 
NTCP. In this context, it may also be that a contamination with plasmid-DNA is another possible reason 
for the low infectivity rate. Because of the concentration process, in that the plasmid-DNA was also 
concentrated, one could assume that it binds to the viral surface membrane during infection procedure and 
then can be detected in the qPCR, too. This disagreement would be wiped out by performing an additional 
DNase digestion. A better possibility to purify and concentrate the HDV pseudo-particles from cell 
culture could be the utilization of a continuous sucrose gradient. This method provides better and clearer 
purification of the hepatitis D virus-like particles and was also used by Sureau et al. (1991) before starting 
infection assays on primary hepatocytes. Nevertheless, the data of the present work show that cell culture 
derived HDV pseudo-particles are infectious in PTHs, too. 
 
4.8. Influence of Mutations within the HBV S-ORF that Arise During Antiviral 
Therapy on the Viral Life Cycle of the Hepatitis D Virus 
The mutation rtM204V in the viral polymerase of HBV is crucial not only for the development of HBV 
resistance mutants and, therefore, antiviral treatment but also influences the viral life cycle of its satellite 
virus: the hepatitis delta virus. The present work has shown that a stop mutation at position sW172 or 
sW196 as well as an amino acid change at position sW196 in the SHBs leads to a block in the secretion of 
HDV pseudo-particles (summarized in Table 6, page 77). It could be assumed, that these stop mutations 
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lead to the loss of the transmembrane domain III and IV and, therefore, also to the loss of the third 
internal loop of the SHBs. The internal loop region is crucial for the interaction of the HDV RNP with the 
HBsAg during envelopment and secretion of HDV. Sureau and coworkers have shown that especially the 
internal loop between transmembrane III and IV is the HDV packaging-domain and essential for an 
effective secretion (Jenna and Sureau 1998, 1999). In 2006, Komla-Soukha and Sureau detected the 
position 196 in the SHBs (sW196) as an essential position for the interaction of the HDV RNP with the 
small HBV surface protein. In contrast to HBV, the present data show that the release of enveloped 
virions was not rescued if an amino acid change to serine or leucine took place at position 196, and thus 
highlight the important function of the position sW196 in the SHBs for HDV secretion, too (Wang et al. 
1991; Komla-Soukha and Sureau 2006). Mutants carrying the functional SHBs (wt, M1T, 172L) were 
encapsidated and secreted similarly to the wild type (summarized in Table 6). In consequence, an HDV 
particle infecting hepatocytes that carries the HBV surface variant sW196* only, would result in a dead 
end for HDV infection cycle. Both, HBV and HDV would still be able to replicate in these hepatocytes, 
but the sW196* variant of the HBV S-ORF would inhibit the envelopment and secretion of both viruses. 
Furthermore, no subviral particles could be secreted. This situation could only be changed, if either the 
cell would be infected by a wild type HBV again providing non-mutated surface proteins, or a mutation 
within the cccDNA pool of the infected hepatocytes restored the sW196* mutation into wild type.  
A stop mutation in the SHBs does not only significantly affect the life cycle of HBV and HDV, but also 
has strong clinical consequences for the antiviral treatment and diagnostic. The HDV infection is a rarely 
occurring disease in the western countries and seems to be restricted to HBsAg-positive intravenous drug 
addicts, mostly (Kucirka et al. 2010). However, chronic HDV infection is still a significant health 
problem in Europe, especially caused by the immigration of individuals from highly endemic regions. 
These immigrants often carry a chronic HBV/HDV co-infection (Farci 2003b). If a co-infection is not 
diagnosed, this will be strongly detrimental for the patients if they are treated with nucleos(t)ide analogs 
because it has been proven that the treatment with these inhibitors does not affect HDV (Niro et al. 2005; 
Mansour et al. 2010; Brichler et al. 2013). The treatment with nucleos(t)ide analogs would decrease the 
viral load of HBV but it would not affect the secretion of infectious HDV particles. As already 
mentioned, a typical resistance mutation emerging during lamivudine treatment is the mutation pattern 
rtM204I sW196S/L/stop. If this mutation pattern was selected, it would inhibit the secretion of hepatitis 
delta virions, but an amino acid change at position 196 from tryptophan to serine or leucine would rescue 
the HBV variants resulting in resistance mutants which then cause an antiviral breakthrough. The change 
from lamivudine to another nucleos(t)ide analog would then decrease the viral load of HBV again, but 
could promote a re-mutation of the rtM204I sW196S/L/stop leading to a rebound of HDV particles once 
again. The sequential treatment with nucleos(t)ide analogs can lead to another complication in the HBV 
therapy and probably in the HDV therapy, too. Nucleos(t)ide analogs that exhibit similar characteristics, 
for example lamivudine and entecavir, can promote the selection for multidrug resistant mutants of HBV. 
These HBV mutants do not only cause a therapy failure of HBV but also can mediate HBV and HDV 
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variants that exhibit mutations in the antigenic loop of the HBsAg, for example the mutation pattern in the 
S-ORF sE164D /sI195M with the corresponding P-ORF mutations rtV519L/rtL526M/rtM550V (Torresi 
et al. 2002b). These mutations could induce a misdetection of HBsAg-diagnostic methods and could lead 
to the misdetection of anti-HBs antibodies in HBV diagnostics. To avoid such multidrug resistant HBV 
and HDV variants, HBsAg-positive carriers should be tested carefully before the onset of an antiviral 
therapy for circulating antiviral resistant HBV variants and in parallel for an HDV co-infection. Patients 
with an HBV/HDV co-infection are treated with a combination of interferon - the only therapeutic 
recommendation for HDV treatment to the present day - in combination with nucleos(t)ide analogs trying 
to decrease the viral load of HBV as well as HDV (Brichler et al. 2013). Unfortunately, the treatment with 
IFN-α and nucleos(t)ide analogs is associated with several side effects and high costs.  
It can be concluded that our current knowledge about the consequences of an antiviral treatment on the 
life cycles of HBV and HDV needs improvement. Further investigations are needed to analyze and 
characterize 1) further HBsAg mutations occurring during antiviral therapy 2) their secretion capacity and 
3) their competence to infect new hepatocytes. These results should lead to a better understanding of the 
viral life cycle of both, HBV and HDV and hopefully also to new treatment options for the co-infected 
patients.  
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5. Perspectives 
The detailed investigation and description of resistance patterns in the viral polymerase induced by the 
antiviral therapy of a chronic HBV infection could be helpful to find out new resistance mutations and, 
therefore, to improve the antiviral therapy. Moreover, the characterization of HBV surface protein 
mutations induced by the long term treatment with nucleos(t)ide analogs could be helpful to optimize the 
sensitivity of several diagnostic methods to detect HBV resistance variants.  
Furthermore, the finding of NTCP as the high affinity receptor for HBV and HDV opens up new 
opportunities to examine the HBV and HDV life cycle. Because of the limited time scale in which PTHs 
are susceptible for HBV and HDV, a stably transfected cell line, which constitutively expresses the 
hepadnaviral high affinity receptor NTCP, would be a more appropriate infection model. Such an 
infection system could be used to study the uptake mechanism and the used endocytotic pathway of both 
viruses. The obtained results could be used to develop new pharmaceuticals that block key proteins or 
enzymes of the HBV and/or HDV entry process and thereby specifically inhibit infection. Additionally, 
with the help of such an infection system, HBV/HDV co- and super-infection assays could be established. 
Due to the fact that a chronic HBV/HDV co-infection leads to a higher prevalence for developing HCC or 
liver cirrhosis, such an infection system would allow a better understanding of the viral life cycle of HBV 
and HDV, and could improve our knowledge of the interaction of both viruses within the cells. In contrast 
to HBV, a specific antiviral drug is not available, but urgently needed. A better understanding of the viral 
life cycle would probably lead to the development of specific antiviral drugs that inhibit HDV replication. 
The clarification of the interaction-machinery and the knowledge of how HDV represses the HBV 
replication in chronically co-infected patients will possibly lead to the development of new antiviral 
pharmaceuticals that probably are able to inhibit the transcription of HBV mRNA. A better understanding 
of the interaction between both viruses could hopefully lead to the development of new therapy strategies 
in HBV/HDV co-infection.  
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9. Appendix 
 
 
Figure 31: Regression profile of patient isolate KW 6a-6. Patient isolate KW 6a-6 was tested in phenotypic resistance assay 
against the four common nucleos(t)ide analogs. Black line shows consensus curve of the wt. Red line shows resistance profile of 
tested patient isolate KW 6a-6.  
 
 
Figure 32: Regression profile of patient isolate KW 11a-1. Patient isolate KW 11a-1 was tested in phenotypic resistance assay 
against the four common nucleos(t)ide analogs. Black line shows consensus curve of the wt. Red line shows resistance profile of 
tested patient isolate KW 11a-1.  
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Figure 33: Regression profile of patient isolate KW 14-8. Patient isolate KW 14-8 was tested in phenotypic resistance assay 
against the four common nucleos(t)ide analogs. Black line shows consensus curve of the wt. Red line shows resistance profile of 
tested patient isolate KW 14-8.  
 
 
Figure 34: Regression profile of patient isolate RK 172-2. Patient isolate RK 172-2 was tested in phenotypic resistance assay 
against the four common nucleos(t)ide analogs. Black line shows consensus curve of the wt. Red line shows resistance profile of 
tested patient isolate RK 172-2.  
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Figure 35: Regression profile of patient isolate RK 172-4. Patient isolate RK 172-4 was tested in phenotypic resistance assay 
against the four common nucleos(t)ide analogs. Black line shows consensus curve of the wt. Red line shows resistance profile of 
tested patient isolate RK 172-4.  
 
 
Figure 36: Analysis of stop mutants transiently transfected in the murine hepatoma cell line AML12. Supernatant of 
AML12 cells transiently transfected with HBV surface protein variants was tested for newly secreted HBsAg and HBV core-
particles, three days after transfection. A) Detected Genome equivalents in the supernatant of stop mutants. B) Results of the 
ELISA against HBV core using a polyclonal antibody against the core antigen derived from rabbit (DAKO). C) Results of the 
ELISA against LHBs using the monoclonal antibody MA18/7. D) Results of the ELISA against SHBs using the monoclonal 
antibody C20/02. Cut-off for each test is presented with red dotted line.  
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Figure 37: Analysis of stop mutants transiently transfected in the human hepatoma cell line HepG2. Supernatant of HepG2 
cells transiently transfected with HBV surface protein variants was tested for newly secreted HBsAg and HBV core-particles, 
three days after transfection. A) Detected genome equivalents in the supernatant of stop mutants. B) Results of the ELISA against 
HBV core using a polyclonal antibody against the core antigen derived from rabbit (DAKO). C) Results of the ELISA against 
LHBs using the monoclonal antibody MA18/7. D) Results of the ELISA against SHBs using the monoclonal antibody C20/02. 
Cut-off for each test is presented with red dotted line. 
 
Figure 38: Immunohistochemical staining of control experiments. As control for primary antibodies, untransfected Huh7 
cells were treated as transfected cells and stained for HBsAg (LHBS: MA18/7, MHBs: Q19/10, SHBs: C20/02, red panel, Alexa-
594) and HBV core (DAKO, green panel, Alexa-488). As control for secondary antibodies, HBV wt transfected cells were 
stained with only secondary antibodies (right section). Cells marked with the yellow arrow are shown in more detail with a cut 
view through z-stack-images of single cells. Scale bars: 50 µm 
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Table 7: Table of measured density and genome equivalents for serum derived and cell culture derived HBV. 
 serum derived HBV cell culture derived HBV (wt) 
treatment - NP40/TCEP + NP40/TCEP - NP40/TCEP + NP40/TCEP 
fractions density 
[g/ml] 
GE/ml density 
[g/ml] 
GE/ml density 
[g/ml] 
GE/ml density 
[g/ml] 
GE/ml 
1 1.47 1.66x103 1.43 1.55x103 1.46 3.40x104 1.45 3.85x104 
2 1.43 1.24x103 1.43 1.85x103 1.43 8.40x103 1.45 5.05x104 
3 1.38 1.24x103 1.40 3.58x103 1.39 1.74x105 1.40 3.78x105 
4 1.34 3.35x103 1.36 1.65x105 1.35 3.83x105 1.35 7.85x105 
5 1.29 2.03x105 1.32 1.23x105 1.30 6.88x104 1.32 2.55x105 
6 1.26 4.10x105 1.28 2.43x104 1.27 2.39x106 1.28 1.27x105 
7 1.21 7.95x104 1.25 8.20x103 1.22 2.58x106 1.24 6.85x104 
8 1.18 1.46x104 1.20 4.70x103 1.18 3.35x105 1.19 4.13x104 
9 1.15 4.55x103 1.16 5.25x103 1.15 8.70x104 1.16 4.53x104 
10 1.12 4.69x103 1.14 5.55x103 1.12 7.25x104 1.13 4.85x104 
11 1.10 3.75x103 1.12 9.18x103 1.10 1.06x105 1.11 1.09x105 
12 1.10 5.00x103 1.09 7.63x104 1.09 2.12x105 1.08 2.37x106 
 
 
Table 8: Table of measured density and genome equivalents for mutant M1T. 
 M1T 
treatment - NP40/TCP + NP40/TCEP 
fractions density [g/ml] GE/ml density [g/ml] GE/ml 
1 1.46 1.84x105 1.42 1.12x105 
2 1.39 3.53x104 1.43 5.80x104 
3 1.37 1.75x106 1.35 1.08x106 
4 1.33 2.39x106 1.31 1.16x106 
5 1.29 1.12x106 1.28 1.33x106 
6 1.25 6.38x105 1.22 4.38x105 
7 1.20 3.80x105 1.19 2.25x105 
8 1.16 1.91x105 1.13 1.31x105 
9 1.13 9.08x104 1.14 1.08x105 
10 1.11 5.55x104 1.11 2.19x105 
11 1.08 1.08x105 1.09 5.38x106 
12 1.08 5.53x104   
 
 
Table 9: Table of measured density and genome equivalents for mutants 172* and 172L. 
 172* 172L 
treatment - NP40/TCP + NP40/TCEP - NP40/TCP + NP40/TCEP 
fractions density  
[g/ml] 
GE/ml density  
[g/ml] 
GE/ml density 
[g/ml] 
GE/ml density  
[g/ml] 
GE/ml 
1 1.46 1.10x105 1.45 6.08x104 1.45 4.20x105 1.45 2.58x106 
2 1.45 3.38x104 1.45 2.95x104 1.45 3.45x104 1.45 1.36x105 
3 1.40 2.75x105 1.40 6.78x105 1.39 2.88x104 1.40 1.75x105 
4 1.36 1.65x106 1.36 3.00x106 1.35 7.88x104 1.35 2.73x105 
5 1.32 5.60x105 1.31 8.30x105 1.32 1.64x105 1.33 2.04x105 
6 1.28 8.45x105 1.27 3.45x105 1.27 8.05x106 1.28 1.85x105 
7 1.24 5.45x106 1.22 1.42x105 1.24 5.23x106 1.24 8.90x104 
8 1.19 3.28x106 1.18 9.13x104 1.19 6.98x105 1.19 3.93x104 
9 1.16 5.73x105 1.15 1.12x105 1.16 2.63x105 1.17 8.78x104 
10 1.13 2.58x105 1.14 1.73x105 1.13 1.35x105 1.15 1.70x105 
11 1.11 2.27x105 1.11 5.83x105 1.11 2.25x105 1.13 7.53x105 
12 1.10 4.98x105 1.10 4.70x106 1.10 5.09x105 1.11 3.18x106 
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Table 10: Table of measured density and genome equivalents for mutants 196*, 196S and 196L. 
 196* 196S 
treatment - NP40/TCP + NP40/TCEP - NP40/TCP + NP40/TCEP 
fractions density  
[g/ml] 
GE/ml density  
[g/ml] 
GE/ml density 
[g/ml] 
GE/ml density  
[g/ml] 
GE/ml 
1 1.47 9.65x104 1.46 7.93x104 1.45 9.50x104 1.39 1.17x105 
2 1.46 3.25x104 1.42 2.40x104 1.43 2.70x104 1.45 5.55x104 
3 1.41 4.20x105 1.41 3.30x105 1.40 1.08x105 1.41 3.80x105 
4 1.37 2.13x106 1.35 1.47x106 1.36 1.39x106 1.34 2.35x106 
5 1.33 9.68x105 1.32 6.78x105 1.33 6.13x105 1.33 2.29x106 
6 1.30 3.55x105 1.27 3.88x105 1.27 1.79x106 1.29 1.21x106 
7 1.26 3.05x105 1.25 1.50x105 1.25 3.80x106 1.25 3.33x105 
8 1.19 1.50x105 1.19 6.20x104 1.19 6.60x105 1.21 1.54x105 
9 1.16 9.70x104 1.16 6.23x104 1.16 2.32x105 1.19 9.13x104 
10 1.14 4.93x104 1.14 9.73x104 1.13 1.11x105 1.15 1.11x105 
11 1.10 3.63x104 1.12 6.50x105 1.12 1.09x105 1.14 1.35x105 
12 1.10 6.88x104 1.10 2.88x106 1.10 3.00x105 1.10 1.54x106 
 
 196L 
treatment - NP40/TCP + NP40/TCEP 
fractions density [g/ml] GE/ml density [g/ml] GE/ml 
1 1.45 3.88x104 1.43 4.48x104 
2 1.43 1.35x104 1.45 1.94x104 
3 1.37 6.45x104 1.38 1.28x105 
4 1.37 8.15x105 1.35 1.07x106 
5 1.32 3.95x105 1.32 1.14x106 
6 1.28 8.68x105 1.27 6.50x105 
7 1.26 4.73x106 1.26 1.88x105 
8 1.20 1.13x106 1.20 1.14x105 
9 1.17 2.85x105 1.18 9.70x104 
10 1.14 1.40x105 1.14 8.08x104 
11 1.12 8.03x104 1.13 3.48x105 
12 1.10 2.22x105 1.13 2.73x106 
 
 
Figure 39: CsCl-gradient of tested mutants with mutations at position 176 and 182 into the SHBs. Supernatant of 
transiently transfected cells with HBV surface protein variants 176* and 182* were treated with NP40 and TCEP (1h, RT), 
layered on a linear CsCl-gradient and ultracentrifuged. 1x106 GE/ml for both HBV surface protein variants were used. The 
gradient was fractionated from the bottom to the top.A) On the left site presented schematic depiction of localization of stop 
mutation at position 176 into the SHBs (modified after Komla-Soukha and Sureau 2006). CsCl-gradient for stop mutant 176 is 
presented on the right site. B) On the left site, presented schematic description of localization of stop mutation at position 182 
into the SHBs. CsCl-gradient for stop mutant 182 is picketed on the right site. Red bars indicate the fractions where enveloped 
virions are expected. Black bars indicate the fractions where uncoated capsids are expected. Representative data of three 
independent experiments are depicted. 
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Table 11: Table of measured density and genome equivalents for mutants 176* and 182*. 
 176* 182* 
treatment - NP40/TCEP + NP40/TCEP - NP40/TCEP + NP40/TCEP 
fractions density 
[g/ml] 
GE/ml density 
[g/ml] 
GE/ml density 
[g/ml] 
GE/ml density 
[g/ml] 
GE/ml 
1 1.43 3.98x104 1.42 1.31x105 1.47 1.40x105 1.45 1.60x105 
2 1.43 9.93x103 1.45 5.08x104 1.42 5.65x104 1.43 5.70x104 
3 1.39 1.02x104 1.41 1.26x104 1.38 1.44x106 1.39 1.10x106 
4 1.36 3.30x104 1.37 1.01x105 1.33 1.06x106 1.35 1.54x106 
5 1.32 1.65x104 1.33 6.95x104 1.30 4.35x105 1.31 6.10x105 
6 1.28 9.55x104 1.30 4.05x104 1.25 7.73x105 1.27 2.43x105 
7 1.25 6.15x105 1.27 3.28x104 1.20 6.28x105 1.22 1.74x105 
8 1.20 8.98x105 1.22 1.86x104 1.16 2.35x105 1.18 1.15x105 
9 1.17 1.16x105 1.19 1.16x104 1.13 1.19x105 1.15 7.35x104 
10 1.14 3.88x104 1.16 1.19x104 1.11 5.55x104 1.14 1.27x105 
11 1.12 2.90x104 1.10 2.49x104 1.09 2.23x105 1.11 4.28x105 
12 1.10 6.88x104 1.12 3.05x105 1.08 8.33x105 1.10 5.70x106 
 
 
 
Figure 40: CsCl-gradient of tested mutants with mutations at position 199 and 216 into the SHBs. Supernatant of 
transiently transfected cells with HBV surface protein variants 199*, 216*TAA and 216*TGA were treated with NP40 and TCEP 
(1h, RT), layered on a linear CsCl-gradient and ultracentrifuged. 1x106 GE/ml for all three HBV surface protein variants were 
used. The gradient was fractionated from the bottom to the top.A) Schematic depiction of localization of stop mutations at 
positions 199 (upper panel) and 216 (lower panel) (modified after Komla-Soukha and Sureau 2006) B) CsCl-gradient of tested 
mutant 199*. C) CsCl-gradient of tested mutant 216TAA. D) CsCl-gradient of tested mutant 216TGA. Red bars indicate the 
fractions where enveloped virions are expected. Black bars indicate the fractions where uncoated capsids are expected. 
Representative data of three independent experiments are depicted. 
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Table 12: Table of measured density and genome equivalents for mutant 199*. 
 199* 
treatment - NP40/TCP + NP40/TCEP 
fractions density[g/ml] GE/ml density[g/ml] GE/ml 
1 1.42 1.95x105 1.42 1.84x105 
2 1.43 7.10x104 1.42 1.17x105 
3 1.39 1.27x106 1.38 2.70x106 
4 1.35 1.39x106 1.34 3.73x105 
5 1.31 3.83x105 1.30 8.20x105 
6 1.26 7.80x105 1.26 5.55x105 
7 1.22 6.15x105 1.22 2.44x105 
8 1.18 2.60x105 1.19 1.20x105 
9 1.15 1.26x105 1.16 8.93x104 
10 1.12 7.35x104 1.14 1.31x105 
11 1.10 5.95x104 1.11 4.15x105 
12 1.09 2.49x105 1.10 4.28x106 
 
 
Table 13: Table of measured density and genome equivalents for mutants 216TAA and 216TGA. 
 216TAA 216TGA 
treatment - NP40/TCEP + NP40/TCEP - NP40/TCEP + NP40/TCEP 
fractions density 
[g/ml] 
GE/ml density 
[g/ml] 
GE/ml density 
[g/ml] 
GE/ml density 
[g/ml] 
GE/ml 
1 1.40 1.26x105 1.42 1.51x105 1.42 2.15x105 1.38 1.81x105 
2 1.41 4.18x104 1.38 5.10x104 1.43 5.35x104 1.39 5.60x104 
3 1.40 1.72x105 1.38 1.06x106 1.36 3.08x105 1.38 1.32x106 
4 1.36 2.24x106 1.32 1.59x106 1.36 2.39x106 1.33 2.33x106 
5 1.30 1.60x106 1.26 1.82x106 1.30 7.33x105 1.29 1.02x106 
6 1.25 3.98x105 1.21 5.23x105 1.27 3.90x105 1.27 7.48x105 
7 1.22 1.42x106 1.17 1.43x105 1.21 1.98x106 1.21 3.50x105 
8 1.19 8.50x105 1.15 8.68x104 1.18 7.83x105 1.19 2.31x105 
9 1.16 4.03x105 1.15 1.11x105 1.15 4.03x105 1.14 8.30x104 
10 1.15 2.73x105 1.11 1.99x105 1.13 1.06x105 1.12 8.33x104 
11 1.11 9.78x104 1.07 3.75x106 1.10 4.03x104 1.12 9.70x104 
12 1.08 3.30x105     1.07 1.40x105 1.09 2.60x106 
 
 
 
Table 14: CsCl-gradient of HDV-positive serum derived from a chronically infected patient. 
fractions - NP40/TCEP + NP40/TCEP 
density [g/ml GE/ml density [g/ml GE/ml 
1 1.45 2.38x106 1.42 3.36x103 
2 1.45 1.09x106 1.42 4.44x103 
3 1.39 3.94x105 1.39 7.00x103 
4 1.35 1.65x105 1.35 2.36x103 
5 1.32 8.20x105 1.32 5.60x103 
6 1.30 1.04x109 1.29 3.18x103 
7 1.29 1.69x109 1.28 3.33x103 
8 1.27 5.50x107 1.25 0 
9 1.19 4.83x107 1.17 0 
10 1.14 1.36x107 1.14 0 
11 1.11 6.45x106 1.12 0 
12 1.11 2.77x107 1.10 0 
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Table 15: Sucrose gradient of a HDV-positive plasma derived from a chronically infected patient. 
fractions density  
sucrose [%] 
protein  
concentration [mg/ml] 
GE/ml 
1 58.00 0.50 1.92x107 
2 57.50 0.00 1.12x107 
3 55.50 0.20 8.65x106 
4 52.00 0.30 1.12x107 
5 49.00 0.20 1.10x108 
6 46.50 0.20 9.13x108 
7 44.50 0.90 8.65x109 
8 42.00 2.10 9.23x109 
9 39.50 4.10 1.49x109 
10 37.50 6.10 1.38x108 
11 35.00 8.70 1.17x108 
12 33.00 10.10 3.08x107 
13 31.00 12.30 7.13x106 
14 29.00 15.10 4.73x106 
15 27.25 18.00 3.13x106 
16 25.50 18.00 1.60x106 
17 23.50 18.70 9.73x105 
18 21.50 18.90 1.47x106 
19 20.00 18.90 1.78x106 
20 18.50 0.00 1.30x106 
21 17.00 23.10 7.40x105 
22 15.00 23.10 7.30x105 
23 12.50 14.10 8.95x105 
24 10.00 6.30 6.35x105 
25 8.00 3.20 1.37x106 
26 6.50 1.10 1.36x106 
27 6.00 0.30 1.01x106 
28 5.00 0.20 7.20x105 
29 4.50 0.00 3.58x105 
30 4.50 0.10 3.58x105 
31 4.00 0.70 5.33x106 
 
 
 
 
Figure 41 Purified HDV from sucrose-gradient of a human plasma chronically infected with HDV. Orange arrow showed 
accumulation of plasma proteins.  
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